Aop:1 Event:142 KeyEvent Hyperplasia, Hyperplasia Aop:1 Event:334 AdverseOutcome Promotion, Hepatocelluar carcinoma Aop:1 Event:57 KeyEvent Proliferation, Cell proliferation in the absence of cytotoxicity Aop:1 Event:294 MolecularInitiatingEvent N/A, Unknown Aop:3 Event:887 KeyEvent Inhibition, NADH-ubiquinone oxidoreductase (complex I) Aop:3 Event:888 MolecularInitiatingEvent Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) Aop:3 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:3 Event:889 KeyEvent Proteostasis, impaired Aop:3 Event:188 KeyEvent Neuroinflammation Aop:3 Event:890 KeyEvent Degeneration of dopaminergic neurons of the nigrostriatal pathway Aop:3 Event:896 AdverseOutcome Parkinsonian motor deficits Aop:4 Event:103 MolecularInitiatingEvent Increase, Ecdysone receptor hyperactivation Aop:4 Event:988 KeyEvent Decrease, Circulating ecdysis triggering hormone Aop:4 Event:1264 KeyEvent Increase, Nuclear receptor E75b gene expression Aop:4 Event:1265 KeyEvent Decrease, Fushi tarazu factor-1 gene expression Aop:4 Event:1266 KeyEvent Decrease, Circulating crustacean cardioactive peptide Aop:4 Event:1267 KeyEvent Decrease, Ecdysis motor program activity Aop:4 Event:993 KeyEvent Decrease, Abdominal muscle contraction Aop:4 Event:990 AdverseOutcome Increase, Incomplete ecdysis Aop:4 Event:350 AdverseOutcome Increase, Mortality Aop:6 Event:858 KeyEvent Decreased, PPARalpha transactivation of gene expression Aop:6 Event:861 KeyEvent Decreased, Ketogenesis (production of ketone bodies) Aop:6 Event:862 KeyEvent Not Increased, Circulating Ketone Bodies Aop:6 Event:864 AdverseOutcome Decreased, Body Weight Aop:6 Event:863 KeyEvent Increased, Catabolism of Muscle Protein Aop:6 Event:998 MolecularInitiatingEvent Binding of antagonist, PPAR alpha Aop:6 Event:1000 KeyEvent stabilization, PPAR alpha co-repressor Aop:6 Event:1528 KeyEvent Fatty Acid Beta Oxidation, Decreased Aop:7 Event:219 KeyEvent Reduction, Plasma 17beta-estradiol concentrations Aop:7 Event:3 KeyEvent Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Aop:7 Event:406 AdverseOutcome decreased, Fertility Aop:7 Event:405 AdverseOutcome disrupted, ovarian cycle Aop:7 Event:408 MolecularInitiatingEvent reduction in ovarian granulosa cells, Aromatase (Cyp19a1) Aop:8 Event:239 MolecularInitiatingEvent Activation, Pregnane-X receptor, NR1l2 Aop:8 Event:319 AdverseOutcome Loss, Cochlear function Aop:8 Event:280 KeyEvent Thyroxine (T4) in neuronal tissue, Decreased Aop:8 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:8 Event:295 KeyEvent Induction, Upregulation of glucuronyltransferase activity Aop:8 Event:757 KeyEvent Hippocampal anatomy, Altered Aop:8 Event:758 KeyEvent Hippocampal Physiology, Altered Aop:8 Event:756 KeyEvent Hippocampal gene expression, Altered Aop:8 Event:961 KeyEvent Increased, Clearance of thyroxine from serum Aop:10 Event:64 KeyEvent Reduction, Ionotropic GABA receptor chloride channel conductance Aop:10 Event:616 KeyEvent Occurrence, A paroxysmal depolarizing shift Aop:10 Event:613 AdverseOutcome Occurrence, Epileptic seizure Aop:10 Event:667 MolecularInitiatingEvent Binding at picrotoxin site, iGABAR chloride channel Aop:10 Event:669 KeyEvent Reduction, Neuronal synaptic inhibition Aop:10 Event:682 KeyEvent Generation, Amplified excitatory postsynaptic potential (EPSP) Aop:11 Event:245 MolecularInitiatingEvent Activation, PXR/SXR Aop:12 Event:195 KeyEvent Inhibition, NMDARs Aop:12 Event:352 AdverseOutcome N/A, Neurodegeneration Aop:12 Event:52 KeyEvent Decreased, Calcium influx Aop:12 Event:201 MolecularInitiatingEvent Binding of antagonist, NMDA receptors Aop:12 Event:381 KeyEvent Reduced levels of BDNF Aop:12 Event:55 KeyEvent Increase, Cell injury/death Aop:12 Event:188 KeyEvent Neuroinflammation Aop:12 Event:341 AdverseOutcome Impairment, Learning and memory Aop:13 Event:201 MolecularInitiatingEvent Binding of antagonist, NMDA receptors Aop:13 Event:52 KeyEvent Decreased, Calcium influx Aop:13 Event:195 KeyEvent Inhibition, NMDARs Aop:13 Event:341 AdverseOutcome Impairment, Learning and memory Aop:13 Event:381 KeyEvent Reduced levels of BDNF Aop:13 Event:382 KeyEvent Aberrant, Dendritic morphology Aop:13 Event:385 KeyEvent Decrease of synaptogenesis Aop:13 Event:386 KeyEvent Decrease of neuronal network function Aop:13 Event:383 KeyEvent Reduced, Presynaptic release of glutamate Aop:13 Event:55 KeyEvent Increase, Cell injury/death Aop:14 Event:122 MolecularInitiatingEvent Increase, Glucocorticoid receptor activation Aop:14 Event:202 KeyEvent Inhibition, Nuclear factor kappa B (NF-kB) Aop:14 Event:152 KeyEvent Suppression, Inflammatory cytokines Aop:14 Event:168 KeyEvent Decreased, Lymphocytes Aop:14 Event:145 KeyEvent Induction, IKB inhibitory protein Aop:14 Event:323 AdverseOutcome Increased, Disease susceptibility Aop:14 Event:403 KeyEvent Suppression, Immune system Aop:15 Event:336 AdverseOutcome Increase, Heritable mutations in offspring Aop:15 Event:97 MolecularInitiatingEvent Alkylation, DNA Aop:15 Event:185 KeyEvent Increase, Mutations Aop:15 Event:155 KeyEvent Inadequate DNA repair Aop:16 Event:351 AdverseOutcome Increased Mortality Aop:16 Event:12 MolecularInitiatingEvent Acetylcholinesterase (AchE) Inhibition Aop:16 Event:10 KeyEvent Acetylcholine accumulation in synapses Aop:16 Event:445 KeyEvent Respiratory distress/arrest Aop:16 Event:39 KeyEvent Increased Cholinergic Signaling Aop:16 Event:1703 KeyEvent Dysregulation of heart rate and vascular tone Aop:16 Event:360 AdverseOutcome Decrease, Population growth rate Aop:17 Event:1487 MolecularInitiatingEvent Binding, Thiol/seleno-proteins involved in protection against oxidative stress Aop:17 Event:1392 KeyEvent Increase, Oxidative Stress Aop:17 Event:1488 KeyEvent Glutamate dyshomeostasis Aop:17 Event:55 KeyEvent Increase, Cell injury/death Aop:17 Event:188 KeyEvent Neuroinflammation Aop:17 Event:386 KeyEvent Decrease of neuronal network function Aop:17 Event:341 AdverseOutcome Impairment, Learning and memory Aop:17 Event:1492 KeyEvent Tissue resident cell activation Aop:17 Event:1493 KeyEvent Increased Pro-inflammatory mediators Aop:17 Event:1538 KeyEvent Decreased protection against oxidative stress Aop:18 Event:227 MolecularInitiatingEvent Activation, PPARα Aop:18 Event:406 AdverseOutcome decreased, Fertility Aop:18 Event:266 KeyEvent Decrease, Steroidogenic acute regulatory protein (STAR) Aop:18 Event:447 KeyEvent Reduction, Cholesterol transport in mitochondria Aop:18 Event:413 KeyEvent Reduction, Testosterone synthesis in Leydig cells Aop:18 Event:289 KeyEvent Decrease, Translocator protein (TSPO) Aop:18 Event:348 AdverseOutcome Malformation, Male reproductive tract Aop:18 Event:1690 KeyEvent Decrease, circulating testosterone levels Aop:19 Event:310 KeyEvent Alteration, Wnt pathway Aop:19 Event:240 KeyEvent Feminisation or incomplete development, Primary and accessory male sex organs Aop:19 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:19 Event:337 AdverseOutcome N/A, Impairment of reproductive capacity Aop:19 Event:26 MolecularInitiatingEvent Antagonism, Androgen receptor Aop:21 Event:18 MolecularInitiatingEvent Activation, AhR Aop:21 Event:944 KeyEvent dimerization, AHR/ARNT Aop:21 Event:317 KeyEvent Altered, Cardiovascular development/function Aop:21 Event:1269 KeyEvent Increase, COX-2 expression Aop:21 Event:947 KeyEvent Increase, Early Life Stage Mortality Aop:23 Event:360 AdverseOutcome Decrease, Population growth rate Aop:23 Event:25 MolecularInitiatingEvent Agonism, Androgen receptor Aop:23 Event:274 KeyEvent Reduction, Testosterone synthesis by ovarian theca cells Aop:23 Event:3 KeyEvent Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Aop:23 Event:219 KeyEvent Reduction, Plasma 17beta-estradiol concentrations Aop:23 Event:285 KeyEvent Reduction, Vitellogenin synthesis in liver Aop:23 Event:78 KeyEvent Reduction, Cumulative fecundity and spawning Aop:23 Event:221 KeyEvent Reduction, Plasma vitellogenin concentrations Aop:23 Event:309 KeyEvent Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Aop:23 Event:129 KeyEvent Reduction, Gonadotropins, circulating concentrations Aop:25 Event:360 AdverseOutcome Decrease, Population growth rate Aop:25 Event:36 MolecularInitiatingEvent Inhibition, Aromatase Aop:25 Event:219 KeyEvent Reduction, Plasma 17beta-estradiol concentrations Aop:25 Event:285 KeyEvent Reduction, Vitellogenin synthesis in liver Aop:25 Event:309 KeyEvent Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Aop:25 Event:3 KeyEvent Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Aop:25 Event:78 KeyEvent Reduction, Cumulative fecundity and spawning Aop:25 Event:221 KeyEvent Reduction, Plasma vitellogenin concentrations Aop:26 Event:51 MolecularInitiatingEvent Inhibition, Ca++ ATPase Aop:26 Event:50 KeyEvent Increase, Ca++ (intracellular) Aop:26 Event:178 KeyEvent Mitochondrial electron transport chain, disrupted Aop:26 Event:40 KeyEvent Mitochondrial ATP production, decreased Aop:26 Event:193 KeyEvent Decreased, Nitric Oxide Aop:26 Event:166 KeyEvent Decreased, Long-term potentiation (LTP) Aop:26 Event:1392 AdverseOutcome Increase, Oxidative Stress Aop:26 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:27 Event:41 MolecularInitiatingEvent Inhibition, Bile Salt Export Pump (ABCB11) Aop:27 Event:288 KeyEvent Activation of specific nuclear receptors, Transcriptional change Aop:27 Event:214 KeyEvent Bile accumulation, Pathological condition Aop:27 Event:87 KeyEvent Release, Cytokine Aop:27 Event:149 KeyEvent Increase, Inflammation Aop:27 Event:209 KeyEvent Peptide Oxidation Aop:27 Event:357 AdverseOutcome Cholestasis, Pathology Aop:27 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:28 Event:79 MolecularInitiatingEvent Inhibition, Cyclooxygenase activity Aop:28 Event:243 KeyEvent Reduction, Prostaglandin E2 concentration Aop:28 Event:49 KeyEvent Reduction, Ca and HCO3 transport to shell gland Aop:28 Event:106 KeyEvent Reduction, Eggshell thickness Aop:28 Event:119 KeyEvent N/A, Gap Aop:28 Event:253 AdverseOutcome N/A, Reproductive failure Aop:29 Event:111 MolecularInitiatingEvent Agonism, Estrogen receptor Aop:29 Event:78 KeyEvent Reduction, Cumulative fecundity and spawning Aop:29 Event:220 KeyEvent Increase, Plasma vitellogenin concentrations Aop:29 Event:307 KeyEvent Increase, Vitellogenin synthesis in liver Aop:29 Event:252 KeyEvent Increase, Renal pathology due to VTG deposition Aop:29 Event:360 AdverseOutcome Decrease, Population growth rate Aop:29 Event:363 AdverseOutcome Altered, Reproductive behaviour Aop:29 Event:339 AdverseOutcome Altered, Larval development Aop:29 Event:364 AdverseOutcome Impaired development of, Reproductive organs Aop:30 Event:360 AdverseOutcome Decrease, Population growth rate Aop:30 Event:112 MolecularInitiatingEvent Antagonism, Estrogen receptor Aop:30 Event:285 KeyEvent Reduction, Vitellogenin synthesis in liver Aop:30 Event:221 KeyEvent Reduction, Plasma vitellogenin concentrations Aop:30 Event:309 KeyEvent Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Aop:30 Event:78 KeyEvent Reduction, Cumulative fecundity and spawning Aop:31 Event:213 MolecularInitiatingEvent N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III) Aop:31 Event:21 KeyEvent Altered regulation, Alpha hemoglobin Aop:31 Event:250 KeyEvent Damaging, Red blood cells; hemolysis Aop:31 Event:118 KeyEvent Formation, Formation of hemoglobin adducts Aop:31 Event:131 KeyEvent Down Regulation, Gulcose-6-phosphate dehydrogenase Aop:31 Event:246 KeyEvent Increase, RBC congestion in liver Aop:31 Event:161 KeyEvent Increase, Liver and splenic hemosiderosis Aop:31 Event:173 KeyEvent N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number Aop:31 Event:321 AdverseOutcome N/A, Cyanosis occurs Aop:31 Event:1392 KeyEvent Increase, Oxidative Stress Aop:32 Event:77 KeyEvent Production, Critical Metabolites (CGA 330050 and CGA 265307) Aop:32 Event:164 KeyEvent Induction, Liver “Dysfunctional” Changes by CGA 330050 Aop:32 Event:147 KeyEvent Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 Aop:32 Event:270 KeyEvent Induction, Sustained Hepatotoxicity Aop:32 Event:269 KeyEvent Induction, Sustained Cell Proliferation Aop:32 Event:347 KeyEvent Formation, Liver tumor Aop:33 Event:9 MolecularInitiatingEvent Activation, 5HT2c Aop:33 Event:759 AdverseOutcome Increased, Kidney Failure Aop:33 Event:294 KeyEvent N/A, Unknown Aop:34 Event:167 MolecularInitiatingEvent Activation, LXR Aop:34 Event:54 KeyEvent Up Regulation, CD36 Aop:34 Event:115 KeyEvent Increase, Fatty acid influx Aop:34 Event:66 KeyEvent Activation, ChREBP Aop:34 Event:264 KeyEvent Activation, SREBP-1c Aop:34 Event:116 KeyEvent Activation, FAS Aop:34 Event:258 KeyEvent Activation, SCD-1 Aop:34 Event:89 KeyEvent Synthesis, De Novo Fatty Acid (FA) Aop:34 Event:291 KeyEvent Accumulation, Triglyceride Aop:34 Event:345 AdverseOutcome N/A, Liver Steatosis Aop:34 Event:228 MolecularInitiatingEvent peroxisome proliferator activated receptor promoter demethylation Aop:34 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:35 Event:46 MolecularInitiatingEvent Accumulation, Biological membranes Aop:35 Event:169 KeyEvent Disruption, Membrane integrity Aop:36 Event:231 MolecularInitiatingEvent Decreased, PPAR-alpha activation Aop:36 Event:232 MolecularInitiatingEvent Decreased, PPAR-beta activation Aop:36 Event:233 MolecularInitiatingEvent Decreased, PPAR-gamma activation Aop:36 Event:327 KeyEvent Accumulation, Fatty acid Aop:36 Event:140 KeyEvent Decreased, HSD17B10 expression Aop:36 Event:179 KeyEvent Decrease, Fatty acid beta-oxidation Aop:36 Event:8 KeyEvent Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity Aop:36 Event:459 AdverseOutcome Increase, Liver steatosis Aop:37 Event:227 MolecularInitiatingEvent Activation, PPARα Aop:37 Event:1170 KeyEvent Increase, Phenotypic enzyme activity Aop:37 Event:716 KeyEvent Increase, cell proliferation (hepatocytes) Aop:37 Event:1171 KeyEvent Increase, Clonal Expansion of Altered Hepatic Foci Aop:37 Event:719 AdverseOutcome Increase, hepatocellular adenomas and carcinomas Aop:38 Event:344 AdverseOutcome Increase, Liver fibrosis Aop:38 Event:244 MolecularInitiatingEvent Alkylation, Protein Aop:38 Event:55 KeyEvent Increase, Cell injury/death Aop:38 Event:265 KeyEvent Increase, Hepatic stellate cell activation Aop:38 Event:68 KeyEvent Increase, Collagen accumulation Aop:38 Event:1492 KeyEvent Tissue resident cell activation Aop:38 Event:1493 KeyEvent Increased Pro-inflammatory mediators Aop:39 Event:313 AdverseOutcome Increase, Allergic Respiratory Hypersensitivity Response Aop:39 Event:398 KeyEvent Activation, Dendritic Cells Aop:39 Event:272 KeyEvent Activation/Proliferation, T-cells Aop:39 Event:396 MolecularInitiatingEvent Covalent Binding, Protein Aop:39 Event:1496 KeyEvent Increased, secretion of proinflammatory mediators Aop:40 Event:396 MolecularInitiatingEvent Covalent Binding, Protein Aop:40 Event:827 AdverseOutcome sensitisation, skin Aop:40 Event:826 KeyEvent Activation, Keratinocytes Aop:40 Event:398 KeyEvent Activation, Dendritic Cells Aop:40 Event:272 KeyEvent Activation/Proliferation, T-cells Aop:41 Event:139 KeyEvent N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects Aop:41 Event:165 MolecularInitiatingEvent Activation, Long term AHR receptor driven direct and indirect gene expression changes Aop:41 Event:853 KeyEvent Changes/Inhibition, Cellular Homeostasis and Apoptosis Aop:41 Event:854 KeyEvent Alterations, Cellular proliferation / hyperplasia Aop:41 Event:856 AdverseOutcome Formation, Hepatocellular and Bile duct tumors Aop:42 Event:279 MolecularInitiatingEvent Thyroperoxidase, Inhibition Aop:42 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:42 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:42 Event:280 KeyEvent Thyroxine (T4) in neuronal tissue, Decreased Aop:42 Event:402 AdverseOutcome Cognitive function, decreased Aop:42 Event:756 KeyEvent Hippocampal gene expression, Altered Aop:42 Event:757 KeyEvent Hippocampal anatomy, Altered Aop:42 Event:758 KeyEvent Hippocampal Physiology, Altered Aop:43 Event:305 MolecularInitiatingEvent Inhibition, VegfR2 Aop:43 Event:28 KeyEvent Reduction, Angiogenesis Aop:43 Event:110 KeyEvent Impairment, Endothelial network Aop:43 Event:298 KeyEvent Insufficiency, Vascular Aop:43 Event:1001 AdverseOutcome Increased, Developmental Defects Aop:46 Event:373 MolecularInitiatingEvent Formation, Pro-mutagenic DNA Adducts Aop:46 Event:378 AdverseOutcome Tumorigenesis, Hepatocellular carcinoma Aop:46 Event:376 KeyEvent Increased, Induced Mutations in Critical Genes Aop:46 Event:409 KeyEvent Metabolism of AFB1, Production of Reactive Electrophiles Aop:46 Event:491 KeyEvent Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) Aop:46 Event:493 KeyEvent Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts Aop:48 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:48 Event:341 AdverseOutcome Impairment, Learning and memory Aop:48 Event:55 KeyEvent Increase, Cell injury/death Aop:48 Event:352 KeyEvent N/A, Neurodegeneration Aop:48 Event:388 KeyEvent Overactivation, NMDARs Aop:48 Event:389 KeyEvent Increased, Intracellular Calcium overload Aop:48 Event:618 KeyEvent Decreased, Neuronal network function in adult brain Aop:48 Event:875 MolecularInitiatingEvent Binding of agonist, Ionotropic glutamate receptors Aop:48 Event:188 KeyEvent Neuroinflammation Aop:51 Event:406 AdverseOutcome decreased, Fertility Aop:51 Event:414 KeyEvent Increase, Luteinizing hormone (LH) Aop:51 Event:415 KeyEvent Hyperplasia, Leydig cell Aop:51 Event:416 KeyEvent Increase proliferation, Leydig cell Aop:51 Event:227 MolecularInitiatingEvent Activation, PPARα Aop:51 Event:413 KeyEvent Reduction, Testosterone synthesis in Leydig cells Aop:51 Event:447 KeyEvent Reduction, Cholesterol transport in mitochondria Aop:51 Event:1690 KeyEvent Decrease, circulating testosterone levels Aop:52 Event:111 MolecularInitiatingEvent Agonism, Estrogen receptor Aop:52 Event:417 AdverseOutcome skewed, sex ratio Aop:53 Event:111 MolecularInitiatingEvent Agonism, Estrogen receptor Aop:53 Event:418 KeyEvent Increased, Vitellogenin synthesis Aop:53 Event:220 KeyEvent Increase, Plasma vitellogenin concentrations Aop:53 Event:419 KeyEvent Increased, renal vitellogenin deposition Aop:53 Event:421 KeyEvent Increased, glomerular rupture and renal hemorrhaging Aop:53 Event:422 KeyEvent Increased, nephropathy Aop:54 Event:425 KeyEvent Decrease of Thyroidal iodide Aop:54 Event:280 KeyEvent Thyroxine (T4) in neuronal tissue, Decreased Aop:54 Event:381 KeyEvent Reduced levels of BDNF Aop:54 Event:385 KeyEvent Decrease of synaptogenesis Aop:54 Event:341 AdverseOutcome Impairment, Learning and memory Aop:54 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:54 Event:851 KeyEvent Decrease of GABAergic interneurons Aop:54 Event:424 MolecularInitiatingEvent Inhibition, Na+/I- symporter (NIS) Aop:54 Event:386 KeyEvent Decrease of neuronal network function Aop:54 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:57 Event:18 MolecularInitiatingEvent Activation, AhR Aop:57 Event:450 KeyEvent Decrease, Very low-density lipoprotein export capacity Aop:57 Event:451 KeyEvent Inhibition, Mitochondrial fatty acid beta-oxidation Aop:57 Event:327 KeyEvent Accumulation, Fatty acid Aop:57 Event:216 KeyEvent Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) Aop:57 Event:291 KeyEvent Accumulation, Triglyceride Aop:57 Event:54 KeyEvent Up Regulation, CD36 Aop:57 Event:465 KeyEvent Increased, Fatty acid influx Aop:57 Event:466 KeyEvent Up Regulation, LDLR (low density lipoprotein receptor) Aop:57 Event:467 KeyEvent Increased, LDL uptake Aop:57 Event:80 KeyEvent Up Regulation, CYP1A1 Aop:57 Event:462 KeyEvent Up Regulation, SCD-1 Aop:57 Event:459 AdverseOutcome Increase, Liver steatosis Aop:58 Event:456 MolecularInitiatingEvent Suppression, Constitutive androstane receptor, NR1l3 Aop:58 Event:457 KeyEvent Activation, SREBF1 Aop:58 Event:66 KeyEvent Activation, ChREBP Aop:58 Event:458 KeyEvent Increased, De Novo FA synthesis Aop:58 Event:459 AdverseOutcome Increase, Liver steatosis Aop:58 Event:454 KeyEvent Increased, Triglyceride formation Aop:58 Event:54 KeyEvent Up Regulation, CD36 Aop:58 Event:462 KeyEvent Up Regulation, SCD-1 Aop:58 Event:463 KeyEvent Up Regulation, FAS Aop:58 Event:468 MolecularInitiatingEvent Inhibition, PPAR alpha Aop:58 Event:167 MolecularInitiatingEvent Activation, LXR Aop:58 Event:228 MolecularInitiatingEvent peroxisome proliferator activated receptor promoter demethylation Aop:58 Event:451 KeyEvent Inhibition, Mitochondrial fatty acid beta-oxidation Aop:58 Event:327 KeyEvent Accumulation, Fatty acid Aop:58 Event:470 KeyEvent Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) Aop:58 Event:465 KeyEvent Increased, Fatty acid influx Aop:59 Event:461 MolecularInitiatingEvent Suppression, HNF4alpha Aop:60 Event:245 MolecularInitiatingEvent Activation, PXR/SXR Aop:60 Event:459 AdverseOutcome Increase, Liver steatosis Aop:60 Event:471 KeyEvent Inhibition, FoxA2 Aop:60 Event:179 KeyEvent Decrease, Fatty acid beta-oxidation Aop:60 Event:472 KeyEvent Down Regulation, CPT1A Aop:60 Event:474 KeyEvent Down Regulation, HMGCS2 Aop:60 Event:462 KeyEvent Up Regulation, SCD-1 Aop:60 Event:54 KeyEvent Up Regulation, CD36 Aop:60 Event:465 KeyEvent Increased, Fatty acid influx Aop:60 Event:477 KeyEvent Decreased, Ketogenesis Aop:60 Event:454 KeyEvent Increased, Triglyceride formation Aop:60 Event:327 KeyEvent Accumulation, Fatty acid Aop:61 Event:478 MolecularInitiatingEvent Activation, NRF2 Aop:61 Event:479 MolecularInitiatingEvent Activation, NR1H4 Aop:61 Event:480 KeyEvent Activation, SHP Aop:61 Event:227 KeyEvent Activation, PPARα Aop:61 Event:482 KeyEvent Decreased, DHB4/HSD17B4 Aop:61 Event:451 KeyEvent Inhibition, Mitochondrial fatty acid beta-oxidation Aop:61 Event:483 KeyEvent Activation, LXR alpha Aop:61 Event:459 AdverseOutcome Increase, Liver steatosis Aop:61 Event:878 KeyEvent Inhibition, SREBP1c Aop:61 Event:879 KeyEvent Activation, MTTP Aop:61 Event:880 KeyEvent Increased, ApoB100 Aop:61 Event:881 KeyEvent Increased, Triglyceride Aop:61 Event:458 KeyEvent Increased, De Novo FA synthesis Aop:62 Event:484 KeyEvent Activation, AKT2 Aop:62 Event:459 AdverseOutcome Increase, Liver steatosis Aop:62 Event:486 MolecularInitiatingEvent systemic inflammation leading to hepatic steatosis Aop:62 Event:457 KeyEvent Activation, SREBF1 Aop:63 Event:675 AdverseOutcome Reduced, Reproductive Success Aop:63 Event:79 MolecularInitiatingEvent Inhibition, Cyclooxygenase activity Aop:63 Event:488 KeyEvent Decrease, Ovulation Aop:63 Event:685 KeyEvent Reduced, Prostaglandins, ovary Aop:63 Event:360 AdverseOutcome Decrease, Population growth rate Aop:64 Event:494 MolecularInitiatingEvent Glucocorticoid Receptor Agonist, Activation Aop:64 Event:495 KeyEvent Repressed expression of steroidogenic enzymes Aop:64 Event:496 KeyEvent Increased apoptosis, decreased fetal/adult Leydig Cells Aop:64 Event:413 KeyEvent Reduction, Testosterone synthesis in Leydig cells Aop:64 Event:520 KeyEvent Decreased sperm quantity or quality in the adult, Decreased fertility Aop:64 Event:406 AdverseOutcome decreased, Fertility Aop:64 Event:1690 KeyEvent Decrease, circulating testosterone levels Aop:65 Event:424 MolecularInitiatingEvent Inhibition, Na+/I- symporter (NIS) Aop:65 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:65 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:65 Event:280 KeyEvent Thyroxine (T4) in neuronal tissue, Decreased Aop:65 Event:186 KeyEvent Altered, Neuroanatomy Aop:65 Event:192 KeyEvent Altered, Neurophysiology Aop:65 Event:402 AdverseOutcome Cognitive function, decreased Aop:66 Event:505 AdverseOutcome Decreased sperm quantity / quality in the adult, Decreased fertility Aop:66 Event:653 MolecularInitiatingEvent Decreased testosterone by the fetal Leydig cells, Increased corticosterone Aop:66 Event:654 MolecularInitiatingEvent Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid receptor agonists Aop:66 Event:655 KeyEvent Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells Aop:66 Event:656 KeyEvent Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) Aop:66 Event:657 KeyEvent Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells Aop:67 Event:505 AdverseOutcome Decreased sperm quantity / quality in the adult, Decreased fertility Aop:67 Event:658 MolecularInitiatingEvent Decreased testosterone by the fetal Leydig cells, Increased estradiol Aop:67 Event:659 MolecularInitiatingEvent Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists Aop:67 Event:655 KeyEvent Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells Aop:67 Event:660 KeyEvent decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells Aop:67 Event:656 KeyEvent Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) Aop:68 Event:505 AdverseOutcome Decreased sperm quantity / quality in the adult, Decreased fertility Aop:68 Event:661 MolecularInitiatingEvent Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome Aop:68 Event:655 KeyEvent Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells Aop:68 Event:657 KeyEvent Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells Aop:68 Event:656 KeyEvent Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) Aop:69 Event:642 MolecularInitiatingEvent Decreased Cholesterol, Decreased De Novo Biosynthesis of Choleseterol Aop:69 Event:643 MolecularInitiatingEvent Decreased Cholesterol, Decreased Uptake of Lipoproteins Aop:69 Event:644 MolecularInitiatingEvent Decreased Cholesterol, Decreased Transport of Cholesterol to the Inner Mitochondrial Membrane Aop:69 Event:645 KeyEvent Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells Aop:69 Event:646 AdverseOutcome Decreased Cholesterol, Decreased sperm quantity and/or quality in the adult testis Aop:70 Event:520 AdverseOutcome Decreased sperm quantity or quality in the adult, Decreased fertility Aop:70 Event:640 MolecularInitiatingEvent Decreased steroidogenesis, Proteomic alterations in the adult Leydig cell Aop:70 Event:647 KeyEvent Decreased, steroidogenic protein expression Aop:70 Event:648 KeyEvent Decreased steroidogenesis, Increased Apoptosis of Adult Leydig Cells Aop:70 Event:649 KeyEvent Decreased steroidogenesis, Alterations in the Leydig Cell Cytoskeleton Aop:71 Event:525 KeyEvent Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells Aop:71 Event:520 AdverseOutcome Decreased sperm quantity or quality in the adult, Decreased fertility Aop:71 Event:650 MolecularInitiatingEvent Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid Aop:71 Event:651 KeyEvent Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testosterone by adult Leydig cells Aop:71 Event:652 KeyEvent Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig cells Aop:72 Event:228 MolecularInitiatingEvent peroxisome proliferator activated receptor promoter demethylation Aop:72 Event:1028 KeyEvent Activation of specific nuclear receptors, PPAR-gamma activation Aop:72 Event:1447 AdverseOutcome obesity Aop:72 Event:1448 KeyEvent activation of CCAAT/enhancer-binding protein alpha Aop:72 Event:1449 KeyEvent increased adipogenesis Aop:72 Event:1450 KeyEvent decreased dopamine Aop:72 Event:1451 KeyEvent decreased reward Aop:72 Event:1452 KeyEvent decreased DNA methylation of tyrosine hydroxylase Aop:72 Event:1453 KeyEvent decreased methylation of dopamine transporter promoter Aop:72 Event:1454 MolecularInitiatingEvent chronic high fat diet Aop:73 Event:526 MolecularInitiatingEvent Inhibition, Inhibition of Dopamine-beta-hydroxylase Aop:73 Event:527 AdverseOutcome Decreased, Decreased fecundity Aop:73 Event:528 KeyEvent Decreased, Synthesis of NE Aop:73 Event:529 KeyEvent Decreased, GnRH cfos activity Aop:73 Event:530 KeyEvent Decreased, GnRH pulsatility/release Aop:73 Event:531 KeyEvent Decreased, LH Surge Aop:73 Event:532 KeyEvent Delayed, Ovulation Aop:73 Event:533 KeyEvent Decreased, Cortical granule release/distribution upon fertilization Aop:73 Event:534 KeyEvent Altered, Formation of cortical envelope Aop:73 Event:535 KeyEvent Abnormal, Sperm penetration (polyspermy) Aop:73 Event:536 KeyEvent Altered, Chromosome number (polyploid) zygote Aop:74 Event:543 AdverseOutcome Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult testis Aop:74 Event:662 MolecularInitiatingEvent Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis Aop:74 Event:655 KeyEvent Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells Aop:74 Event:540 KeyEvent Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells Aop:74 Event:541 KeyEvent Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells Aop:77 Event:559 MolecularInitiatingEvent Activation, Nicotinic acetylcholine receptor Aop:77 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:77 Event:341 KeyEvent Impairment, Learning and memory Aop:77 Event:560 KeyEvent Abnormal, Foraging activity and behavior Aop:77 Event:563 AdverseOutcome Death/Failure, Colony Aop:77 Event:1107 KeyEvent Weakened, Colony Aop:77 Event:1243 KeyEvent Altered, Ca2+-calmodulin activated signal transduction Aop:78 Event:559 MolecularInitiatingEvent Activation, Nicotinic acetylcholine receptor Aop:78 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:78 Event:386 KeyEvent Decrease of neuronal network function Aop:78 Event:341 KeyEvent Impairment, Learning and memory Aop:78 Event:564 KeyEvent Abnormal, Roll change within caste Aop:78 Event:565 KeyEvent Reduced, Brood care Aop:78 Event:566 AdverseOutcome impaired, Larval development Aop:78 Event:563 AdverseOutcome Death/Failure, Colony Aop:79 Event:559 MolecularInitiatingEvent Activation, Nicotinic acetylcholine receptor Aop:79 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:79 Event:563 AdverseOutcome Death/Failure, Colony Aop:79 Event:568 KeyEvent impaired, Hive thermoregulation Aop:79 Event:1107 KeyEvent Weakened, Colony Aop:80 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:80 Event:570 KeyEvent Accumulation, Damaged mitochondrial DNA Aop:80 Event:571 KeyEvent Accelerated, Aging Aop:80 Event:572 AdverseOutcome Decrease, Number of worker bees Aop:80 Event:568 AdverseOutcome impaired, Hive thermoregulation Aop:80 Event:563 AdverseOutcome Death/Failure, Colony Aop:80 Event:664 KeyEvent Overwhelmed, Mitochondrial DNA repair mechanisms Aop:80 Event:559 MolecularInitiatingEvent Activation, Nicotinic acetylcholine receptor Aop:81 Event:573 KeyEvent Increase, Energetic demands and therefore metabolic stress Aop:81 Event:574 KeyEvent Increased, Appetite and hunger Aop:81 Event:560 KeyEvent Abnormal, Foraging activity and behavior Aop:81 Event:572 AdverseOutcome Decrease, Number of worker bees Aop:81 Event:563 AdverseOutcome Death/Failure, Colony Aop:82 Event:564 KeyEvent Abnormal, Roll change within caste Aop:82 Event:565 KeyEvent Reduced, Brood care Aop:82 Event:566 AdverseOutcome impaired, Larval development Aop:82 Event:563 AdverseOutcome Death/Failure, Colony Aop:84 Event:403 KeyEvent Suppression, Immune system Aop:84 Event:576 KeyEvent Increased, Viral susceptibility Aop:84 Event:577 KeyEvent impaired, Development Aop:84 Event:572 AdverseOutcome Decrease, Number of worker bees Aop:84 Event:568 AdverseOutcome impaired, Hive thermoregulation Aop:84 Event:563 AdverseOutcome Death/Failure, Colony Aop:85 Event:403 KeyEvent Suppression, Immune system Aop:85 Event:576 KeyEvent Increased, Viral susceptibility Aop:85 Event:560 KeyEvent Abnormal, Foraging activity and behavior Aop:85 Event:572 AdverseOutcome Decrease, Number of worker bees Aop:85 Event:563 AdverseOutcome Death/Failure, Colony Aop:86 Event:578 KeyEvent Decreased, Glucose oxidase enzyme activity Aop:86 Event:579 KeyEvent Decreased, Hydrogen peroxide production Aop:86 Event:580 KeyEvent Reduced, Antiseptic incorporated in food Aop:86 Event:564 KeyEvent Abnormal, Roll change within caste Aop:86 Event:561 KeyEvent Reduced, Food storage Aop:86 Event:566 AdverseOutcome impaired, Larval development Aop:86 Event:563 AdverseOutcome Death/Failure, Colony Aop:87 Event:559 MolecularInitiatingEvent Activation, Nicotinic acetylcholine receptor Aop:87 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:87 Event:341 KeyEvent Impairment, Learning and memory Aop:87 Event:560 KeyEvent Abnormal, Foraging activity and behavior Aop:87 Event:563 AdverseOutcome Death/Failure, Colony Aop:87 Event:1107 KeyEvent Weakened, Colony Aop:87 Event:1108 KeyEvent Abnormal, Role change within caste Aop:87 Event:1243 KeyEvent Altered, Ca2+-calmodulin activated signal transduction Aop:88 Event:559 MolecularInitiatingEvent Activation, Nicotinic acetylcholine receptor Aop:88 Event:341 KeyEvent Impairment, Learning and memory Aop:88 Event:563 AdverseOutcome Death/Failure, Colony Aop:88 Event:560 KeyEvent Abnormal, Foraging activity and behavior Aop:88 Event:663 KeyEvent Desensitization, Nicotinic acetylcholine receptor Aop:88 Event:1107 KeyEvent Weakened, Colony Aop:88 Event:1243 KeyEvent Altered, Ca2+-calmodulin activated signal transduction Aop:89 Event:559 MolecularInitiatingEvent Activation, Nicotinic acetylcholine receptor Aop:89 Event:341 KeyEvent Impairment, Learning and memory Aop:89 Event:563 AdverseOutcome Death/Failure, Colony Aop:89 Event:560 KeyEvent Abnormal, Foraging activity and behavior Aop:89 Event:663 KeyEvent Desensitization, Nicotinic acetylcholine receptor Aop:89 Event:1107 KeyEvent Weakened, Colony Aop:89 Event:1108 KeyEvent Abnormal, Role change within caste Aop:89 Event:1243 KeyEvent Altered, Ca2+-calmodulin activated signal transduction Aop:90 Event:559 MolecularInitiatingEvent Activation, Nicotinic acetylcholine receptor Aop:90 Event:341 KeyEvent Impairment, Learning and memory Aop:90 Event:564 KeyEvent Abnormal, Roll change within caste Aop:90 Event:565 KeyEvent Reduced, Brood care Aop:90 Event:566 AdverseOutcome impaired, Larval development Aop:90 Event:563 AdverseOutcome Death/Failure, Colony Aop:90 Event:663 KeyEvent Desensitization, Nicotinic acetylcholine receptor Aop:90 Event:386 KeyEvent Decrease of neuronal network function Aop:91 Event:584 MolecularInitiatingEvent Inhibition, sodium channel Aop:91 Event:585 KeyEvent Decreased, Sodium conductance 1 Aop:91 Event:586 KeyEvent Reduced, swimming speed Aop:91 Event:587 AdverseOutcome Reduced, feeding 1 Aop:91 Event:588 AdverseOutcome Increased, predation Aop:91 Event:592 AdverseOutcome Reduced, survival Aop:93 Event:585 KeyEvent Decreased, Sodium conductance 1 Aop:93 Event:586 KeyEvent Reduced, swimming speed Aop:93 Event:588 AdverseOutcome Increased, predation Aop:93 Event:584 MolecularInitiatingEvent Inhibition, sodium channel Aop:94 Event:584 MolecularInitiatingEvent Inhibition, sodium channel Aop:94 Event:444 KeyEvent Increased, Atrioventricular block and bradycardia Aop:94 Event:445 KeyEvent Respiratory distress/arrest Aop:94 Event:590 KeyEvent N/A, hypoxia Aop:94 Event:591 AdverseOutcome Increased, amputations Aop:94 Event:585 KeyEvent Decreased, Sodium conductance 1 Aop:95 Event:585 KeyEvent Decreased, Sodium conductance 1 Aop:95 Event:586 KeyEvent Reduced, swimming speed Aop:95 Event:587 KeyEvent Reduced, feeding 1 Aop:95 Event:588 KeyEvent Increased, predation Aop:95 Event:592 AdverseOutcome Reduced, survival Aop:95 Event:593 MolecularInitiatingEvent Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel Aop:96 Event:598 MolecularInitiatingEvent modulation, sodium channel Aop:96 Event:599 KeyEvent prolonged, Depolarization of neuronal membrane Aop:96 Event:600 KeyEvent Overactivation, Neuronotransmitter release Aop:96 Event:601 KeyEvent Overactivation, muscle contraction Aop:96 Event:602 KeyEvent Increased, Ataxia, paralysis, or hyperactivity Aop:96 Event:351 AdverseOutcome Increased Mortality Aop:97 Event:619 MolecularInitiatingEvent Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Aop:97 Event:623 AdverseOutcome Increase, predation Aop:97 Event:625 KeyEvent Increased, muscular waves in foot Aop:97 Event:1139 KeyEvent Increased, water retention in foot Aop:97 Event:1142 KeyEvent Increased, valve movement Aop:97 Event:1143 KeyEvent Depletion, energy reserves Aop:97 Event:624 KeyEvent Increased, foot detachment Aop:97 Event:622 KeyEvent Increased, locomotion Aop:97 Event:626 KeyEvent Increased, serotonin (5-HT) Aop:97 Event:360 AdverseOutcome Decrease, Population growth rate Aop:98 Event:619 MolecularInitiatingEvent Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Aop:98 Event:626 KeyEvent Increased, serotonin (5-HT) Aop:98 Event:627 KeyEvent Decreased, anxiety Aop:98 Event:629 KeyEvent Decreased, sheltering Aop:98 Event:588 AdverseOutcome Increased, predation Aop:99 Event:633 KeyEvent Decrease, histaminergic neuron excitation Aop:99 Event:634 KeyEvent N/A, sedation Aop:99 Event:635 KeyEvent Decreased, locomotion Aop:99 Event:636 AdverseOutcome Decreased, survival Aop:99 Event:588 AdverseOutcome Increased, predation Aop:99 Event:638 MolecularInitiatingEvent Antagonism, Histamine Receptor (H2) Aop:99 Event:341 KeyEvent Impairment, Learning and memory Aop:100 Event:79 MolecularInitiatingEvent Inhibition, Cyclooxygenase activity Aop:100 Event:671 KeyEvent Reduced, Prostaglandin F2alpha concentration, plasma Aop:100 Event:672 KeyEvent Reduced, Prostaglandin F2alpha synthesis, ovary Aop:100 Event:673 KeyEvent Reduced, Spawning behavior Aop:100 Event:674 KeyEvent Reduced, Ability to attract spawning mates Aop:100 Event:675 AdverseOutcome Reduced, Reproductive Success Aop:100 Event:360 AdverseOutcome Decrease, Population growth rate Aop:101 Event:79 MolecularInitiatingEvent Inhibition, Cyclooxygenase activity Aop:101 Event:674 KeyEvent Reduced, Ability to attract spawning mates Aop:101 Event:675 AdverseOutcome Reduced, Reproductive Success Aop:101 Event:678 KeyEvent Reduced, Pheromone release Aop:101 Event:681 KeyEvent Decreased, Prostaglandin F2alpha synthesis, ovary Aop:101 Event:671 KeyEvent Reduced, Prostaglandin F2alpha concentration, plasma Aop:101 Event:360 AdverseOutcome Decrease, Population growth rate Aop:102 Event:687 KeyEvent Reduced, Prostaglandin E2 concentration, hypothalamus Aop:102 Event:689 KeyEvent Reduced, Gonadotropin releasing hormone, hypothalamus Aop:102 Event:690 KeyEvent Reduced, Luteinizing hormone (LH), plasma Aop:102 Event:691 KeyEvent Reduced, Maturation inducing steroid, plasma Aop:102 Event:692 KeyEvent Reduced, Maturation inducing steroid receptor signalling, oocyte Aop:102 Event:694 KeyEvent Reduced, Meiotic prophase I/metaphase I transition, oocyte Aop:102 Event:693 KeyEvent Increased, cyclic adenosine monophosphate Aop:102 Event:675 AdverseOutcome Reduced, Reproductive Success Aop:102 Event:79 MolecularInitiatingEvent Inhibition, Cyclooxygenase activity Aop:102 Event:360 AdverseOutcome Decrease, Population growth rate Aop:103 Event:79 MolecularInitiatingEvent Inhibition, Cyclooxygenase activity Aop:103 Event:687 KeyEvent Reduced, Prostaglandin E2 concentration, hypothalamus Aop:103 Event:689 KeyEvent Reduced, Gonadotropin releasing hormone, hypothalamus Aop:103 Event:690 KeyEvent Reduced, Luteinizing hormone (LH), plasma Aop:103 Event:691 KeyEvent Reduced, Maturation inducing steroid, plasma Aop:103 Event:692 KeyEvent Reduced, Maturation inducing steroid receptor signalling, oocyte Aop:103 Event:695 KeyEvent Upregulated, Spindle assembly checkpoint protein Mad2-oocyte Aop:103 Event:696 KeyEvent Increased, Chromosome misseggregation Aop:103 Event:675 AdverseOutcome Reduced, Reproductive Success Aop:103 Event:360 AdverseOutcome Decrease, Population growth rate Aop:104 Event:697 MolecularInitiatingEvent impaired, ion channels Aop:104 Event:351 AdverseOutcome Increased Mortality Aop:104 Event:698 KeyEvent Altered, Action Potential Aop:104 Event:699 KeyEvent Increased, cardiac arrthymia Aop:105 Event:708 KeyEvent Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) Aop:105 Event:709 KeyEvent Increase, Cytotoxicity (renal tubular cell) Aop:105 Event:710 KeyEvent Increase, Regenerative cell proliferation (tubular epithelial cells) Aop:105 Event:713 AdverseOutcome Increase, Adenomas/carcinomas (renal tubular) Aop:105 Event:767 KeyEvent Increase, Hyperplasia (renal tubular cells) Aop:105 Event:714 MolecularInitiatingEvent Increased, Binding of chemicals to 2u (serum) Aop:106 Event:718 MolecularInitiatingEvent Binding, Tubulin Aop:106 Event:720 KeyEvent Disruption, Microtubule dynamics Aop:106 Event:721 KeyEvent Disorganization, Meiotic Spindle Aop:106 Event:728 AdverseOutcome Increase, Aneuploid offspring Aop:106 Event:752 KeyEvent Altered, Meiotic chromosome dynamics Aop:106 Event:723 KeyEvent Altered, Chromosome number Aop:107 Event:715 MolecularInitiatingEvent Activation, Constitutive androstane receptor Aop:107 Event:716 KeyEvent Increase, cell proliferation (hepatocytes) Aop:107 Event:719 AdverseOutcome Increase, hepatocellular adenomas and carcinomas Aop:107 Event:774 KeyEvent Increase, Preneoplastic foci (hepatocytes) Aop:107 Event:1214 KeyEvent Altered gene expression specific to CAR activation, Hepatocytes Aop:108 Event:719 AdverseOutcome Increase, hepatocellular adenomas and carcinomas Aop:108 Event:768 KeyEvent Increase, Cytotoxicity Aop:108 Event:209 KeyEvent Peptide Oxidation Aop:108 Event:726 KeyEvent Increased, Induction of pyruvate dehydrogenase (PDH) Aop:108 Event:724 MolecularInitiatingEvent Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme Aop:108 Event:769 KeyEvent Increase, Oxidative metabolism Aop:109 Event:733 KeyEvent Increase, Necrosis (terminal bronchiolar cells) Aop:109 Event:734 KeyEvent Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) Aop:109 Event:735 KeyEvent Increase, Hyperplasia (terminal bronchiolar cells) Aop:109 Event:736 AdverseOutcome Increase, Adenomas/carcinomas (bronchioloalveolar) Aop:109 Event:770 MolecularInitiatingEvent Increase, Cytotoxicity (club cells) Aop:110 Event:739 KeyEvent Increase, Hypertrophy and proliferation (follicular cell) Aop:110 Event:740 KeyEvent Increase, Hyperplasia (follicular cells) Aop:110 Event:741 AdverseOutcome Increase, Adenomas/carcinomas (follicular cell) Aop:110 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:110 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:110 Event:1023 KeyEvent Increased, Thyroid-stimulating hormone (TSH) Aop:110 Event:424 MolecularInitiatingEvent Inhibition, Na+/I- symporter (NIS) Aop:111 Event:743 KeyEvent Decreased, Testosterone binding to androgen receptor (hypothalamus) Aop:111 Event:744 KeyEvent Increase, Hyperplasia (Leydig cells) Aop:111 Event:745 AdverseOutcome Increase, Leydig cell tumors Aop:111 Event:754 KeyEvent Increased, Luteinizing hormone (LH) Aop:111 Event:1614 MolecularInitiatingEvent Decrease, androgen receptor activation Aop:112 Event:746 MolecularInitiatingEvent Increase, Dopaminergic activity Aop:112 Event:747 KeyEvent Decreased, Prolactin Aop:112 Event:749 KeyEvent Decreased, Progesterone from corpus luteum Aop:112 Event:772 KeyEvent Increase, Hyperplasia (glandular epithelial cells of endometrium) Aop:112 Event:773 AdverseOutcome Increase, Endometrial adenocarcinomas Aop:112 Event:111 KeyEvent Agonism, Estrogen receptor Aop:113 Event:760 MolecularInitiatingEvent Activation, Glutamate-gated chloride channel Aop:113 Event:761 KeyEvent Increased, Chloride conductance Aop:113 Event:763 KeyEvent hyperpolarisation, neuron Aop:113 Event:764 KeyEvent N/A, Ataxia, paralysis, or hyperactivity Aop:113 Event:351 AdverseOutcome Increased Mortality Aop:113 Event:765 AdverseOutcome Decreased, population 1 Aop:114 Event:766 MolecularInitiatingEvent Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme Aop:114 Event:775 KeyEvent Increased, Plasma tyrosine Aop:114 Event:776 KeyEvent Increase, Cytotoxicity (corneal cells) Aop:114 Event:777 KeyEvent Increase, Inflammation (corneal cells) Aop:114 Event:778 KeyEvent Increase, Regenerative cell proliferation (corneal cells) Aop:114 Event:779 AdverseOutcome Increase, Papillomas/carcinomas (squamous cells) Aop:115 Event:780 MolecularInitiatingEvent Increase, Cytotoxicity (epithelial cells) Aop:115 Event:149 KeyEvent Increase, Inflammation Aop:115 Event:781 KeyEvent Increase, Regenerative cell proliferation (forestomach epithelial cells) Aop:115 Event:782 KeyEvent Increase, Hyperplasia (forestomach epithelial cells) Aop:115 Event:779 AdverseOutcome Increase, Papillomas/carcinomas (squamous cells) Aop:116 Event:783 MolecularInitiatingEvent Increase, Cytotoxicity (tubular epithelial cells) Aop:116 Event:710 KeyEvent Increase, Regenerative cell proliferation (tubular epithelial cells) Aop:116 Event:784 KeyEvent Increase, Hyperplasia (tubular epithelial cells) Aop:116 Event:713 AdverseOutcome Increase, Adenomas/carcinomas (renal tubular) Aop:117 Event:716 KeyEvent Increase, cell proliferation (hepatocytes) Aop:117 Event:774 KeyEvent Increase, Preneoplastic foci (hepatocytes) Aop:117 Event:719 AdverseOutcome Increase, hepatocellular adenomas and carcinomas Aop:117 Event:25 MolecularInitiatingEvent Agonism, Androgen receptor Aop:118 Event:786 MolecularInitiatingEvent Increase, Cytotoxicity (hepatocytes) Aop:118 Event:787 KeyEvent Increase, Regenerative cell proliferation (hepatocytes) Aop:118 Event:774 KeyEvent Increase, Preneoplastic foci (hepatocytes) Aop:118 Event:719 AdverseOutcome Increase, hepatocellular adenomas and carcinomas Aop:119 Event:279 MolecularInitiatingEvent Thyroperoxidase, Inhibition Aop:119 Event:739 KeyEvent Increase, Hypertrophy and proliferation (follicular cell) Aop:119 Event:740 KeyEvent Increase, Hyperplasia (follicular cells) Aop:119 Event:741 AdverseOutcome Increase, Adenomas/carcinomas (follicular cell) Aop:119 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:119 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:119 Event:1023 KeyEvent Increased, Thyroid-stimulating hormone (TSH) Aop:120 Event:791 KeyEvent Increased, Leutinizing hormone (LH) Aop:120 Event:744 KeyEvent Increase, Hyperplasia (Leydig cells) Aop:120 Event:745 AdverseOutcome Increase, Leydig cell tumors Aop:120 Event:1690 KeyEvent Decrease, circulating testosterone levels Aop:120 Event:1617 MolecularInitiatingEvent Inhibition, 5α-reductase Aop:121 Event:793 MolecularInitiatingEvent Increase, Urinary bladder calculi Aop:121 Event:794 KeyEvent Increase, Cytotoxicity (urothelial cells) Aop:121 Event:795 KeyEvent Increase, Regenerative cell proliferation (urothelial cells) Aop:121 Event:796 KeyEvent Increase, Hyperplasia (urothelial) Aop:121 Event:797 AdverseOutcome Increase, Adenomas/carcinomas (urothelial) Aop:122 Event:798 MolecularInitiatingEvent Inhibition, Prolyl hydroxylases Aop:122 Event:799 KeyEvent Increased, HIF-1 heterodimer Aop:122 Event:800 KeyEvent Decreased, Aromatase (Cyp19a1) mRNA Aop:122 Event:3 KeyEvent Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Aop:122 Event:219 KeyEvent Reduction, Plasma 17beta-estradiol concentrations Aop:122 Event:285 KeyEvent Reduction, Vitellogenin synthesis in liver Aop:122 Event:221 KeyEvent Reduction, Plasma vitellogenin concentrations Aop:122 Event:309 KeyEvent Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Aop:122 Event:78 AdverseOutcome Reduction, Cumulative fecundity and spawning Aop:122 Event:360 AdverseOutcome Decrease, Population growth rate Aop:123 Event:801 MolecularInitiatingEvent modulation, Unknown Aop:123 Event:799 KeyEvent Increased, HIF-1 heterodimer Aop:123 Event:802 KeyEvent Increased, HIF-1 alpha transcription Aop:123 Event:800 KeyEvent Decreased, Aromatase (Cyp19a1) mRNA Aop:123 Event:219 KeyEvent Reduction, Plasma 17beta-estradiol concentrations Aop:123 Event:3 KeyEvent Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Aop:123 Event:285 KeyEvent Reduction, Vitellogenin synthesis in liver Aop:123 Event:221 KeyEvent Reduction, Plasma vitellogenin concentrations Aop:123 Event:309 KeyEvent Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Aop:123 Event:78 AdverseOutcome Reduction, Cumulative fecundity and spawning Aop:123 Event:360 AdverseOutcome Decrease, Population growth rate Aop:124 Event:804 MolecularInitiatingEvent Inhibition, HMG-CoA reductase Aop:124 Event:805 KeyEvent Decreased, mevalonate Aop:124 Event:807 KeyEvent Decreased, cholesterol Aop:124 Event:809 KeyEvent malformed, Male reproductive tract Aop:124 Event:330 AdverseOutcome Decrease, Fertility Aop:124 Event:1690 KeyEvent Decrease, circulating testosterone levels Aop:126 Event:848 KeyEvent Decreased, Binding of NE to NE receptors on GnRH neurons Aop:126 Event:849 MolecularInitiatingEvent Inhibition, Antgonism of NE receptor Aop:126 Event:529 KeyEvent Decreased, GnRH cfos activity Aop:126 Event:530 KeyEvent Decreased, GnRH pulsatility/release Aop:126 Event:531 KeyEvent Decreased, LH Surge Aop:126 Event:532 KeyEvent Delayed, Ovulation Aop:126 Event:533 KeyEvent Decreased, Cortical granule release/distribution upon fertilization Aop:126 Event:534 KeyEvent Altered, Formation of cortical envelope Aop:126 Event:535 KeyEvent Abnormal, Sperm penetration (polyspermy) Aop:126 Event:536 KeyEvent Altered, Chromosome number (polyploid) zygote Aop:126 Event:527 AdverseOutcome Decreased, Decreased fecundity Aop:128 Event:277 MolecularInitiatingEvent Thyroid hormone synthesis, Decreased Aop:128 Event:814 AdverseOutcome Occurrence, Kidney toxicity Aop:128 Event:819 KeyEvent Decreased, Glomerular filtration Aop:128 Event:820 KeyEvent Decreased, Renal plasma flow Aop:128 Event:821 KeyEvent Decreased, Sodium reabsorption Aop:128 Event:813 KeyEvent Increased, Serum creatinine Aop:128 Event:823 KeyEvent Occurrence, Cystic dilatation (renal tubule) Aop:128 Event:824 KeyEvent Occurrence, Cytoplasmic vacuolization (podocyte) Aop:128 Event:818 KeyEvent Occurrence, Cytoplasmic vacuolization (Renal tubule) Aop:128 Event:825 KeyEvent Decreased, Renal ability to dilute urine Aop:128 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:130 Event:828 MolecularInitiatingEvent Inhibition, Phospholipase A Aop:130 Event:829 KeyEvent Damage, Lipid bilayer Aop:130 Event:831 KeyEvent Disturbance, Lysosomal function Aop:130 Event:833 KeyEvent Occurrence, Cytoplasmic vacuolization (hepatocyte) Aop:130 Event:835 KeyEvent Occurrence, Ballooning degeneration (hepatocyte) Aop:130 Event:837 KeyEvent Occurrence, Cytoplasmic vacuolization (kupffer cell) Aop:130 Event:838 KeyEvent Induction, Microvesicular fat Aop:130 Event:839 KeyEvent Formation, Mallory body Aop:130 Event:840 AdverseOutcome Formation, Liver fibrosis Aop:130 Event:836 KeyEvent Occurrence, Cytoplasmic vacuolization (Bile duct cell) Aop:130 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:131 Event:18 MolecularInitiatingEvent Activation, AhR Aop:131 Event:844 KeyEvent Oxidation, Uroporphyrinogen Aop:131 Event:845 KeyEvent Inhibition, UROD Aop:131 Event:846 KeyEvent Accumulation, Highly carboxylated porphyrins Aop:131 Event:369 AdverseOutcome Uroporphyria Aop:131 Event:850 KeyEvent Induction, CYP1A2/CYP1A5 Aop:134 Event:424 MolecularInitiatingEvent Inhibition, Na+/I- symporter (NIS) Aop:134 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:134 Event:425 KeyEvent Decrease of Thyroidal iodide Aop:134 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:134 Event:280 KeyEvent Thyroxine (T4) in neuronal tissue, Decreased Aop:134 Event:756 KeyEvent Hippocampal gene expression, Altered Aop:134 Event:757 KeyEvent Hippocampal anatomy, Altered Aop:134 Event:758 KeyEvent Hippocampal Physiology, Altered Aop:134 Event:402 AdverseOutcome Cognitive function, decreased Aop:136 Event:867 MolecularInitiatingEvent Decrease, Intracellular pH Aop:136 Event:868 KeyEvent Increase, Tissue Degeneration, Necrosis & Atrophy Aop:136 Event:870 KeyEvent Increase, Cell Proliferation Aop:136 Event:869 KeyEvent Increase, Respiratory or Squamous Metaplasia Aop:136 Event:768 KeyEvent Increase, Cytotoxicity Aop:136 Event:872 AdverseOutcome Increase, Site of Contact Nasal Tumors Aop:136 Event:876 KeyEvent Increase, Mutations in Critical Genes Aop:138 Event:877 MolecularInitiatingEvent Inhibition, organic anion transporter 1 (OAT1) Aop:138 Event:1096 KeyEvent Increased, blood uric acid concentration Aop:138 Event:1097 KeyEvent Occurrence, renal proximal tubular necrosis Aop:138 Event:1098 KeyEvent Increased, blood potassium concentration Aop:138 Event:351 AdverseOutcome Increased Mortality Aop:138 Event:1102 KeyEvent Occurrence, tophi (urate) deposition Aop:138 Event:1106 KeyEvent Occurrence, cardiac arrhythmia Aop:138 Event:360 AdverseOutcome Decrease, Population growth rate Aop:138 Event:1392 KeyEvent Increase, Oxidative Stress Aop:139 Event:97 MolecularInitiatingEvent Alkylation, DNA Aop:139 Event:155 KeyEvent Inadequate DNA repair Aop:139 Event:185 KeyEvent Increase, Mutations Aop:139 Event:885 AdverseOutcome Increase, Cancer Aop:141 Event:155 KeyEvent Inadequate DNA repair Aop:141 Event:185 KeyEvent Increase, Mutations Aop:141 Event:885 AdverseOutcome Increase, Cancer Aop:141 Event:97 MolecularInitiatingEvent Alkylation, DNA Aop:144 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:144 Event:55 KeyEvent Increase, Cell injury/death Aop:144 Event:1539 MolecularInitiatingEvent Endocytotic lysosomal uptake Aop:144 Event:898 KeyEvent Disruption, Lysosome Aop:144 Event:1493 KeyEvent Increased Pro-inflammatory mediators Aop:144 Event:1494 KeyEvent Leukocyte recruitment/activation Aop:144 Event:265 KeyEvent Increase, Hepatic stellate cell activation Aop:144 Event:68 KeyEvent Increase, Collagen accumulation Aop:144 Event:344 AdverseOutcome Increase, Liver fibrosis Aop:148 Event:941 MolecularInitiatingEvent Activation, EGFR Aop:148 Event:962 KeyEvent Increase, Mucin production Aop:148 Event:1250 AdverseOutcome Decrease, Lung function Aop:148 Event:2117 KeyEvent Increase, goblet cell number Aop:149 Event:209 MolecularInitiatingEvent Peptide Oxidation Aop:149 Event:927 KeyEvent KE1 : S-Glutathionylation, eNOS Aop:149 Event:935 KeyEvent KE2 : Decrease, GTPCH-1 Aop:149 Event:934 KeyEvent KE3 : Decrease, Tetrahydrobiopterin Aop:149 Event:932 KeyEvent KE4 : Uncoupling, eNOS Aop:149 Event:933 KeyEvent KE6 : Depletion, Nitric Oxide Aop:149 Event:937 KeyEvent KE7 : Impaired, Vasodilation Aop:149 Event:951 KeyEvent KE8 : Increase, Vascular Resistance Aop:149 Event:952 AdverseOutcome Hypertension Aop:149 Event:973 KeyEvent KE5 : Decrease, AKT/eNOS activity Aop:150 Event:18 MolecularInitiatingEvent Activation, AhR Aop:150 Event:944 KeyEvent dimerization, AHR/ARNT Aop:150 Event:945 KeyEvent reduced dimerization, ARNT/HIF1-alpha Aop:150 Event:110 KeyEvent Impairment, Endothelial network Aop:150 Event:317 KeyEvent Altered, Cardiovascular development/function Aop:150 Event:947 AdverseOutcome Increase, Early Life Stage Mortality Aop:150 Event:948 KeyEvent reduced production, VEGF Aop:151 Event:18 MolecularInitiatingEvent Activation, AhR Aop:151 Event:944 KeyEvent dimerization, AHR/ARNT Aop:151 Event:945 KeyEvent reduced dimerization, ARNT/HIF1-alpha Aop:151 Event:948 KeyEvent reduced production, VEGF Aop:151 Event:1891 KeyEvent abnormal, placental vasculature morphology Aop:151 Event:1892 KeyEvent increase, placental insufficiency Aop:151 Event:1893 AdverseOutcome increase, Preeclampsia Aop:152 Event:957 MolecularInitiatingEvent Binding, Transthyretin in serum Aop:152 Event:958 KeyEvent Displacement, Serum thyroxine (T4) from transthyretin Aop:152 Event:959 KeyEvent Increased, Free serum thyroxine (T4) Aop:152 Event:960 KeyEvent Increased, Uptake of thyroxine into tissue Aop:152 Event:961 KeyEvent Increased, Clearance of thyroxine from serum Aop:152 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:152 Event:280 KeyEvent Thyroxine (T4) in neuronal tissue, Decreased Aop:152 Event:756 KeyEvent Hippocampal gene expression, Altered Aop:152 Event:757 KeyEvent Hippocampal anatomy, Altered Aop:152 Event:758 KeyEvent Hippocampal Physiology, Altered Aop:152 Event:402 AdverseOutcome Cognitive function, decreased Aop:153 Event:964 MolecularInitiatingEvent Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol Aop:153 Event:968 KeyEvent Decreased, release of kisspeptin from anteroventral periventricular nucleus (AVPV) neurons Aop:153 Event:969 KeyEvent Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons Aop:153 Event:970 KeyEvent Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituitary Gonadotrophs Aop:153 Event:971 KeyEvent Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required for ovulation Aop:153 Event:972 AdverseOutcome Decreased fertility, Reduced number of oocytes ovulated Aop:153 Event:1056 KeyEvent Decrease, E2 blood concentrations at hypothalamus Aop:153 Event:3 KeyEvent Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Aop:153 Event:219 KeyEvent Reduction, Plasma 17beta-estradiol concentrations Aop:154 Event:979 KeyEvent Interference, nuclear localization of NFAT Aop:154 Event:981 KeyEvent Reduction, NFAT/AP-1 complex formation Aop:154 Event:984 AdverseOutcome Impairment, T-cell dependent antibody response Aop:154 Event:1202 KeyEvent Suppression, IL-2 and IL-4 production Aop:154 Event:980 MolecularInitiatingEvent Inhibition, Calcineurin Activity Aop:155 Event:1002 MolecularInitiatingEvent Inhibition, Deiodinase 2 Aop:155 Event:1003 KeyEvent Decreased, Triiodothyronine (T3) Aop:155 Event:1004 KeyEvent Reduced, Posterior swim bladder inflation Aop:155 Event:1005 KeyEvent Reduced, Swimming performance Aop:155 Event:360 AdverseOutcome Decrease, Population growth rate Aop:155 Event:351 AdverseOutcome Increased Mortality Aop:156 Event:1002 MolecularInitiatingEvent Inhibition, Deiodinase 2 Aop:156 Event:360 AdverseOutcome Decrease, Population growth rate Aop:156 Event:1003 KeyEvent Decreased, Triiodothyronine (T3) Aop:156 Event:1007 KeyEvent Reduced, Anterior swim bladder inflation Aop:156 Event:1005 KeyEvent Reduced, Swimming performance Aop:156 Event:351 AdverseOutcome Increased Mortality Aop:157 Event:1009 MolecularInitiatingEvent Inhibition, Deiodinase 1 Aop:157 Event:360 AdverseOutcome Decrease, Population growth rate Aop:157 Event:1003 KeyEvent Decreased, Triiodothyronine (T3) Aop:157 Event:1004 KeyEvent Reduced, Posterior swim bladder inflation Aop:157 Event:1005 KeyEvent Reduced, Swimming performance Aop:157 Event:351 AdverseOutcome Increased Mortality Aop:158 Event:1009 MolecularInitiatingEvent Inhibition, Deiodinase 1 Aop:158 Event:360 AdverseOutcome Decrease, Population growth rate Aop:158 Event:1003 KeyEvent Decreased, Triiodothyronine (T3) Aop:158 Event:1007 KeyEvent Reduced, Anterior swim bladder inflation Aop:158 Event:1005 KeyEvent Reduced, Swimming performance Aop:158 Event:351 AdverseOutcome Increased Mortality Aop:159 Event:279 MolecularInitiatingEvent Thyroperoxidase, Inhibition Aop:159 Event:360 AdverseOutcome Decrease, Population growth rate Aop:159 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:159 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:159 Event:1007 KeyEvent Reduced, Anterior swim bladder inflation Aop:159 Event:1005 KeyEvent Reduced, Swimming performance Aop:159 Event:1003 KeyEvent Decreased, Triiodothyronine (T3) Aop:159 Event:351 AdverseOutcome Increased Mortality Aop:160 Event:351 AdverseOutcome Increased Mortality Aop:160 Event:762 MolecularInitiatingEvent Activation, ionotropic GABA Receptor chloride channel Aop:160 Event:1012 KeyEvent Increased, Inhibitory postsynaptic potential Aop:160 Event:1014 KeyEvent Induction, Somatic muscle paralysis Aop:160 Event:761 KeyEvent Increased, Chloride conductance Aop:160 Event:1015 KeyEvent Increased, Neuronal synaptic inhibition Aop:160 Event:1016 KeyEvent Inhibition, Feeding Aop:161 Event:351 AdverseOutcome Increased Mortality Aop:161 Event:1015 KeyEvent Increased, Neuronal synaptic inhibition Aop:161 Event:1012 KeyEvent Increased, Inhibitory postsynaptic potential Aop:161 Event:1016 KeyEvent Inhibition, Feeding Aop:161 Event:761 KeyEvent Increased, Chloride conductance Aop:161 Event:1018 MolecularInitiatingEvent Activation, Glutamate-gated chloride channels Aop:161 Event:1019 KeyEvent Induction, pharyngeal muscle paralysis Aop:162 Event:1023 KeyEvent Increased, Thyroid-stimulating hormone (TSH) Aop:162 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:162 Event:741 AdverseOutcome Increase, Adenomas/carcinomas (follicular cell) Aop:162 Event:740 KeyEvent Increase, Hyperplasia (follicular cells) Aop:162 Event:739 KeyEvent Increase, Hypertrophy and proliferation (follicular cell) Aop:162 Event:295 KeyEvent Induction, Upregulation of glucuronyltransferase activity Aop:162 Event:961 KeyEvent Increased, Clearance of thyroxine from serum Aop:163 Event:1028 MolecularInitiatingEvent Activation of specific nuclear receptors, PPAR-gamma activation Aop:163 Event:1029 KeyEvent Increased, adipogenesis Aop:163 Event:1032 KeyEvent Increased, secretion of local growth factors Aop:163 Event:1033 KeyEvent Increased, proliferation of mesenchymal cells Aop:163 Event:1034 KeyEvent Increased, IGF-1 (mouse) Aop:163 Event:1035 KeyEvent Increased, Firbrosarcoma Aop:163 Event:1036 KeyEvent Increased, liposarcoma Aop:163 Event:1037 KeyEvent Increased, hemagiosarcoma Aop:164 Event:1038 MolecularInitiatingEvent Activation, beta-2 adrenergic receptor Aop:164 Event:1039 KeyEvent Increased activity, beta-2 adrenergic receptor Aop:164 Event:1040 KeyEvent relaxation, smooth muscle Aop:164 Event:1042 KeyEvent Proliferation/Clonal Expansion, smooth muscle Aop:164 Event:1043 KeyEvent Hypertrophy/hyperplasia, smooth muscle Aop:164 Event:1044 AdverseOutcome Promotion, mesovarian leiomyomas Aop:165 Event:1045 KeyEvent Decreased, Ovarian E2 Aop:165 Event:1046 KeyEvent Suppression, Estrogen receptor (ER) activity Aop:165 Event:1047 KeyEvent Increased, secretion of GnRH from hypothalamus Aop:165 Event:1049 KeyEvent Increased, secrection of FSH from anterior pituitary Aop:165 Event:1050 KeyEvent Increased, secretion of LH from anterior pituitary Aop:165 Event:1051 KeyEvent Hyperplasia, ovarian stromal cells Aop:165 Event:1052 KeyEvent Hyperplasia, ovarian epithelium Aop:165 Event:1053 AdverseOutcome Promotion, ovarian adenomas Aop:165 Event:1054 AdverseOutcome Promotion, ovarian granular cell tumors Aop:165 Event:1056 KeyEvent Decrease, E2 blood concentrations at hypothalamus Aop:166 Event:1057 KeyEvent Increased, PPAR-alpha activation Aop:166 Event:1058 KeyEvent Decreased, bile flow Aop:166 Event:1059 KeyEvent Increased, cholestasis Aop:166 Event:1060 KeyEvent Alteration, lipid metabolism Aop:166 Event:1061 KeyEvent prolonged, elevation of serun CCK Aop:166 Event:1062 KeyEvent Increased, Cellular proliferation / hyperplasia of acinar cells Aop:166 Event:1063 AdverseOutcome Increased, Pancreatic acinar tumors Aop:167 Event:1066 KeyEvent Promotion, Sine oculis homeobox 1 positive progenitor cells in endometrium Aop:167 Event:1068 KeyEvent Endometrial squamous metaplasia, Increase Aop:167 Event:1070 AdverseOutcome Increased, adenosquamous carcinomas of endometrium Aop:167 Event:2329 KeyEvent Sine oculis homeobox 1 gene expression, increased Aop:167 Event:2330 KeyEvent Sine oculis homeobox 1 protein expression, increased Aop:167 Event:111 MolecularInitiatingEvent Agonism, Estrogen receptor Aop:167 Event:772 KeyEvent Increase, Hyperplasia (glandular epithelial cells of endometrium) Aop:168 Event:1071 KeyEvent Decreased, GnRH pulsatility/release in hypothalamus Aop:168 Event:1072 KeyEvent Decreased, LH Surge from anterior pituitary Aop:168 Event:1074 KeyEvent interruption, Ovulation Aop:168 Event:1075 KeyEvent prolonged, estrus cycle Aop:168 Event:1076 KeyEvent Increased, circulating estrogen levels Aop:168 Event:1077 KeyEvent Increased, prolactin exposure Aop:168 Event:1078 KeyEvent Hyperplasia, Mammary gland Aop:168 Event:1079 AdverseOutcome Increased, Adenomas/carcinomas (mammary) Aop:168 Event:1080 KeyEvent Increased, latency period Aop:169 Event:1071 KeyEvent Decreased, GnRH pulsatility/release in hypothalamus Aop:169 Event:1072 KeyEvent Decreased, LH Surge from anterior pituitary Aop:169 Event:1075 KeyEvent prolonged, estrus cycle Aop:169 Event:1074 KeyEvent interruption, Ovulation Aop:169 Event:1076 KeyEvent Increased, circulating estrogen levels Aop:169 Event:1081 KeyEvent Increased, lactotroph hyperplasia and hypertrophy Aop:169 Event:1082 AdverseOutcome Increased, adenomas (pituitary) Aop:170 Event:1083 KeyEvent Decreased, Dopaminergic activity Aop:170 Event:1084 KeyEvent Increased, prolactin secretion Aop:170 Event:1085 KeyEvent Increased, hyperplasia (mammary gland) Aop:170 Event:1080 KeyEvent Increased, latency period Aop:170 Event:1079 AdverseOutcome Increased, Adenomas/carcinomas (mammary) Aop:171 Event:1086 KeyEvent persistent, cytotoxicity (pleura or peritoneum) Aop:171 Event:1087 KeyEvent Increased, inflammation Aop:171 Event:1032 KeyEvent Increased, secretion of local growth factors Aop:171 Event:1089 KeyEvent Increased, Cell Proliferation (mesothelium) Aop:171 Event:1090 AdverseOutcome Increased, mesotheliomas Aop:171 Event:1392 KeyEvent Increase, Oxidative Stress Aop:173 Event:1495 MolecularInitiatingEvent Substance interaction with the lung resident cell membrane components Aop:173 Event:1496 KeyEvent Increased, secretion of proinflammatory mediators Aop:173 Event:1497 KeyEvent Increased, recruitment of inflammatory cells Aop:173 Event:1498 KeyEvent Loss of alveolar capillary membrane integrity Aop:173 Event:1499 KeyEvent Increased, activation of T (T) helper (h) type 2 cells Aop:173 Event:1500 KeyEvent Increased, fibroblast proliferation and myofibroblast differentiation Aop:173 Event:1458 AdverseOutcome Pulmonary fibrosis Aop:173 Event:68 KeyEvent Increase, Collagen accumulation Aop:175 Event:279 MolecularInitiatingEvent Thyroperoxidase, Inhibition Aop:175 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:175 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:175 Event:1101 AdverseOutcome Altered, Amphibian metamorphosis Aop:176 Event:424 MolecularInitiatingEvent Inhibition, Na+/I- symporter (NIS) Aop:176 Event:425 KeyEvent Decrease of Thyroidal iodide Aop:176 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:176 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:176 Event:1101 AdverseOutcome Altered, Amphibian metamorphosis Aop:177 Event:1104 KeyEvent Decreased, Prostaglandin F2alpha concentration, plasma Aop:177 Event:1105 KeyEvent Occurrence, renal ischemia Aop:177 Event:1097 KeyEvent Occurrence, renal proximal tubular necrosis Aop:177 Event:1098 KeyEvent Increased, blood potassium concentration Aop:177 Event:351 AdverseOutcome Increased Mortality Aop:177 Event:1103 MolecularInitiatingEvent Inhibition, Cyclooxygenase 1 activity Aop:177 Event:1106 KeyEvent Occurrence, cardiac arrhythmia Aop:177 Event:1096 KeyEvent Increased, blood uric acid concentration Aop:177 Event:1102 KeyEvent Occurrence, tophi (urate) deposition Aop:177 Event:360 AdverseOutcome Decrease, Population growth rate Aop:177 Event:1392 KeyEvent Increase, Oxidative Stress Aop:178 Event:559 MolecularInitiatingEvent Activation, Nicotinic acetylcholine receptor Aop:178 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:178 Event:1107 KeyEvent Weakened, Colony Aop:178 Event:563 AdverseOutcome Death/Failure, Colony Aop:179 Event:1109 KeyEvent Increased, Deformed Wing Virus levels Aop:179 Event:1107 KeyEvent Weakened, Colony Aop:179 Event:563 AdverseOutcome Death/Failure, Colony Aop:180 Event:560 KeyEvent Abnormal, Foraging activity and behavior Aop:180 Event:1107 KeyEvent Weakened, Colony Aop:180 Event:563 AdverseOutcome Death/Failure, Colony Aop:181 Event:1107 KeyEvent Weakened, Colony Aop:181 Event:563 AdverseOutcome Death/Failure, Colony Aop:182 Event:560 KeyEvent Abnormal, Foraging activity and behavior Aop:182 Event:1107 KeyEvent Weakened, Colony Aop:182 Event:563 AdverseOutcome Death/Failure, Colony Aop:183 Event:1110 KeyEvent Increased, Energetic demands and therefore metabolic stress Aop:183 Event:560 KeyEvent Abnormal, Foraging activity and behavior Aop:183 Event:1107 KeyEvent Weakened, Colony Aop:183 Event:563 AdverseOutcome Death/Failure, Colony Aop:184 Event:1108 KeyEvent Abnormal, Role change within caste Aop:184 Event:1107 KeyEvent Weakened, Colony Aop:184 Event:563 AdverseOutcome Death/Failure, Colony Aop:185 Event:1107 KeyEvent Weakened, Colony Aop:185 Event:563 AdverseOutcome Death/Failure, Colony Aop:186 Event:1114 MolecularInitiatingEvent Unknown, MIE Aop:186 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:186 Event:1097 KeyEvent Occurrence, renal proximal tubular necrosis Aop:186 Event:1098 KeyEvent Increased, blood potassium concentration Aop:186 Event:1106 KeyEvent Occurrence, cardiac arrhythmia Aop:186 Event:351 AdverseOutcome Increased Mortality Aop:186 Event:1392 KeyEvent Increase, Oxidative Stress Aop:187 Event:1122 KeyEvent Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis Aop:187 Event:1130 KeyEvent Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) Aop:187 Event:1131 KeyEvent Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) Aop:187 Event:1132 KeyEvent Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal Aop:187 Event:1133 KeyEvent Hemostasis, Depletion from blood of fully functional carboxylated clotting factors Aop:187 Event:1134 MolecularInitiatingEvent Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone Aop:187 Event:1135 KeyEvent Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction Aop:187 Event:1136 AdverseOutcome Impaired recruitment , Population trajectory Aop:187 Event:1138 MolecularInitiatingEvent Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP Aop:187 Event:1151 KeyEvent Osteoporosis and vascular calcification, Bone deterioration Aop:187 Event:1169 MolecularInitiatingEvent Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin Aop:188 Event:1152 MolecularInitiatingEvent Inhibition, Iodotyrosine deiodinase (IYD) Aop:188 Event:425 KeyEvent Decrease of Thyroidal iodide Aop:188 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:188 Event:1101 AdverseOutcome Altered, Amphibian metamorphosis Aop:188 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:189 Event:1009 MolecularInitiatingEvent Inhibition, Deiodinase 1 Aop:189 Event:1116 KeyEvent Decreased, Triiodothyronine (T3) in tissues Aop:189 Event:1003 KeyEvent Decreased, Triiodothyronine (T3) Aop:189 Event:1101 AdverseOutcome Altered, Amphibian metamorphosis Aop:190 Event:1002 MolecularInitiatingEvent Inhibition, Deiodinase 2 Aop:190 Event:1116 KeyEvent Decreased, Triiodothyronine (T3) in tissues Aop:190 Event:1101 AdverseOutcome Altered, Amphibian metamorphosis Aop:190 Event:1023 KeyEvent Increased, Thyroid-stimulating hormone (TSH) Aop:190 Event:1828 KeyEvent Increased, Thyroxine (T4) in serum Aop:190 Event:1829 KeyEvent Altered, Thyroid hormone-dependent gene expression Aop:191 Event:1153 MolecularInitiatingEvent Inhibition, Deiodinase 3 Aop:191 Event:1154 KeyEvent Increased, Triiodothyronine (T3) in tissues Aop:191 Event:1101 AdverseOutcome Altered, Amphibian metamorphosis Aop:191 Event:1829 KeyEvent Altered, Thyroid hormone-dependent gene expression Aop:192 Event:1155 MolecularInitiatingEvent Inhibition, Pendrin Aop:192 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:192 Event:1101 AdverseOutcome Altered, Amphibian metamorphosis Aop:192 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:193 Event:1156 MolecularInitiatingEvent Inhibition, Dual oxidase Aop:193 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:193 Event:1101 AdverseOutcome Altered, Amphibian metamorphosis Aop:193 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:194 Event:1157 MolecularInitiatingEvent Activation, Hepatic nuclear receptor(s) Aop:194 Event:1158 KeyEvent Increased, Hepatic thyroid hormone uptake/transport Aop:194 Event:295 KeyEvent Induction, Upregulation of glucuronyltransferase activity Aop:194 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:194 Event:1101 AdverseOutcome Altered, Amphibian metamorphosis Aop:194 Event:961 KeyEvent Increased, Clearance of thyroxine from serum Aop:195 Event:619 MolecularInitiatingEvent Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Aop:195 Event:626 KeyEvent Increased, serotonin (5-HT) Aop:195 Event:1161 KeyEvent Increased, oocyte maturation Aop:195 Event:1164 AdverseOutcome Increased, Population Aop:195 Event:1255 KeyEvent induced spawning Aop:195 Event:1142 KeyEvent Increased, valve movement Aop:195 Event:1163 KeyEvent Increased, Reproductive Success Aop:195 Event:621 KeyEvent Increase, cilia movement Aop:196 Event:1215 MolecularInitiatingEvent TRPA1 activation, TRPA1 Receptor Aop:196 Event:1218 KeyEvent Opening of calcium channel, Calcium influx Aop:196 Event:1220 KeyEvent Trigeminal nerve activation Aop:196 Event:1222 KeyEvent SP (Substance P) release, Local increase of SP Aop:196 Event:1223 AdverseOutcome Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea Aop:196 Event:1226 AdverseOutcome Increased Respiratory irritability and Chronic Cough, Aop:196 Event:1433 KeyEvent Increased CGRP, neuronal release of CGRP Aop:196 Event:1434 AdverseOutcome Irritation of nasal mucosa inducing sneeze reflex Aop:196 Event:1435 KeyEvent Increased neurokinin A (NKA) by neuronal cells Aop:197 Event:584 MolecularInitiatingEvent Inhibition, sodium channel Aop:197 Event:1176 KeyEvent Decreased, sodium conductance 2 Aop:197 Event:1179 KeyEvent Decreased, GABA release Aop:200 Event:1182 KeyEvent Increase, Cell Proliferation (Epithelial Cells) Aop:200 Event:1183 KeyEvent Decreased, Apoptosis (Epithelial Cells) Aop:200 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:200 Event:1187 KeyEvent Increased, ER binding to DNA (classical pathway) Aop:200 Event:1188 KeyEvent Increased, ER binding to T.F. to DNA (non-classical pathway) Aop:200 Event:1189 KeyEvent Increased, Proliferation (Endothelial cells) Aop:200 Event:1190 KeyEvent Increased, Migration (Endothelial Cells) Aop:200 Event:1191 KeyEvent Increased, Non-genomic signaling Aop:200 Event:1192 KeyEvent Increased, Ductal Hyperplasia Aop:200 Event:1193 AdverseOutcome N/A, Breast Cancer Aop:200 Event:1194 KeyEvent Increase, DNA damage Aop:200 Event:1195 KeyEvent modulation, Extracellular Matrix Composition Aop:200 Event:1196 KeyEvent Increased, Invasion Aop:200 Event:1197 KeyEvent Activation, Fibroblasts Aop:200 Event:1198 KeyEvent Activation, Macrophages Aop:200 Event:1213 KeyEvent Increased, Angiogenesis Aop:200 Event:1239 KeyEvent Altered, Gene Expression Aop:200 Event:1240 KeyEvent Altered, Protein Production Aop:200 Event:1241 KeyEvent Increased, Motility Aop:200 Event:1242 KeyEvent Increased, Second Messenger Production Aop:200 Event:1392 KeyEvent Increase, Oxidative Stress Aop:200 Event:111 MolecularInitiatingEvent Agonism, Estrogen receptor Aop:201 Event:1205 MolecularInitiatingEvent Activation, Juvenile hormone receptor Aop:201 Event:1206 KeyEvent Induction, Doublesex1 gene Aop:201 Event:1208 AdverseOutcome Increased, Male offspring Aop:201 Event:1209 KeyEvent Induction, Male reproductive tract Aop:201 Event:361 AdverseOutcome Decline, Population Aop:201 Event:1210 AdverseOutcome Alteration, Food-web structures Aop:202 Event:1252 MolecularInitiatingEvent Binding to (interferes with) topoisomerase II enzyme Aop:202 Event:1253 KeyEvent MLL chromosomal translocation Aop:202 Event:1254 AdverseOutcome Infant leukaemia Aop:202 Event:1461 KeyEvent Increase, DNA double-strand breaks Aop:203 Event:619 MolecularInitiatingEvent Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Aop:203 Event:1142 KeyEvent Increased, valve movement Aop:203 Event:621 KeyEvent Increase, cilia movement Aop:203 Event:1256 KeyEvent increased mantel display Aop:203 Event:1257 KeyEvent Induced parturition Aop:203 Event:1141 AdverseOutcome Decreased, Reproductive Success Aop:203 Event:626 KeyEvent Increased, serotonin (5-HT) Aop:203 Event:360 AdverseOutcome Decrease, Population growth rate Aop:204 Event:619 MolecularInitiatingEvent Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Aop:204 Event:1142 KeyEvent Increased, valve movement Aop:204 Event:621 KeyEvent Increase, cilia movement Aop:204 Event:1257 KeyEvent Induced parturition Aop:204 Event:1256 KeyEvent increased mantel display Aop:204 Event:1163 AdverseOutcome Increased, Reproductive Success Aop:204 Event:1164 AdverseOutcome Increased, Population Aop:204 Event:626 KeyEvent Increased, serotonin (5-HT) Aop:205 Event:1258 MolecularInitiatingEvent Decompartmentalization Aop:205 Event:1260 MolecularInitiatingEvent Direct mitochondrial inhibition Aop:205 Event:1259 MolecularInitiatingEvent narcosis Aop:205 Event:1262 AdverseOutcome Apoptosis Aop:205 Event:1263 AdverseOutcome Necrosis Aop:205 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:206 Event:1270 MolecularInitiatingEvent Inactivation of PPARγ Aop:206 Event:1271 KeyEvent Increase, Transforming growth factor-beta signaling Aop:206 Event:1275 KeyEvent Collagen Deposition Aop:206 Event:1276 AdverseOutcome Lung fibrosis Aop:206 Event:149 KeyEvent Increase, Inflammation Aop:206 Event:1457 KeyEvent Epithelial Mesenchymal Transition Aop:207 Event:1174 MolecularInitiatingEvent Activation, NADPH Oxidase Aop:207 Event:1277 AdverseOutcome Reproductive failure Aop:207 Event:1279 KeyEvent Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK Aop:207 Event:1280 KeyEvent Activation, HIF-1 Aop:207 Event:1281 KeyEvent Increased, DNA Damage-Repair Aop:207 Event:1262 KeyEvent Apoptosis Aop:207 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:207 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:208 Event:1282 KeyEvent Activation, JAK/STAT pathway Aop:208 Event:1283 KeyEvent Activation, TGF-beta pathway Aop:208 Event:1277 AdverseOutcome Reproductive failure Aop:209 Event:1284 KeyEvent Up Regulation, SREBF2 Aop:209 Event:1285 KeyEvent Up Regulation, Unsaturated fatty acid Aop:209 Event:1286 KeyEvent Down Regulation, GSS and GSTs gene Aop:209 Event:1287 KeyEvent Glutathione synthesis Aop:209 Event:1288 KeyEvent Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene Aop:209 Event:1289 KeyEvent Perturbation of cholesterol Aop:209 Event:1290 KeyEvent Glutathione homeostasis Aop:209 Event:1291 AdverseOutcome Hepatotoxicity Aop:210 Event:209 KeyEvent Peptide Oxidation Aop:210 Event:1292 KeyEvent Activation, JNK Aop:210 Event:1293 KeyEvent Activation, FOXO Aop:210 Event:1294 KeyEvent Inhibition, Wnt pathway Aop:210 Event:1295 KeyEvent Defect of Embryogenesis Aop:210 Event:1277 AdverseOutcome Reproductive failure Aop:212 Event:1502 MolecularInitiatingEvent Histone deacetylase inhibition Aop:212 Event:1503 KeyEvent Histone acetylation, increase Aop:212 Event:1505 KeyEvent Cell cycle, disrupted Aop:212 Event:1262 KeyEvent Apoptosis Aop:212 Event:1506 AdverseOutcome Testicular atrophy Aop:212 Event:1515 KeyEvent Spermatocyte depletion Aop:213 Event:1305 KeyEvent Increase, cytosolic fatty acid Aop:213 Event:1489 AdverseOutcome Increase, Steatohepatitis Aop:213 Event:1490 MolecularInitiatingEvent Inhibition, Fatty Acid Beta Oxidation Aop:213 Event:459 KeyEvent Increase, Liver steatosis Aop:213 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:213 Event:1491 KeyEvent Increased, Oncotic Necrosis Aop:214 Event:1316 KeyEvent Inhibit, serotonin transporter activity Aop:214 Event:1317 KeyEvent Decreased, serotonin transporter activity Aop:214 Event:1318 KeyEvent Decreased, extracellular sodium (Na+) Aop:214 Event:1319 KeyEvent Decreased, extracellular chloride (Cl-) Aop:214 Event:1320 KeyEvent Increased, extracellular serotonin Aop:214 Event:1321 KeyEvent Increased, intracellular sodium (Na+) Aop:214 Event:1322 KeyEvent Increased, intracellular chloride (Cl-) Aop:214 Event:1323 KeyEvent Decreased, intracellular serotonin Aop:214 Event:1324 KeyEvent Decreased, packaged serotonin Aop:214 Event:1325 KeyEvent Decreased, synaptic release Aop:214 Event:1326 KeyEvent Increased, 5-HT3 (5-hydroxytryptamine) Aop:214 Event:1328 KeyEvent Inactivated, 5-HTR (serotonin receptors) Aop:214 Event:1329 KeyEvent Reduce expression, BDNF (Brain-derived neurotrophic factor) Aop:214 Event:1330 KeyEvent Decreased, neuroplasticity Aop:214 Event:1334 KeyEvent Increase, cortisone Aop:214 Event:122 KeyEvent Increase, Glucocorticoid receptor activation Aop:214 Event:1335 KeyEvent Reduced, BDNF (Brain-derived neurotrophic factor) Aop:214 Event:1336 KeyEvent Activation, 5-HT2A (Serotonin 2A) Aop:214 Event:1337 KeyEvent Activate, PLC (Phospholipase C) Aop:214 Event:1338 KeyEvent Increase, inositol triphosphate Aop:214 Event:1339 KeyEvent Increase, intracellular calcium Aop:214 Event:1340 KeyEvent Activate, calmodulin Aop:214 Event:1341 KeyEvent Increase, myosin light chain phosphorylation Aop:214 Event:1342 KeyEvent Increase, vascular smooth muscle contraction Aop:214 Event:1344 AdverseOutcome Increased, seizure Aop:214 Event:1345 AdverseOutcome Increased, agitation Aop:214 Event:1346 AdverseOutcome Increased, depression Aop:214 Event:1343 AdverseOutcome Increase, hypertension Aop:214 Event:1347 KeyEvent Decreased, extracellular serotonin Aop:215 Event:1348 AdverseOutcome Increase, seizure Aop:215 Event:1349 KeyEvent Activated, presynaptic neuron 1 Aop:215 Event:1350 KeyEvent Increased, glutamate Aop:215 Event:1351 KeyEvent Activated, NMDA receptor Aop:215 Event:1321 KeyEvent Increased, intracellular sodium (Na+) Aop:215 Event:1352 KeyEvent Activated, voltage-gated sodium channel Aop:215 Event:1353 KeyEvent Binding to voltage-gated sodium channel Aop:215 Event:1354 KeyEvent Treat, carbamazepine Aop:215 Event:1355 KeyEvent Activated, membrane depolarization Aop:215 Event:1356 KeyEvent Inactive, membrane depolarization Aop:215 Event:1357 KeyEvent Increased, RDX dose Aop:215 Event:1358 KeyEvent Repress, GABA-A receptor Aop:215 Event:1359 KeyEvent Activate, GABA-A receptor Aop:215 Event:1360 KeyEvent Activate, presynaptic neuron 2 Aop:215 Event:1361 KeyEvent Increase, GABA Aop:215 Event:1322 KeyEvent Increased, intracellular chloride (Cl-) Aop:215 Event:1362 AdverseOutcome Increased, hippocampal hyperdepolarization Aop:215 Event:1363 AdverseOutcome Increased, epilepsy Aop:216 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:216 Event:1635 KeyEvent Increase, DNA strand breaks Aop:216 Event:1444 KeyEvent Increase, Follicular atresia Aop:216 Event:1366 KeyEvent Decrease, Oogenesis Aop:216 Event:78 AdverseOutcome Reduction, Cumulative fecundity and spawning Aop:216 Event:360 AdverseOutcome Decrease, Population growth rate Aop:217 Event:1367 AdverseOutcome Inhibit, gastric ulcer formation Aop:217 Event:1368 KeyEvent Inhibition, PTGS-1 (Prostaglandin-endoperoxide synthase 1) Aop:217 Event:1369 KeyEvent Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1) Aop:217 Event:1370 KeyEvent Activation, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Aop:217 Event:1371 KeyEvent Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Aop:217 Event:1372 KeyEvent Increase, bicarbonate Aop:217 Event:1373 KeyEvent Increase, mucous Aop:217 Event:1374 KeyEvent Increase, mucosal blood flow Aop:217 Event:1375 KeyEvent Increase, platelet aggregation Aop:217 Event:1376 KeyEvent Increase, angiogenesis Aop:217 Event:1377 KeyEvent Decrease, leukocyte adherence Aop:217 Event:1378 KeyEvent Increase, leukocyte adherence Aop:217 Event:1379 KeyEvent Activate, leukocyte Aop:217 Event:1380 KeyEvent Activate, mucosal defense Aop:217 Event:1381 KeyEvent Increase, surfactant Aop:217 Event:1382 KeyEvent Decrease, surfactant Aop:217 Event:1383 KeyEvent Activate, phospholipase Aop:217 Event:1384 KeyEvent Increase, ammonium (NH4+) Aop:217 Event:1385 AdverseOutcome Activated, gastric ulcer formation Aop:218 Event:1386 MolecularInitiatingEvent CYP7B activity, inhibition Aop:218 Event:1387 KeyEvent 7α-hydroxypregnenolone synthesis in the brain, decreased Aop:218 Event:1388 KeyEvent Dopamine release in the brain, decreased Aop:218 Event:1389 KeyEvent Locomotor activity, decreased Aop:218 Event:1141 KeyEvent Decreased, Reproductive Success Aop:218 Event:360 AdverseOutcome Decrease, Population growth rate Aop:219 Event:1386 MolecularInitiatingEvent CYP7B activity, inhibition Aop:219 Event:1387 KeyEvent 7α-hydroxypregnenolone synthesis in the brain, decreased Aop:219 Event:1388 KeyEvent Dopamine release in the brain, decreased Aop:219 Event:1390 KeyEvent Sexual behavior, decreased Aop:219 Event:1141 KeyEvent Decreased, Reproductive Success Aop:219 Event:360 AdverseOutcome Decrease, Population growth rate Aop:220 Event:1391 MolecularInitiatingEvent Activation of Cyp2E1 Aop:220 Event:1392 KeyEvent Increase, Oxidative Stress Aop:220 Event:1393 KeyEvent Hepatocytotoxicity Aop:220 Event:1394 KeyEvent Induction, persistent proliferation/sustained proliferation Aop:220 Event:1395 AdverseOutcome Liver Cancer Aop:221 Event:1335 KeyEvent Reduced, BDNF (Brain-derived neurotrophic factor) Aop:221 Event:1330 KeyEvent Decreased, neuroplasticity Aop:221 Event:1328 KeyEvent Inactivated, 5-HTR (serotonin receptors) Aop:221 Event:1347 KeyEvent Decreased, extracellular serotonin Aop:221 Event:1325 KeyEvent Decreased, synaptic release Aop:221 Event:1324 KeyEvent Decreased, packaged serotonin Aop:221 Event:1323 KeyEvent Decreased, intracellular serotonin Aop:221 Event:1317 KeyEvent Decreased, serotonin transporter activity Aop:221 Event:1320 KeyEvent Increased, extracellular serotonin Aop:221 Event:1346 AdverseOutcome Increased, depression Aop:221 Event:1329 KeyEvent Reduce expression, BDNF (Brain-derived neurotrophic factor) Aop:221 Event:1396 MolecularInitiatingEvent Increased, glucocorticoid receptor activity Aop:222 Event:1345 AdverseOutcome Increased, agitation Aop:222 Event:1335 KeyEvent Reduced, BDNF (Brain-derived neurotrophic factor) Aop:222 Event:1329 KeyEvent Reduce expression, BDNF (Brain-derived neurotrophic factor) Aop:222 Event:1328 KeyEvent Inactivated, 5-HTR (serotonin receptors) Aop:222 Event:1330 KeyEvent Decreased, neuroplasticity Aop:222 Event:1347 KeyEvent Decreased, extracellular serotonin Aop:222 Event:1317 KeyEvent Decreased, serotonin transporter activity Aop:222 Event:1320 KeyEvent Increased, extracellular serotonin Aop:222 Event:1325 KeyEvent Decreased, synaptic release Aop:222 Event:1324 KeyEvent Decreased, packaged serotonin Aop:222 Event:1323 KeyEvent Decreased, intracellular serotonin Aop:222 Event:1396 MolecularInitiatingEvent Increased, glucocorticoid receptor activity Aop:223 Event:1320 KeyEvent Increased, extracellular serotonin Aop:223 Event:1347 KeyEvent Decreased, extracellular serotonin Aop:223 Event:1344 AdverseOutcome Increased, seizure Aop:223 Event:1397 MolecularInitiatingEvent Increased, serotonin transporter activity Aop:223 Event:1398 KeyEvent Increased, intracellular serotonin Aop:223 Event:1399 KeyEvent Increased, packaged serotonin Aop:223 Event:1400 KeyEvent Increased, synaptic release Aop:223 Event:1401 KeyEvent Decreased, 5-HT3 Aop:224 Event:1346 AdverseOutcome Increased, depression Aop:224 Event:1320 KeyEvent Increased, extracellular serotonin Aop:224 Event:1347 KeyEvent Decreased, extracellular serotonin Aop:224 Event:1397 MolecularInitiatingEvent Increased, serotonin transporter activity Aop:224 Event:1398 KeyEvent Increased, intracellular serotonin Aop:224 Event:1399 KeyEvent Increased, packaged serotonin Aop:224 Event:1400 KeyEvent Increased, synaptic release Aop:224 Event:1328 KeyEvent Inactivated, 5-HTR (serotonin receptors) Aop:224 Event:1329 KeyEvent Reduce expression, BDNF (Brain-derived neurotrophic factor) Aop:224 Event:1330 KeyEvent Decreased, neuroplasticity Aop:225 Event:1320 KeyEvent Increased, extracellular serotonin Aop:225 Event:1347 KeyEvent Decreased, extracellular serotonin Aop:225 Event:1328 KeyEvent Inactivated, 5-HTR (serotonin receptors) Aop:225 Event:1329 KeyEvent Reduce expression, BDNF (Brain-derived neurotrophic factor) Aop:225 Event:1330 KeyEvent Decreased, neuroplasticity Aop:225 Event:1345 AdverseOutcome Increased, agitation Aop:225 Event:1397 KeyEvent Increased, serotonin transporter activity Aop:225 Event:1398 KeyEvent Increased, intracellular serotonin Aop:225 Event:1399 KeyEvent Increased, packaged serotonin Aop:225 Event:1400 KeyEvent Increased, synaptic release Aop:226 Event:1323 KeyEvent Decreased, intracellular serotonin Aop:226 Event:1324 KeyEvent Decreased, packaged serotonin Aop:226 Event:1325 KeyEvent Decreased, synaptic release Aop:226 Event:1320 KeyEvent Increased, extracellular serotonin Aop:226 Event:1347 KeyEvent Decreased, extracellular serotonin Aop:226 Event:1336 KeyEvent Activation, 5-HT2A (Serotonin 2A) Aop:226 Event:1337 KeyEvent Activate, PLC (Phospholipase C) Aop:226 Event:1338 KeyEvent Increase, inositol triphosphate Aop:226 Event:1339 KeyEvent Increase, intracellular calcium Aop:226 Event:1340 KeyEvent Activate, calmodulin Aop:226 Event:1341 KeyEvent Increase, myosin light chain phosphorylation Aop:226 Event:1342 KeyEvent Increase, vascular smooth muscle contraction Aop:226 Event:1343 AdverseOutcome Increase, hypertension Aop:226 Event:1317 MolecularInitiatingEvent Decreased, serotonin transporter activity Aop:227 Event:1402 MolecularInitiatingEvent Reduced, PTGS1 function Aop:227 Event:1385 AdverseOutcome Activated, gastric ulcer formation Aop:227 Event:1403 KeyEvent Reduced, platelet aggregation Aop:227 Event:1404 KeyEvent Decreased, mucosal blood flow Aop:227 Event:1405 KeyEvent Reduced, mucosal defense Aop:227 Event:1406 KeyEvent Decreased, mucous Aop:227 Event:1407 KeyEvent Decreased, bicarbonate Aop:228 Event:1408 MolecularInitiatingEvent Reduced, PTGS2 function Aop:228 Event:1385 AdverseOutcome Activated, gastric ulcer formation Aop:228 Event:1409 KeyEvent Decreased, angiogenesis Aop:228 Event:1410 KeyEvent Increased, leukocyte adherence Aop:228 Event:1411 KeyEvent Increased, leukocyte activation Aop:229 Event:1412 MolecularInitiatingEvent Helicobacter pylori infection Aop:229 Event:1384 KeyEvent Increase, ammonium (NH4+) Aop:229 Event:1383 KeyEvent Activate, phospholipase Aop:229 Event:1382 KeyEvent Decrease, surfactant Aop:229 Event:1405 KeyEvent Reduced, mucosal defense Aop:229 Event:1385 AdverseOutcome Activated, gastric ulcer formation Aop:230 Event:1349 MolecularInitiatingEvent Activated, presynaptic neuron 1 Aop:230 Event:1350 KeyEvent Increased, glutamate Aop:230 Event:1351 KeyEvent Activated, NMDA receptor Aop:230 Event:1321 KeyEvent Increased, intracellular sodium (Na+) Aop:230 Event:1352 KeyEvent Activated, voltage-gated sodium channel Aop:230 Event:1355 KeyEvent Activated, membrane depolarization Aop:230 Event:1362 KeyEvent Increased, hippocampal hyperdepolarization Aop:230 Event:1344 KeyEvent Increased, seizure Aop:230 Event:1363 AdverseOutcome Increased, epilepsy Aop:230 Event:1354 KeyEvent Treat, carbamazepine Aop:230 Event:1353 KeyEvent Binding to voltage-gated sodium channel Aop:231 Event:1413 MolecularInitiatingEvent Reduced, presynaptic neuron 2 activity Aop:231 Event:1363 AdverseOutcome Increased, epilepsy Aop:231 Event:1414 KeyEvent Decreased, GABA Aop:231 Event:1415 KeyEvent Reduced, GABA-A receptor activation Aop:231 Event:1416 KeyEvent Decreased, intracellular chloride Aop:231 Event:1355 KeyEvent Activated, membrane depolarization Aop:231 Event:1362 KeyEvent Increased, hippocampal hyperdepolarization Aop:231 Event:1344 KeyEvent Increased, seizure Aop:231 Event:1357 KeyEvent Increased, RDX dose Aop:232 Event:1417 MolecularInitiatingEvent NFE2/Nrf2 repression Aop:232 Event:1419 KeyEvent Reduced, FXR activity Aop:232 Event:1420 KeyEvent Reduced, SHP activity Aop:232 Event:1421 KeyEvent Activated, LXR Aop:232 Event:1422 KeyEvent Reduced, PPARalpha Aop:232 Event:1423 KeyEvent Reduced, HSD17B4 activity Aop:232 Event:1424 KeyEvent Reduced, fatty acid beta oxidation Aop:232 Event:459 AdverseOutcome Increase, Liver steatosis Aop:233 Event:1425 MolecularInitiatingEvent Mu Opioid Receptor Agonism Aop:233 Event:1426 KeyEvent Release of G Proteins Aop:233 Event:1427 KeyEvent Opening of G protein gated inward rectifying K channels Aop:233 Event:763 KeyEvent hyperpolarisation, neuron Aop:233 Event:1428 AdverseOutcome Analgesia Aop:234 Event:1425 MolecularInitiatingEvent Mu Opioid Receptor Agonism Aop:234 Event:1426 KeyEvent Release of G Proteins Aop:234 Event:1429 KeyEvent Inhibition of N-type Ca ion channels Aop:234 Event:1430 KeyEvent Inhibition of neurotransmitter vesicle release Aop:234 Event:1428 AdverseOutcome Analgesia Aop:235 Event:1431 MolecularInitiatingEvent Serotonin 1A Receptor Agonism Aop:235 Event:1426 KeyEvent Release of G Proteins Aop:235 Event:1432 AdverseOutcome Anti-depressant Activity Aop:235 Event:1427 KeyEvent Opening of G protein gated inward rectifying K channels Aop:235 Event:763 KeyEvent hyperpolarisation, neuron Aop:236 Event:1431 MolecularInitiatingEvent Serotonin 1A Receptor Agonism Aop:236 Event:1426 KeyEvent Release of G Proteins Aop:236 Event:1429 KeyEvent Inhibition of N-type Ca ion channels Aop:236 Event:1430 KeyEvent Inhibition of neurotransmitter vesicle release Aop:236 Event:1432 AdverseOutcome Anti-depressant Activity Aop:237 Event:1438 KeyEvent Transcription of genes encoding acute phase proteins, Increased Aop:237 Event:1439 KeyEvent Systemic acute phase response Aop:237 Event:1443 AdverseOutcome Atherosclerosis Aop:237 Event:1495 MolecularInitiatingEvent Substance interaction with the lung resident cell membrane components Aop:237 Event:1496 KeyEvent Increased, secretion of proinflammatory mediators Aop:238 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:238 Event:1635 KeyEvent Increase, DNA strand breaks Aop:238 Event:1775 KeyEvent Increase, Oocyte apoptosis Aop:238 Event:1366 KeyEvent Decrease, Oogenesis Aop:238 Event:78 AdverseOutcome Reduction, Cumulative fecundity and spawning Aop:238 Event:360 AdverseOutcome Decrease, Population growth rate Aop:241 Event:1456 KeyEvent Increase, Differentiation of fibroblasts Aop:241 Event:1457 KeyEvent Epithelial Mesenchymal Transition Aop:241 Event:68 KeyEvent Increase, Collagen accumulation Aop:241 Event:1458 AdverseOutcome Pulmonary fibrosis Aop:241 Event:1468 MolecularInitiatingEvent Activation, Latent Transforming Growth Factor Beta 1 Aop:241 Event:1469 KeyEvent Activation, Transforming Growth Factor beta pathway Aop:242 Event:1462 MolecularInitiatingEvent Thiol group of chemicals interact with sulfuhydryl groups of proteins to form thiol adducts Aop:242 Event:1463 KeyEvent Inhibition of lysyl oxidase Aop:242 Event:1464 KeyEvent Reduction of collagen crosslinking Aop:242 Event:1465 KeyEvent Weak collagen matrix Aop:242 Event:1466 KeyEvent Notochord distortion or malformations Aop:242 Event:1005 KeyEvent Reduced, Swimming performance Aop:242 Event:1467 AdverseOutcome Growth, reduction Aop:242 Event:636 AdverseOutcome Decreased, survival Aop:245 Event:1471 MolecularInitiatingEvent Increase, Uncoupling of photophosphorylation Aop:245 Event:1472 KeyEvent Decrease, ATP production Aop:245 Event:1473 KeyEvent Decrease, Chlorophyll synthesis Aop:245 Event:1474 KeyEvent Decrease, Light harvest capacity Aop:245 Event:1475 KeyEvent Decrease, Photosynthesis Aop:245 Event:1476 KeyEvent Decrease, Glycolysis Aop:245 Event:1477 KeyEvent Oxidative phosphorylation, decreased Aop:245 Event:40 KeyEvent Mitochondrial ATP production, decreased Aop:245 Event:1478 KeyEvent Decrease, Leaf cell mitosis Aop:245 Event:1479 KeyEvent Decrease, Leaf development Aop:245 Event:1521 AdverseOutcome Decrease, Growth Aop:256 Event:1481 MolecularInitiatingEvent Inhibition of mitochondrial DNA polymerase gamma (Pol gamma) Aop:256 Event:1482 KeyEvent Depletion, mtDNA Aop:256 Event:709 KeyEvent Increase, Cytotoxicity (renal tubular cell) Aop:256 Event:814 AdverseOutcome Occurrence, Kidney toxicity Aop:256 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:257 Event:1486 MolecularInitiatingEvent Binding of substrate, endocytic receptor Aop:257 Event:831 KeyEvent Disturbance, Lysosomal function Aop:257 Event:898 KeyEvent Disruption, Lysosome Aop:257 Event:709 KeyEvent Increase, Cytotoxicity (renal tubular cell) Aop:257 Event:814 AdverseOutcome Occurrence, Kidney toxicity Aop:258 Event:244 MolecularInitiatingEvent Alkylation, Protein Aop:258 Event:40 KeyEvent Mitochondrial ATP production, decreased Aop:258 Event:709 KeyEvent Increase, Cytotoxicity (renal tubular cell) Aop:258 Event:814 AdverseOutcome Occurrence, Kidney toxicity Aop:258 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:260 Event:1508 MolecularInitiatingEvent CYP2E1 Activation Aop:260 Event:1509 MolecularInitiatingEvent Protein Adduct Formation Aop:260 Event:1511 KeyEvent Lipid Peroxidation Aop:260 Event:1512 KeyEvent Unfolded Protein Response Aop:260 Event:1513 KeyEvent General Apoptosis Aop:260 Event:1514 AdverseOutcome Neurodegeneration Aop:260 Event:1392 KeyEvent Increase, Oxidative Stress Aop:261 Event:1529 MolecularInitiatingEvent Blockade, L-Type Calcium Channels Aop:261 Event:1530 KeyEvent Decrease, Calcium currents Aop:261 Event:1531 KeyEvent Decrease, Calcium binding to Troponin C Aop:261 Event:1532 KeyEvent Decrease, Cardiac contractility Aop:261 Event:1533 KeyEvent Decrease, Cardiac ejection fraction Aop:261 Event:1535 AdverseOutcome Heart failure Aop:261 Event:1536 KeyEvent Disruption, Intracellular calcium mobilization Aop:261 Event:1537 KeyEvent Disruption, Sarcomere assembly Aop:263 Event:1446 MolecularInitiatingEvent Decrease, Coupling of oxidative phosphorylation Aop:263 Event:1521 AdverseOutcome Decrease, Growth Aop:263 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:263 Event:1821 KeyEvent Decrease, Cell proliferation Aop:264 Event:1446 MolecularInitiatingEvent Decrease, Coupling of oxidative phosphorylation Aop:264 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:264 Event:55 KeyEvent Increase, Cell injury/death Aop:264 Event:1521 AdverseOutcome Decrease, Growth Aop:265 Event:1446 MolecularInitiatingEvent Decrease, Coupling of oxidative phosphorylation Aop:265 Event:2064 KeyEvent Increase, Cytosolic calcium Aop:265 Event:55 KeyEvent Increase, Cell injury/death Aop:265 Event:1521 AdverseOutcome Decrease, Growth Aop:266 Event:1446 MolecularInitiatingEvent Decrease, Coupling of oxidative phosphorylation Aop:266 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:266 Event:1562 KeyEvent Decreased Na/K ATPase activity Aop:266 Event:1527 KeyEvent Increase, Cell membrane depolarization Aop:266 Event:55 KeyEvent Increase, Cell injury/death Aop:266 Event:1521 AdverseOutcome Decrease, Growth Aop:267 Event:1446 MolecularInitiatingEvent Decrease, Coupling of oxidative phosphorylation Aop:267 Event:2070 KeyEvent Increase, Glycolysis Aop:267 Event:2071 KeyEvent Decrease, Glucose pool Aop:267 Event:1821 KeyEvent Decrease, Cell proliferation Aop:267 Event:1521 AdverseOutcome Decrease, Growth Aop:268 Event:1446 MolecularInitiatingEvent Decrease, Coupling of oxidative phosphorylation Aop:268 Event:2072 KeyEvent Increase, Mitochondrial swelling Aop:268 Event:55 KeyEvent Increase, Cell injury/death Aop:268 Event:1521 AdverseOutcome Decrease, Growth Aop:271 Event:279 MolecularInitiatingEvent Thyroperoxidase, Inhibition Aop:271 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:271 Event:219 KeyEvent Reduction, Plasma 17beta-estradiol concentrations Aop:271 Event:221 KeyEvent Reduction, Plasma vitellogenin concentrations Aop:271 Event:78 AdverseOutcome Reduction, Cumulative fecundity and spawning Aop:272 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:272 Event:1635 KeyEvent Increase, DNA strand breaks Aop:272 Event:155 KeyEvent Inadequate DNA repair Aop:272 Event:185 KeyEvent Increase, Mutations Aop:272 Event:1636 KeyEvent Increase, Chromosomal aberrations Aop:272 Event:870 KeyEvent Increase, Cell Proliferation Aop:272 Event:1556 AdverseOutcome Increase, lung cancer Aop:273 Event:1542 MolecularInitiatingEvent Inhibition, Mitochondrial complex III Aop:273 Event:1543 MolecularInitiatingEvent Mitochondrial Complex IV inhibition Aop:273 Event:1544 MolecularInitiatingEvent Mitochondrial Complex V inhibition Aop:273 Event:1545 KeyEvent Decreased, mitochondrial oxidative phosphorylation Aop:273 Event:1547 KeyEvent Mitochondrial Injury Aop:273 Event:1548 AdverseOutcome Necrotic Tissue Aop:273 Event:1549 AdverseOutcome Liver Injury Aop:273 Event:888 MolecularInitiatingEvent Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) Aop:273 Event:887 MolecularInitiatingEvent Inhibition, NADH-ubiquinone oxidoreductase (complex I) Aop:273 Event:889 KeyEvent Proteostasis, impaired Aop:273 Event:55 KeyEvent Increase, Cell injury/death Aop:273 Event:1653 MolecularInitiatingEvent Binding of inhibitor to mitochondrial complex III Aop:273 Event:1654 MolecularInitiatingEvent Binding of inhibitor to mitochondrial complex IV Aop:273 Event:1655 MolecularInitiatingEvent Binding of inhibitor to mitochondrial complex V Aop:273 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:273 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:274 Event:1502 MolecularInitiatingEvent Histone deacetylase inhibition Aop:274 Event:1557 KeyEvent Neural crest cell migration, reduced Aop:274 Event:1558 KeyEvent Collagen production, reduced Aop:274 Event:1559 AdverseOutcome Facial cartilage structures are reduced in size and morphologically distorted Aop:275 Event:1502 MolecularInitiatingEvent Histone deacetylase inhibition Aop:275 Event:1503 KeyEvent Histone acetylation, increase Aop:275 Event:1239 KeyEvent Altered, Gene Expression Aop:275 Event:1560 KeyEvent Cell differentiation, altered Aop:275 Event:1561 AdverseOutcome Neural tube defects Aop:276 Event:888 MolecularInitiatingEvent Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) Aop:276 Event:887 KeyEvent Inhibition, NADH-ubiquinone oxidoreductase (complex I) Aop:276 Event:1477 KeyEvent Oxidative phosphorylation, decreased Aop:276 Event:1562 KeyEvent Decreased Na/K ATPase activity Aop:276 Event:1563 KeyEvent Decreased proximal tubular vectorial transport Aop:276 Event:1564 AdverseOutcome Chemical induced Fanconi syndrome Aop:277 Event:1700 MolecularInitiatingEvent Impaired IL-1R1 signaling in T cell Aop:277 Event:1702 KeyEvent Suppression of T cell activation Aop:277 Event:202 KeyEvent Inhibition, Nuclear factor kappa B (NF-kB) Aop:277 Event:984 AdverseOutcome Impairment, T-cell dependent antibody response Aop:278 Event:1574 MolecularInitiatingEvent Inhibition, IKK complex Aop:278 Event:202 KeyEvent Inhibition, Nuclear factor kappa B (NF-kB) Aop:278 Event:1575 KeyEvent Activation, Caspase 8 pathway Aop:278 Event:55 KeyEvent Increase, Cell injury/death Aop:278 Event:1576 KeyEvent Activation, Tissue resident cells (Kuppfer cells) Aop:278 Event:1548 AdverseOutcome Necrotic Tissue Aop:278 Event:1549 AdverseOutcome Liver Injury Aop:278 Event:1579 KeyEvent Increase, proinflammatory mediators (TNFalpha) Aop:279 Event:1580 MolecularInitiatingEvent Binding of microtubule stabilizing agents (MSA) to microtubules Aop:279 Event:1581 KeyEvent Disturbance in microtubule dynamic instability Aop:279 Event:1582 KeyEvent Impaired axonial transport Aop:279 Event:1583 AdverseOutcome Sensory axonal peripheral neuropathy Aop:280 Event:1584 MolecularInitiatingEvent Interaction of α-diketones with arginine residues Aop:280 Event:1585 KeyEvent Proteasomal dysfunction Aop:280 Event:1586 KeyEvent Airway epithelial injury Aop:280 Event:149 KeyEvent Increase, Inflammation Aop:280 Event:1457 KeyEvent Epithelial Mesenchymal Transition Aop:280 Event:1587 KeyEvent Fibroproliferative airway lesions Aop:280 Event:1588 AdverseOutcome Bronchiolitis obliterans Aop:281 Event:12 MolecularInitiatingEvent Acetylcholinesterase (AchE) Inhibition Aop:281 Event:10 KeyEvent Acetylcholine accumulation in synapses Aop:281 Event:1602 KeyEvent Increased Muscarinic Acetylcholine Receptors Aop:281 Event:388 KeyEvent Overactivation, NMDARs Aop:281 Event:389 KeyEvent Increased, Intracellular Calcium overload Aop:281 Event:55 KeyEvent Increase, Cell injury/death Aop:281 Event:1623 KeyEvent Occurrence, Focal Seizure Aop:281 Event:352 AdverseOutcome N/A, Neurodegeneration Aop:281 Event:1788 KeyEvent Status epilepticus Aop:281 Event:1350 KeyEvent Increased, glutamate Aop:282 Event:1594 KeyEvent Oxidation of membrane lipids Aop:282 Event:1595 KeyEvent Oxidation/denatuation of membrane proteins Aop:282 Event:1599 AdverseOutcome Inflamatory events in light-exposed tissues Aop:282 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:284 Event:1487 MolecularInitiatingEvent Binding, Thiol/seleno-proteins involved in protection against oxidative stress Aop:284 Event:926 KeyEvent Oxidation, Glutathione (To be considered with MIE) Aop:284 Event:1538 KeyEvent Decreased protection against oxidative stress Aop:284 Event:1392 KeyEvent Increase, Oxidative Stress Aop:284 Event:178 KeyEvent Mitochondrial electron transport chain, disrupted Aop:284 Event:768 KeyEvent Increase, Cytotoxicity Aop:284 Event:1603 AdverseOutcome Chronic kidney disease Aop:285 Event:1604 MolecularInitiatingEvent Inhibition of N-linked glycosylation Aop:285 Event:1605 KeyEvent Accumulation of misfolded proteins Aop:285 Event:1512 KeyEvent Unfolded Protein Response Aop:285 Event:1262 KeyEvent Apoptosis Aop:285 Event:1606 KeyEvent Activation, Stellate cell Aop:285 Event:459 KeyEvent Increase, Liver steatosis Aop:285 Event:1549 AdverseOutcome Liver Injury Aop:286 Event:1542 MolecularInitiatingEvent Inhibition, Mitochondrial complex III Aop:286 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:286 Event:1821 KeyEvent Decrease, Cell proliferation Aop:286 Event:1521 AdverseOutcome Decrease, Growth Aop:287 Event:1542 MolecularInitiatingEvent Inhibition, Mitochondrial complex III Aop:287 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:287 Event:1825 KeyEvent Increase, Cell death Aop:287 Event:1521 AdverseOutcome Decrease, Growth Aop:288 Event:1609 MolecularInitiatingEvent Inhibition, Cytochrome P450 enzyme (CYP17A1) activity Aop:288 Event:1610 KeyEvent Reduction, dehydroepiandrosterone Aop:288 Event:1611 KeyEvent Reduction, androstenedione Aop:288 Event:1613 KeyEvent Decrease, dihydrotestosterone (DHT) levels Aop:288 Event:1614 KeyEvent Decrease, androgen receptor activation Aop:288 Event:1615 KeyEvent Impaired inguinoscrotal testicular descent phase Aop:288 Event:1616 AdverseOutcome Malformation, cryptorchidism - maldescended testis Aop:288 Event:1690 KeyEvent Decrease, circulating testosterone levels Aop:289 Event:1617 MolecularInitiatingEvent Inhibition, 5α-reductase Aop:289 Event:1613 KeyEvent Decrease, dihydrotestosterone (DHT) levels Aop:289 Event:219 KeyEvent Reduction, Plasma 17beta-estradiol concentrations Aop:289 Event:221 KeyEvent Reduction, Plasma vitellogenin concentrations Aop:289 Event:78 KeyEvent Reduction, Cumulative fecundity and spawning Aop:289 Event:360 AdverseOutcome Decrease, Population growth rate Aop:290 Event:1785 MolecularInitiatingEvent Increase, Mitochondrial ATP synthase antagonism Aop:290 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:290 Event:1821 KeyEvent Decrease, Cell proliferation Aop:290 Event:1521 AdverseOutcome Decrease, Growth Aop:291 Event:1785 MolecularInitiatingEvent Increase, Mitochondrial ATP synthase antagonism Aop:291 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:291 Event:1825 KeyEvent Increase, Cell death Aop:291 Event:1521 AdverseOutcome Decrease, Growth Aop:292 Event:1627 MolecularInitiatingEvent Inhibition of tyrosinase Aop:292 Event:1628 KeyEvent Reduction of L-Dopaquinone Aop:292 Event:1629 KeyEvent Reduction in melanin level Aop:292 Event:1630 KeyEvent Reduction of melanosome level Aop:292 Event:1631 KeyEvent Reduction fo Pigmentation pattern Aop:292 Event:360 AdverseOutcome Decrease, Population growth rate Aop:293 Event:1194 MolecularInitiatingEvent Increase, DNA damage Aop:293 Event:1193 AdverseOutcome N/A, Breast Cancer Aop:293 Event:1492 KeyEvent Tissue resident cell activation Aop:293 Event:1493 KeyEvent Increased Pro-inflammatory mediators Aop:293 Event:1632 KeyEvent Increase in reactive oxygen and nitrogen species (RONS) Aop:293 Event:1494 KeyEvent Leukocyte recruitment/activation Aop:293 Event:1182 KeyEvent Increase, Cell Proliferation (Epithelial Cells) Aop:293 Event:1192 AdverseOutcome Increased, Ductal Hyperplasia Aop:293 Event:185 AdverseOutcome Increase, Mutations Aop:294 Event:1632 MolecularInitiatingEvent Increase in reactive oxygen and nitrogen species (RONS) Aop:294 Event:1194 AdverseOutcome Increase, DNA damage Aop:294 Event:185 AdverseOutcome Increase, Mutations Aop:294 Event:1193 AdverseOutcome N/A, Breast Cancer Aop:294 Event:1182 KeyEvent Increase, Cell Proliferation (Epithelial Cells) Aop:294 Event:1492 KeyEvent Tissue resident cell activation Aop:294 Event:1493 KeyEvent Increased Pro-inflammatory mediators Aop:294 Event:1494 KeyEvent Leukocyte recruitment/activation Aop:294 Event:1192 AdverseOutcome Increased, Ductal Hyperplasia Aop:296 Event:1634 MolecularInitiatingEvent Increase, Oxidative DNA damage Aop:296 Event:155 KeyEvent Inadequate DNA repair Aop:296 Event:1635 KeyEvent Increase, DNA strand breaks Aop:296 Event:185 AdverseOutcome Increase, Mutations Aop:296 Event:1636 AdverseOutcome Increase, Chromosomal aberrations Aop:297 Event:1637 MolecularInitiatingEvent Retinaldehyde dehydrogenase inhibition Aop:297 Event:1640 KeyEvent Altered, Photoreceptor patterning Aop:297 Event:1641 KeyEvent Decreased retinoic acid (RA) synthesis Aop:297 Event:1642 KeyEvent Decreased plasma RA level Aop:297 Event:1643 KeyEvent Altered, Visual function Aop:297 Event:360 AdverseOutcome Decrease, Population growth rate Aop:298 Event:1651 AdverseOutcome Treatment-resistant gastric cancer Aop:298 Event:1754 KeyEvent Increase, porcupine-induced Wnt secretion and Wnt signaling activation Aop:298 Event:1755 KeyEvent beta-catenin activation Aop:298 Event:1457 KeyEvent Epithelial Mesenchymal Transition Aop:298 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:299 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:299 Event:1634 KeyEvent Increase, Oxidative DNA damage Aop:299 Event:1444 KeyEvent Increase, Follicular atresia Aop:299 Event:1366 KeyEvent Decrease, Oogenesis Aop:299 Event:78 AdverseOutcome Reduction, Cumulative fecundity and spawning Aop:299 Event:360 AdverseOutcome Decrease, Population growth rate Aop:299 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:300 Event:1656 MolecularInitiatingEvent Antagonism, Thyroid Receptor Aop:300 Event:756 KeyEvent Hippocampal gene expression, Altered Aop:300 Event:757 KeyEvent Hippocampal anatomy, Altered Aop:300 Event:758 KeyEvent Hippocampal Physiology, Altered Aop:300 Event:402 AdverseOutcome Cognitive function, decreased Aop:301 Event:1657 MolecularInitiatingEvent Inhibition of cystathionine beta-synthase Aop:301 Event:1661 KeyEvent Increased Homocysteine level Aop:301 Event:1665 KeyEvent Increased, Plasma HCY level Aop:301 Event:1666 KeyEvent Induced, dysfunction of microcirculation Aop:301 Event:1667 AdverseOutcome Impaired,anterior-posterior axis development Aop:302 Event:1677 KeyEvent Reduced tidal volume Aop:302 Event:1498 KeyEvent Loss of alveolar capillary membrane integrity Aop:302 Event:1672 MolecularInitiatingEvent Inhibition of lung surfactant function Aop:302 Event:1673 KeyEvent Alveolar collapse Aop:302 Event:1250 AdverseOutcome Decrease, Lung function Aop:303 Event:1668 MolecularInitiatingEvent Frustrated phagocytosis Aop:303 Event:87 KeyEvent Release, Cytokine Aop:303 Event:1497 KeyEvent Increased, recruitment of inflammatory cells Aop:303 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:303 Event:1669 KeyEvent Increased, DNA damage and mutation Aop:303 Event:870 KeyEvent Increase, Cell Proliferation Aop:303 Event:1670 AdverseOutcome Lung cancer Aop:304 Event:1680 MolecularInitiatingEvent Inhibition, TBX1 Aop:304 Event:1681 KeyEvent Disruption, Neural crest cell migration Aop:304 Event:1682 KeyEvent Disruption, Progenitor cells of second heart field Aop:304 Event:1683 KeyEvent Impairment, Fourth pharyngeal arch development Aop:304 Event:1684 KeyEvent Abnormalities, Cardiac outflow tract formation Aop:304 Event:1685 AdverseOutcome Anomalies, Congenital cardiac conotruncal Aop:305 Event:1617 MolecularInitiatingEvent Inhibition, 5α-reductase Aop:305 Event:1613 KeyEvent Decrease, dihydrotestosterone (DHT) levels Aop:305 Event:1614 KeyEvent Decrease, androgen receptor activation Aop:305 Event:1688 AdverseOutcome anogenital distance (AGD), decreased Aop:305 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:306 Event:26 MolecularInitiatingEvent Antagonism, Androgen receptor Aop:306 Event:1614 KeyEvent Decrease, androgen receptor activation Aop:306 Event:1688 AdverseOutcome anogenital distance (AGD), decreased Aop:306 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:307 Event:1690 KeyEvent Decrease, circulating testosterone levels Aop:307 Event:1614 KeyEvent Decrease, androgen receptor activation Aop:307 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:307 Event:1688 AdverseOutcome anogenital distance (AGD), decreased Aop:307 Event:2298 KeyEvent Decrease, intratesticular testosterone levels Aop:309 Event:1691 MolecularInitiatingEvent Antagonism,LH receptor Aop:309 Event:1692 KeyEvent Reduction, Progesterone synthesis Aop:309 Event:1693 KeyEvent Decreased, Progesterone levels Aop:309 Event:1694 KeyEvent Reduction, progesterone uptake, decresed maturation Aop:309 Event:1695 KeyEvent Impaired ovulation Aop:309 Event:1696 KeyEvent Decrease of egg production and cummulative fecundity Aop:309 Event:679 AdverseOutcome Decline, Population trajectory Aop:310 Event:18 MolecularInitiatingEvent Activation, AhR Aop:310 Event:1697 KeyEvent Increase, DNA methyltransferase expression Aop:310 Event:1698 KeyEvent Increase, hypermethylation of the promotor region of gonadotropin releasing hormone receptor Aop:310 Event:1699 KeyEvent Decrease, expression of gonadotropin releasing hormone receptor Aop:310 Event:3 KeyEvent Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Aop:310 Event:219 KeyEvent Reduction, Plasma 17beta-estradiol concentrations Aop:310 Event:285 KeyEvent Reduction, Vitellogenin synthesis in liver Aop:310 Event:221 KeyEvent Reduction, Plasma vitellogenin concentrations Aop:310 Event:309 KeyEvent Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Aop:310 Event:944 KeyEvent dimerization, AHR/ARNT Aop:310 Event:78 AdverseOutcome Reduction, Cumulative fecundity and spawning Aop:310 Event:360 AdverseOutcome Decrease, Population growth rate Aop:311 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:311 Event:1634 KeyEvent Increase, Oxidative DNA damage Aop:311 Event:1775 KeyEvent Increase, Oocyte apoptosis Aop:311 Event:1366 KeyEvent Decrease, Oogenesis Aop:311 Event:78 AdverseOutcome Reduction, Cumulative fecundity and spawning Aop:311 Event:360 AdverseOutcome Decrease, Population growth rate Aop:311 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:312 Event:12 MolecularInitiatingEvent Acetylcholinesterase (AchE) Inhibition Aop:312 Event:10 KeyEvent Acetylcholine accumulation in synapses Aop:312 Event:39 KeyEvent Increased Cholinergic Signaling Aop:312 Event:1705 KeyEvent Impaired coordination and movement Aop:312 Event:351 AdverseOutcome Increased Mortality Aop:312 Event:360 AdverseOutcome Decrease, Population growth rate Aop:313 Event:1706 MolecularInitiatingEvent Stimulation, TLR7/8 Aop:313 Event:1707 KeyEvent Increase, IL-23 from matured dendritic cells Aop:313 Event:1708 KeyEvent Th17 cell migration and inflammation induction Aop:313 Event:1709 AdverseOutcome Psoriatic skin disease Aop:313 Event:1822 KeyEvent Maturation of TNF/iNOS-Producing Dendritic Cells Aop:314 Event:1710 MolecularInitiatingEvent Binding to estrogen receptor (ER)-α in immune cells Aop:314 Event:1711 KeyEvent Induction of GATA3 expression Aop:314 Event:1712 KeyEvent Increase of Th2 cells producing IL-4 Aop:314 Event:1713 KeyEvent Increase of anti-DNA antibody from autoreactive B cell Aop:314 Event:1714 AdverseOutcome Exacerbation of systemic lupus erythematosus (SLE) Aop:315 Event:1715 MolecularInitiatingEvent Inhibition of JAK3 Aop:315 Event:1716 KeyEvent Blockade of STAT5 phosphorylation Aop:315 Event:1717 KeyEvent Suppression of STAT5 binding to cytokine gene promoters Aop:315 Event:1718 KeyEvent Suppression of IL-4 production Aop:315 Event:1719 AdverseOutcome Impairment of T-cell dependent antibody response Aop:316 Event:1720 MolecularInitiatingEvent Trypsin inhibition Aop:316 Event:1721 KeyEvent Increased intestinal monitor peptide level Aop:316 Event:1722 KeyEvent Increased blood CCK level Aop:316 Event:1723 KeyEvent Increased exocrine secretion from pancreatic acinar cells Aop:316 Event:1724 KeyEvent Acinar cell proliferation Aop:316 Event:1725 AdverseOutcome Pancreatic acinar cell tumors Aop:318 Event:122 MolecularInitiatingEvent Increase, Glucocorticoid receptor activation Aop:318 Event:860 KeyEvent Decreased, Mitochondrial Fatty Acid Beta Oxidation Aop:318 Event:459 AdverseOutcome Increase, Liver steatosis Aop:318 Event:291 KeyEvent Accumulation, Triglyceride Aop:318 Event:1834 KeyEvent Decrease, Acyl-CoA dehydrogenases Aop:319 Event:1752 KeyEvent Increased Angiotensin II Aop:319 Event:1740 MolecularInitiatingEvent Induced dysregulation of ACE2 Aop:319 Event:68 KeyEvent Increase, Collagen accumulation Aop:319 Event:1276 AdverseOutcome Lung fibrosis Aop:319 Event:1851 KeyEvent Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) Aop:319 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:319 Event:1172 KeyEvent Increased activation, Nuclear factor kappa B (NF-kB) Aop:319 Event:1496 KeyEvent Increased, secretion of proinflammatory mediators Aop:319 Event:1854 KeyEvent Dysregulation, ACE2 expression and activity Aop:320 Event:1496 KeyEvent Increased, secretion of proinflammatory mediators Aop:320 Event:1738 KeyEvent SARS-CoV-2 cell entry Aop:320 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:320 Event:1748 KeyEvent Increase, the risk of acute respiratory failure Aop:320 Event:1750 KeyEvent Increased inflammatory immune responses Aop:320 Event:351 AdverseOutcome Increased Mortality Aop:320 Event:1848 KeyEvent Toll Like Receptor (TLR) Dysregulation Aop:320 Event:1847 KeyEvent Increased SARS-CoV-2 production Aop:320 Event:1901 KeyEvent Interferon-I antiviral response, antagonized by SARS-CoV-2 Aop:322 Event:97 MolecularInitiatingEvent Alkylation, DNA Aop:322 Event:155 KeyEvent Inadequate DNA repair Aop:322 Event:1635 KeyEvent Increase, DNA strand breaks Aop:322 Event:1365 KeyEvent Increase, Apoptosis Aop:322 Event:1757 AdverseOutcome Reduce, Sperm count Aop:323 Event:227 MolecularInitiatingEvent Activation, PPARα Aop:323 Event:807 KeyEvent Decreased, cholesterol Aop:323 Event:1756 KeyEvent Decreased, plasma 11-ketotestosterone level Aop:323 Event:1758 KeyEvent Impaired, Spermatogenesis Aop:323 Event:360 AdverseOutcome Decrease, Population growth rate Aop:323 Event:2147 AdverseOutcome Decreased, Viable Offspring Aop:324 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:324 Event:1392 KeyEvent Increase, Oxidative Stress Aop:324 Event:1446 KeyEvent Decrease, Coupling of oxidative phosphorylation Aop:324 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:324 Event:55 KeyEvent Increase, Cell injury/death Aop:324 Event:1521 AdverseOutcome Decrease, Growth Aop:325 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:325 Event:1392 KeyEvent Increase, Oxidative Stress Aop:325 Event:1446 KeyEvent Decrease, Coupling of oxidative phosphorylation Aop:325 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:325 Event:2327 KeyEvent Decrease, Cell growth Aop:325 Event:1521 AdverseOutcome Decrease, Growth Aop:326 Event:1521 AdverseOutcome Decrease, Growth Aop:326 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:326 Event:1392 KeyEvent Increase, Oxidative Stress Aop:326 Event:1446 KeyEvent Decrease, Coupling of oxidative phosphorylation Aop:326 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:326 Event:1821 KeyEvent Decrease, Cell proliferation Aop:327 Event:1767 KeyEvent Increase, Protein oxidation Aop:327 Event:1768 KeyEvent Increase, Abnormal osmoregulation Aop:327 Event:1769 KeyEvent Increase, Body fluid overload Aop:327 Event:350 AdverseOutcome Increase, Mortality Aop:327 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:328 Event:1770 KeyEvent Decrease, Mitochondrial membrane potential Aop:328 Event:1477 KeyEvent Oxidative phosphorylation, decreased Aop:328 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:328 Event:350 AdverseOutcome Increase, Mortality Aop:328 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:329 Event:1445 KeyEvent Increase, Lipid peroxidation Aop:329 Event:1772 KeyEvent Decrease, Triglyceride Aop:329 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:329 Event:350 AdverseOutcome Increase, Mortality Aop:329 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:330 Event:1634 KeyEvent Increase, Oxidative DNA damage Aop:330 Event:1461 KeyEvent Increase, DNA double-strand breaks Aop:330 Event:1365 KeyEvent Increase, Apoptosis Aop:330 Event:350 AdverseOutcome Increase, Mortality Aop:330 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:331 Event:1521 AdverseOutcome Decrease, Growth Aop:331 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:331 Event:1392 KeyEvent Increase, Oxidative Stress Aop:331 Event:1445 KeyEvent Increase, Lipid peroxidation Aop:331 Event:1446 KeyEvent Decrease, Coupling of oxidative phosphorylation Aop:331 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:331 Event:55 KeyEvent Increase, Cell injury/death Aop:332 Event:1445 KeyEvent Increase, Lipid peroxidation Aop:332 Event:1521 AdverseOutcome Decrease, Growth Aop:332 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:332 Event:1392 KeyEvent Increase, Oxidative Stress Aop:332 Event:1446 KeyEvent Decrease, Coupling of oxidative phosphorylation Aop:332 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:332 Event:2327 KeyEvent Decrease, Cell growth Aop:333 Event:1446 KeyEvent Decrease, Coupling of oxidative phosphorylation Aop:333 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:333 Event:1821 KeyEvent Decrease, Cell proliferation Aop:333 Event:1521 AdverseOutcome Decrease, Growth Aop:333 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:333 Event:1445 KeyEvent Increase, Lipid peroxidation Aop:333 Event:1392 KeyEvent Increase, Oxidative Stress Aop:334 Event:122 MolecularInitiatingEvent Increase, Glucocorticoid receptor activation Aop:334 Event:1761 KeyEvent Inhibition, Fin regeneration Aop:334 Event:1005 KeyEvent Reduced, Swimming performance Aop:334 Event:360 AdverseOutcome Decrease, Population growth rate Aop:334 Event:2245 KeyEvent Altered Cell Differentiation Signaling Aop:334 Event:2089 KeyEvent Altered Bone Cell Homeostasis Aop:335 Event:1762 KeyEvent Urothelial cell injury/death Aop:335 Event:795 KeyEvent Increase, Regenerative cell proliferation (urothelial cells) Aop:335 Event:796 KeyEvent Increase, Hyperplasia (urothelial) Aop:335 Event:1763 AdverseOutcome Urothelial Tumor Aop:335 Event:177 MolecularInitiatingEvent Increase, Mitochondrial dysfunction Aop:336 Event:1619 MolecularInitiatingEvent Increase, DNA methyltransferase inhibition Aop:336 Event:1773 KeyEvent Decrease, Global DNA methylation Aop:336 Event:1774 KeyEvent Increase, Caspase transcription Aop:336 Event:1775 KeyEvent Increase, Oocyte apoptosis Aop:336 Event:1366 KeyEvent Decrease, Oogenesis Aop:336 Event:328 AdverseOutcome Decrease, Fecundity Aop:336 Event:360 AdverseOutcome Decrease, Population growth rate Aop:337 Event:1619 MolecularInitiatingEvent Increase, DNA methyltransferase inhibition Aop:337 Event:1773 KeyEvent Decrease, Global DNA methylation Aop:337 Event:1774 KeyEvent Increase, Caspase transcription Aop:337 Event:1776 KeyEvent Increase, Ovarian somatic cell apoptosis Aop:337 Event:1777 KeyEvent Increase, Ovarian follicle breakdown Aop:337 Event:1366 KeyEvent Decrease, Oogenesis Aop:337 Event:328 AdverseOutcome Decrease, Fecundity Aop:337 Event:360 AdverseOutcome Decrease, Population growth rate Aop:338 Event:1619 MolecularInitiatingEvent Increase, DNA methyltransferase inhibition Aop:338 Event:1774 KeyEvent Increase, Caspase transcription Aop:338 Event:1775 KeyEvent Increase, Oocyte apoptosis Aop:338 Event:1366 KeyEvent Decrease, Oogenesis Aop:338 Event:328 AdverseOutcome Decrease, Fecundity Aop:338 Event:360 AdverseOutcome Decrease, Population growth rate Aop:338 Event:1461 KeyEvent Increase, DNA double-strand breaks Aop:339 Event:1619 MolecularInitiatingEvent Increase, DNA methyltransferase inhibition Aop:339 Event:1774 KeyEvent Increase, Caspase transcription Aop:339 Event:1776 KeyEvent Increase, Ovarian somatic cell apoptosis Aop:339 Event:1777 KeyEvent Increase, Ovarian follicle breakdown Aop:339 Event:1366 KeyEvent Decrease, Oogenesis Aop:339 Event:328 AdverseOutcome Decrease, Fecundity Aop:339 Event:360 AdverseOutcome Decrease, Population growth rate Aop:339 Event:1461 KeyEvent Increase, DNA double-strand breaks Aop:340 Event:1619 MolecularInitiatingEvent Increase, DNA methyltransferase inhibition Aop:340 Event:1773 KeyEvent Decrease, Global DNA methylation Aop:340 Event:1778 KeyEvent Decrease, Heritable DNA methylation (F3) Aop:340 Event:1779 KeyEvent Increase, Caspase transcription (F3) Aop:340 Event:1780 KeyEvent Increase, Oocyte apoptosis (F3) Aop:340 Event:1781 AdverseOutcome Decrease, Fecundity (F3) Aop:340 Event:360 AdverseOutcome Decrease, Population growth rate Aop:340 Event:1782 KeyEvent Decrease, Oogenesis (F3) Aop:341 Event:1619 MolecularInitiatingEvent Increase, DNA methyltransferase inhibition Aop:341 Event:1773 KeyEvent Decrease, Global DNA methylation Aop:341 Event:1778 KeyEvent Decrease, Heritable DNA methylation (F3) Aop:341 Event:1779 KeyEvent Increase, Caspase transcription (F3) Aop:341 Event:1783 KeyEvent Increase, Ovarian somatic cell apoptosis (F3) Aop:341 Event:1784 KeyEvent Increase, Ovarian follicle breakdown (F3) Aop:341 Event:1782 KeyEvent Decrease, Oogenesis (F3) Aop:341 Event:1781 AdverseOutcome Decrease, Fecundity (F3) Aop:341 Event:360 AdverseOutcome Decrease, Population growth rate Aop:342 Event:103 MolecularInitiatingEvent Increase, Ecdysone receptor hyperactivation Aop:342 Event:2373 KeyEvent Increase, Mis-timed ecdysone receptor-responsive nuclear receptor cascade Aop:342 Event:988 KeyEvent Decrease, Circulating ecdysis triggering hormone Aop:342 Event:1266 KeyEvent Decrease, Circulating crustacean cardioactive peptide Aop:342 Event:1267 KeyEvent Decrease, Ecdysis motor program activity Aop:342 Event:993 KeyEvent Decrease, Abdominal muscle contraction Aop:342 Event:990 AdverseOutcome Increase, Incomplete ecdysis Aop:342 Event:350 AdverseOutcome Increase, Mortality Aop:343 Event:2374 MolecularInitiatingEvent Increase, Ecdysone receptor antagonism Aop:343 Event:2375 KeyEvent Decrease, Mis-timed ecdysone receptor-responsive nuclear receptor cascade Aop:343 Event:988 KeyEvent Decrease, Circulating ecdysis triggering hormone Aop:343 Event:1266 KeyEvent Decrease, Circulating crustacean cardioactive peptide Aop:343 Event:1267 KeyEvent Decrease, Ecdysis motor program activity Aop:343 Event:993 KeyEvent Decrease, Abdominal muscle contraction Aop:343 Event:990 AdverseOutcome Increase, Incomplete ecdysis Aop:343 Event:350 AdverseOutcome Increase, Mortality Aop:344 Event:1614 KeyEvent Decrease, androgen receptor activation Aop:344 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:344 Event:26 MolecularInitiatingEvent Antagonism, Androgen receptor Aop:344 Event:1786 AdverseOutcome Nipple retention (NR), increased Aop:345 Event:26 MolecularInitiatingEvent Antagonism, Androgen receptor Aop:345 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:345 Event:1800 KeyEvent Granulosa cell proliferation of gonadotropin-independent follicles, Reduced Aop:345 Event:405 AdverseOutcome disrupted, ovarian cycle Aop:345 Event:406 AdverseOutcome decreased, Fertility Aop:345 Event:1614 KeyEvent Decrease, androgen receptor activation Aop:346 Event:36 MolecularInitiatingEvent Inhibition, Aromatase Aop:346 Event:1789 KeyEvent Reduction, 17beta-estradiol synthesis by the undifferentiated gonad Aop:346 Event:1790 KeyEvent Increased, Differentiation to Testis Aop:346 Event:1791 KeyEvent Increased, Male Biased Sex Ratio Aop:346 Event:360 AdverseOutcome Decrease, Population growth rate Aop:347 Event:1792 MolecularInitiatingEvent Toll-like receptor 4 activation Aop:347 Event:1270 MolecularInitiatingEvent Inactivation of PPARγ Aop:347 Event:1292 KeyEvent Activation, JNK Aop:347 Event:1793 KeyEvent Activator protein 1 activation Aop:347 Event:1794 KeyEvent Pin-1 activation Aop:347 Event:1795 KeyEvent Latent Transforming growth Factor beta expression Aop:347 Event:1283 KeyEvent Activation, TGF-beta pathway Aop:347 Event:1457 KeyEvent Epithelial Mesenchymal Transition Aop:347 Event:1458 AdverseOutcome Pulmonary fibrosis Aop:348 Event:1799 MolecularInitiatingEvent Inhibition of 11β-HSD Aop:348 Event:1756 KeyEvent Decreased, plasma 11-ketotestosterone level Aop:348 Event:1758 KeyEvent Impaired, Spermatogenesis Aop:348 Event:360 AdverseOutcome Decrease, Population growth rate Aop:348 Event:406 KeyEvent decreased, Fertility Aop:349 Event:1796 MolecularInitiatingEvent 11β-hydroxylase inhibition Aop:349 Event:1756 KeyEvent Decreased, plasma 11-ketotestosterone level Aop:349 Event:1798 KeyEvent Decreased spermatogenesis Aop:349 Event:1835 KeyEvent Cortisol and 11β-(OH) testosterone decreased Aop:349 Event:1836 KeyEvent Decreased plasma Cortisol level Aop:349 Event:1837 KeyEvent decreased oocyte maturation Aop:349 Event:360 AdverseOutcome Decrease, Population growth rate Aop:349 Event:406 KeyEvent decreased, Fertility Aop:358 Event:1806 MolecularInitiatingEvent Inhibition, Chitinase Aop:358 Event:996 KeyEvent Decrease, Digestion of old cuticle Aop:358 Event:1524 KeyEvent Increase, Premature molting Aop:358 Event:350 AdverseOutcome Increase, Mortality Aop:359 Event:1807 MolecularInitiatingEvent Inhibition, Chitobiase Aop:359 Event:996 KeyEvent Decrease, Digestion of old cuticle Aop:359 Event:1524 KeyEvent Increase, Premature molting Aop:359 Event:350 AdverseOutcome Increase, Mortality Aop:360 Event:1522 MolecularInitiatingEvent Inhibition, Chitin synthase 1 Aop:360 Event:1523 KeyEvent Decrease, Cuticular chitin content Aop:360 Event:1524 KeyEvent Increase, Premature molting Aop:360 Event:350 AdverseOutcome Increase, Mortality Aop:361 Event:1525 MolecularInitiatingEvent Increase, Sulfonylurea receptor binding Aop:361 Event:1527 KeyEvent Increase, Cell membrane depolarization Aop:361 Event:1526 KeyEvent Increase, Opening of voltage-dependent calcium channel Aop:361 Event:1523 KeyEvent Decrease, Cuticular chitin content Aop:361 Event:1524 KeyEvent Increase, Premature molting Aop:361 Event:350 AdverseOutcome Increase, Mortality Aop:362 Event:1814 MolecularInitiatingEvent benzoquinone imine and acylglucuronide metabolites Aop:362 Event:1817 KeyEvent Apoptotic cell death Aop:362 Event:1818 KeyEvent Immune cell activation Aop:362 Event:1819 KeyEvent IFNγ signaling Aop:362 Event:1633 KeyEvent Increase in inflammation Aop:362 Event:1820 AdverseOutcome Immune mediated hepatitis Aop:362 Event:1815 KeyEvent Increase, Endoplasmic reticulum stress Aop:362 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:363 Event:279 MolecularInitiatingEvent Thyroperoxidase, Inhibition Aop:363 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:363 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:363 Event:1003 KeyEvent Decreased, Triiodothyronine (T3) Aop:363 Event:351 AdverseOutcome Increased Mortality Aop:363 Event:360 AdverseOutcome Decrease, Population growth rate Aop:363 Event:1877 KeyEvent Altered, retinal layer structure Aop:363 Event:1643 KeyEvent Altered, Visual function Aop:364 Event:279 MolecularInitiatingEvent Thyroperoxidase, Inhibition Aop:364 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:364 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:364 Event:1003 KeyEvent Decreased, Triiodothyronine (T3) Aop:364 Event:1878 KeyEvent Decreased, Eye size Aop:364 Event:351 AdverseOutcome Increased Mortality Aop:364 Event:360 AdverseOutcome Decrease, Population growth rate Aop:364 Event:1643 KeyEvent Altered, Visual function Aop:365 Event:279 MolecularInitiatingEvent Thyroperoxidase, Inhibition Aop:365 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:365 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:365 Event:1003 KeyEvent Decreased, Triiodothyronine (T3) Aop:365 Event:1640 KeyEvent Altered, Photoreceptor patterning Aop:365 Event:351 AdverseOutcome Increased Mortality Aop:365 Event:360 AdverseOutcome Decrease, Population growth rate Aop:365 Event:1643 KeyEvent Altered, Visual function Aop:366 Event:957 MolecularInitiatingEvent Binding, Transthyretin in serum Aop:366 Event:959 KeyEvent Increased, Free serum thyroxine (T4) Aop:366 Event:1158 KeyEvent Increased, Hepatic thyroid hormone uptake/transport Aop:366 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:366 Event:1101 AdverseOutcome Altered, Amphibian metamorphosis Aop:366 Event:1830 KeyEvent Displacement, Serum thyroxine (T4) from carrier protein Aop:366 Event:961 KeyEvent Increased, Clearance of thyroxine from serum Aop:367 Event:1831 MolecularInitiatingEvent Binding, Thyroid binding globulin in serum Aop:367 Event:1830 KeyEvent Displacement, Serum thyroxine (T4) from carrier protein Aop:367 Event:959 KeyEvent Increased, Free serum thyroxine (T4) Aop:367 Event:1158 KeyEvent Increased, Hepatic thyroid hormone uptake/transport Aop:367 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:367 Event:1101 AdverseOutcome Altered, Amphibian metamorphosis Aop:367 Event:961 KeyEvent Increased, Clearance of thyroxine from serum Aop:368 Event:1840 MolecularInitiatingEvent Inhibition, cytochrome oxidase Aop:368 Event:1825 KeyEvent Increase, Cell death Aop:368 Event:2312 AdverseOutcome Increased, nasal lesions Aop:372 Event:26 MolecularInitiatingEvent Antagonism, Androgen receptor Aop:372 Event:1614 KeyEvent Decrease, androgen receptor activation Aop:372 Event:1616 KeyEvent Malformation, cryptorchidism - maldescended testis Aop:372 Event:1839 AdverseOutcome Testicular Cancer Aop:372 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:374 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:374 Event:188 KeyEvent Neuroinflammation Aop:374 Event:352 KeyEvent N/A, Neurodegeneration Aop:374 Event:1841 AdverseOutcome Encephalitis Aop:375 Event:381 KeyEvent Reduced levels of BDNF Aop:376 Event:25 MolecularInitiatingEvent Agonism, Androgen receptor Aop:376 Event:1790 KeyEvent Increased, Differentiation to Testis Aop:376 Event:1791 KeyEvent Increased, Male Biased Sex Ratio Aop:376 Event:360 AdverseOutcome Decrease, Population growth rate Aop:377 Event:1842 MolecularInitiatingEvent Prolonged TLR9 activation Aop:377 Event:1843 AdverseOutcome Multi Organ Failure involving Acute Respiratory Distress Syndrome Aop:377 Event:1844 KeyEvent systemic inflammatory response syndrome Aop:377 Event:1848 KeyEvent Toll Like Receptor (TLR) Dysregulation Aop:377 Event:351 AdverseOutcome Increased Mortality Aop:377 Event:1897 KeyEvent increased MyD88 activation Aop:377 Event:1895 KeyEvent NLRP3 inflammasome activity, increased Aop:377 Event:1392 KeyEvent Increase, Oxidative Stress Aop:377 Event:1869 KeyEvent Diminished protective oxidative stress response Aop:377 Event:1708 KeyEvent Th17 cell migration and inflammation induction Aop:377 Event:55 KeyEvent Increase, Cell injury/death Aop:377 Event:1825 KeyEvent Increase, Cell death Aop:377 Event:1898 KeyEvent Increase, Damage-associated molecular pattern release Aop:377 Event:1857 KeyEvent Platelet-neutrophil interactions, Increased Aop:377 Event:1493 KeyEvent Increased Pro-inflammatory mediators Aop:377 Event:1496 KeyEvent Increased, secretion of proinflammatory mediators Aop:377 Event:1899 KeyEvent formation of neutrophil extracellular traps (NETs) Aop:377 Event:1868 KeyEvent Hyperinflammation Aop:377 Event:87 KeyEvent Release, Cytokine Aop:377 Event:1809 KeyEvent Increase, Tissue/organ damage Aop:377 Event:1748 KeyEvent Increase, the risk of acute respiratory failure Aop:377 Event:1535 KeyEvent Heart failure Aop:377 Event:759 KeyEvent Increased, Kidney Failure Aop:377 Event:814 KeyEvent Occurrence, Kidney toxicity Aop:377 Event:1172 KeyEvent Increased activation, Nuclear factor kappa B (NF-kB) Aop:377 Event:902 KeyEvent Inflammation, Liver Aop:377 Event:1900 KeyEvent increased platelet surface TLR9 expression Aop:377 Event:1497 KeyEvent Increased, recruitment of inflammatory cells Aop:377 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:377 Event:1846 KeyEvent Thrombosis and Disseminated Intravascular Coagulation Aop:378 Event:1848 MolecularInitiatingEvent Toll Like Receptor (TLR) Dysregulation Aop:379 Event:1845 KeyEvent Coagulation Aop:379 Event:1846 AdverseOutcome Thrombosis and Disseminated Intravascular Coagulation Aop:379 Event:1847 KeyEvent Increased SARS-CoV-2 production Aop:379 Event:1738 KeyEvent SARS-CoV-2 cell entry Aop:379 Event:1869 KeyEvent Diminished protective oxidative stress response Aop:379 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:379 Event:1901 KeyEvent Interferon-I antiviral response, antagonized by SARS-CoV-2 Aop:381 Event:1849 KeyEvent Impaired gustatory nerve Aop:381 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:381 Event:1850 AdverseOutcome dysgeusia Aop:381 Event:1787 KeyEvent Downregulation, ACE2 Aop:381 Event:1752 KeyEvent Increased Angiotensin II Aop:381 Event:1856 KeyEvent Imbalanced salty and sweet taste responses Aop:382 Event:1851 MolecularInitiatingEvent Binding of agonist, Angiotensin II receptor type 1 receptor (AT1R) Aop:382 Event:1496 KeyEvent Increased, secretion of proinflammatory mediators Aop:382 Event:68 KeyEvent Increase, Collagen accumulation Aop:382 Event:1276 AdverseOutcome Lung fibrosis Aop:382 Event:1172 KeyEvent Increased activation, Nuclear factor kappa B (NF-kB) Aop:382 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:383 Event:1740 MolecularInitiatingEvent Induced dysregulation of ACE2 Aop:383 Event:344 AdverseOutcome Increase, Liver fibrosis Aop:383 Event:1852 KeyEvent Increased Ang II type 1 receptor (AT1R) Aop:383 Event:1501 KeyEvent Increase, Extracellular matrix deposition Aop:383 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:383 Event:1743 KeyEvent Increase plasma Ang II Aop:384 Event:1853 MolecularInitiatingEvent Hyperactivation of ACE/Ang-II/AT1R axis Aop:384 Event:1752 KeyEvent Increased Angiotensin II Aop:384 Event:1603 AdverseOutcome Chronic kidney disease Aop:384 Event:1852 KeyEvent Increased Ang II type 1 receptor (AT1R) Aop:384 Event:1855 KeyEvent Increased Sodium-sensitive hypertension Aop:384 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:385 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:385 Event:1854 KeyEvent Dysregulation, ACE2 expression and activity Aop:385 Event:1787 KeyEvent Downregulation, ACE2 Aop:385 Event:1752 KeyEvent Increased Angiotensin II Aop:385 Event:2096 KeyEvent Occurrence, (Micro)vascular dysfunction Aop:386 Event:1861 KeyEvent Increase, D1 protein deactivation Aop:386 Event:1862 KeyEvent Decrease, Photosystem II efficiency Aop:386 Event:1475 KeyEvent Decrease, Photosynthesis Aop:386 Event:1472 KeyEvent Decrease, ATP production Aop:386 Event:1863 AdverseOutcome Decrease, Reproduction Aop:386 Event:360 AdverseOutcome Decrease, Population growth rate Aop:386 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:386 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:387 Event:1770 KeyEvent Decrease, Mitochondrial membrane potential Aop:387 Event:1477 KeyEvent Oxidative phosphorylation, decreased Aop:387 Event:40 KeyEvent Mitochondrial ATP production, decreased Aop:387 Event:1863 AdverseOutcome Decrease, Reproduction Aop:387 Event:360 AdverseOutcome Decrease, Population growth rate Aop:387 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:387 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:387 Event:1472 KeyEvent Decrease, ATP production Aop:388 Event:1864 KeyEvent Increase, Programmed cell death Aop:388 Event:1863 AdverseOutcome Decrease, Reproduction Aop:388 Event:360 AdverseOutcome Decrease, Population growth rate Aop:388 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:388 Event:1194 KeyEvent Increase, DNA damage Aop:389 Event:1865 MolecularInitiatingEvent Increase, Oxygen-evolving complex damage Aop:389 Event:1862 KeyEvent Decrease, Photosystem II efficiency Aop:389 Event:1475 KeyEvent Decrease, Photosynthesis Aop:389 Event:1472 KeyEvent Decrease, ATP production Aop:389 Event:1479 KeyEvent Decrease, Leaf development Aop:389 Event:1863 AdverseOutcome Decrease, Reproduction Aop:389 Event:360 AdverseOutcome Decrease, Population growth rate Aop:392 Event:1866 MolecularInitiatingEvent Fibrinolysis, decreased Aop:392 Event:1867 MolecularInitiatingEvent Bradykinin system, hyperactivated Aop:392 Event:1496 KeyEvent Increased, secretion of proinflammatory mediators Aop:392 Event:1497 KeyEvent Increased, recruitment of inflammatory cells Aop:392 Event:1868 AdverseOutcome Hyperinflammation Aop:393 Event:1158 MolecularInitiatingEvent Increased, Hepatic thyroid hormone uptake/transport Aop:393 Event:1505 KeyEvent Cell cycle, disrupted Aop:393 Event:1844 KeyEvent systemic inflammatory response syndrome Aop:393 Event:1555 KeyEvent Increase cell proliferation Aop:393 Event:1262 KeyEvent Apoptosis Aop:393 Event:1829 KeyEvent Altered, Thyroid hormone-dependent gene expression Aop:394 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:394 Event:1738 KeyEvent SARS-CoV-2 cell entry Aop:394 Event:1870 KeyEvent Sustentacular cells, decrease Aop:394 Event:1871 KeyEvent olfactory sensory neurons, decrease Aop:394 Event:1872 KeyEvent Olfactory epithelium degeneration Aop:394 Event:1873 AdverseOutcome impaired olfactory function (anosmia) Aop:394 Event:1847 KeyEvent Increased SARS-CoV-2 production Aop:395 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:395 Event:1738 KeyEvent SARS-CoV-2 cell entry Aop:395 Event:1874 KeyEvent blood brain barrier disruption Aop:395 Event:1846 KeyEvent Thrombosis and Disseminated Intravascular Coagulation Aop:395 Event:1875 AdverseOutcome Cerebrovascular disease (stroke) Aop:396 Event:1550 MolecularInitiatingEvent Deposition of Ionizing Energy Aop:396 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:396 Event:1194 KeyEvent Increase, DNA damage Aop:396 Event:752 KeyEvent Altered, Meiotic chromosome dynamics Aop:396 Event:1775 KeyEvent Increase, Oocyte apoptosis Aop:396 Event:1798 KeyEvent Decreased spermatogenesis Aop:396 Event:406 KeyEvent decreased, Fertility Aop:396 Event:1696 AdverseOutcome Decrease of egg production and cummulative fecundity Aop:396 Event:997 AdverseOutcome Decreased, Population size Aop:396 Event:1863 AdverseOutcome Decrease, Reproduction Aop:396 Event:1505 KeyEvent Cell cycle, disrupted Aop:396 Event:1366 KeyEvent Decrease, Oogenesis Aop:396 Event:1392 KeyEvent Increase, Oxidative Stress Aop:397 Event:1879 MolecularInitiatingEvent Bulky DNA adducts, increase Aop:397 Event:155 KeyEvent Inadequate DNA repair Aop:397 Event:185 AdverseOutcome Increase, Mutations Aop:398 Event:1880 MolecularInitiatingEvent Decreased, ALDH1A (RALDH) enzyme activity Aop:398 Event:1881 KeyEvent Decreased, all-trans retinoic acid (atRA) concentration Aop:398 Event:1882 KeyEvent Disrupted, initiation of meiosis of oogonia in the ovary Aop:398 Event:1883 KeyEvent Decreased, size of the ovarian reserve Aop:398 Event:406 AdverseOutcome decreased, Fertility Aop:398 Event:405 KeyEvent disrupted, ovarian cycle Aop:399 Event:1884 MolecularInitiatingEvent Inhibition of Fyna Aop:399 Event:1885 KeyEvent Inhibition of Plxna2 Aop:399 Event:1886 KeyEvent Overexpression of rasl11b Aop:399 Event:1821 KeyEvent Decrease, Cell proliferation Aop:399 Event:1878 KeyEvent Decreased, Eye size Aop:399 Event:351 AdverseOutcome Increased Mortality Aop:399 Event:360 AdverseOutcome Decrease, Population growth rate Aop:399 Event:1643 KeyEvent Altered, Visual function Aop:400 Event:1888 KeyEvent Increased (ectopic) all-trans retinoic acid concentration Aop:400 Event:1889 KeyEvent Premature initiation of meiosis in fetal male germ cells Aop:400 Event:1890 KeyEvent Decrease (loss of) fetal male germ cells Aop:400 Event:1757 KeyEvent Reduce, Sperm count Aop:400 Event:1887 MolecularInitiatingEvent Inhibition of CYP26B1 activity Aop:400 Event:406 AdverseOutcome decreased, Fertility Aop:401 Event:2029 MolecularInitiatingEvent protein-coupled estrogen receptor 1 (GPER) activation Aop:401 Event:1310 KeyEvent Activation, PI3K Aop:401 Event:1299 KeyEvent Activation, AKT Aop:401 Event:1300 KeyEvent Activation, mTORC1 Aop:401 Event:227 KeyEvent Activation, PPARα Aop:401 Event:1995 KeyEvent Abnormal lipid metabolism Aop:401 Event:472 KeyEvent Down Regulation, CPT1A Aop:401 Event:1284 KeyEvent Up Regulation, SREBF2 Aop:401 Event:462 KeyEvent Up Regulation, SCD-1 Aop:401 Event:1489 AdverseOutcome Increase, Steatohepatitis Aop:402 Event:279 MolecularInitiatingEvent Thyroperoxidase, Inhibition Aop:402 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:402 Event:771 KeyEvent Decrease, Serum thyroid hormone (T4/T3) Aop:402 Event:2093 KeyEvent Brain thyroid hormone (T4/T3) decreased Aop:402 Event:1829 KeyEvent Altered, Thyroid hormone-dependent gene expression Aop:402 Event:2094 KeyEvent Abnormal, neuroblast migration Aop:402 Event:2095 AdverseOutcome Periventricular heterotopia formation Aop:402 Event:1348 AdverseOutcome Increase, seizure Aop:405 Event:12 MolecularInitiatingEvent Acetylcholinesterase (AchE) Inhibition Aop:405 Event:10 KeyEvent Acetylcholine accumulation in synapses Aop:405 Event:39 KeyEvent Increased Cholinergic Signaling Aop:405 Event:386 KeyEvent Decrease of neuronal network function Aop:405 Event:402 AdverseOutcome Cognitive function, decreased Aop:406 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:406 Event:1738 KeyEvent SARS-CoV-2 cell entry Aop:406 Event:1847 KeyEvent Increased SARS-CoV-2 production Aop:406 Event:1869 KeyEvent Diminished protective oxidative stress response Aop:406 Event:1895 KeyEvent NLRP3 inflammasome activity, increased Aop:406 Event:1868 AdverseOutcome Hyperinflammation Aop:407 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:407 Event:1738 KeyEvent SARS-CoV-2 cell entry Aop:407 Event:1847 KeyEvent Increased SARS-CoV-2 production Aop:407 Event:1869 KeyEvent Diminished protective oxidative stress response Aop:407 Event:1895 KeyEvent NLRP3 inflammasome activity, increased Aop:407 Event:1967 AdverseOutcome Pyroptosis Aop:409 Event:1668 MolecularInitiatingEvent Frustrated phagocytosis Aop:409 Event:1496 KeyEvent Increased, secretion of proinflammatory mediators Aop:409 Event:1497 KeyEvent Increased, recruitment of inflammatory cells Aop:409 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:409 Event:1669 KeyEvent Increased, DNA damage and mutation Aop:409 Event:1896 KeyEvent Genomic instability Aop:409 Event:870 KeyEvent Increase, Cell Proliferation Aop:409 Event:1090 AdverseOutcome Increased, mesotheliomas Aop:410 Event:1903 KeyEvent foxi1 expression, increased Aop:410 Event:1904 KeyEvent six1b expression, increased Aop:410 Event:1905 KeyEvent eya1 expression, inhibited Aop:410 Event:1825 KeyEvent Increase, Cell death Aop:410 Event:1930 KeyEvent altered, inner ear development Aop:410 Event:1008 KeyEvent Reduced, Hearing Aop:410 Event:1647 MolecularInitiatingEvent GSK3beta inactivation Aop:410 Event:1902 KeyEvent Repression of Gbx2 expression Aop:410 Event:351 AdverseOutcome Increased Mortality Aop:410 Event:360 AdverseOutcome Decrease, Population growth rate Aop:411 Event:1908 KeyEvent Cilia Beat Frequency, Decreased Aop:411 Event:1909 KeyEvent Mucociliary Clearance, Decreased Aop:411 Event:1250 AdverseOutcome Decrease, Lung function Aop:411 Event:1392 MolecularInitiatingEvent Increase, Oxidative Stress Aop:412 Event:1913 KeyEvent Endothelial cell dysfunction Aop:412 Event:1857 KeyEvent Platelet-neutrophil interactions, Increased Aop:412 Event:87 KeyEvent Release, Cytokine Aop:412 Event:1914 KeyEvent Platelet activation, Increased Aop:412 Event:1915 KeyEvent Neutrophil activation, Increased Aop:412 Event:1916 AdverseOutcome Thromboinflammation, Increased Aop:413 Event:926 MolecularInitiatingEvent Oxidation, Glutathione (To be considered with MIE) Aop:413 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:413 Event:759 KeyEvent Increased, Kidney Failure Aop:413 Event:1607 KeyEvent Increase, Necrosis Aop:413 Event:351 AdverseOutcome Increased Mortality Aop:413 Event:1445 KeyEvent Increase, Lipid peroxidation Aop:414 Event:18 MolecularInitiatingEvent Activation, AhR Aop:414 Event:1457 KeyEvent Epithelial Mesenchymal Transition Aop:414 Event:1501 KeyEvent Increase, Extracellular matrix deposition Aop:414 Event:1276 KeyEvent Lung fibrosis Aop:414 Event:1920 KeyEvent Altered gene expression, TGF-β dependent fibrosis pathway Aop:415 Event:18 MolecularInitiatingEvent Activation, AhR Aop:415 Event:1921 KeyEvent Altered gene expression, NF-kB dependent Interleukin-6 pathway Aop:415 Event:1457 KeyEvent Epithelial Mesenchymal Transition Aop:415 Event:1501 KeyEvent Increase, Extracellular matrix deposition Aop:415 Event:1276 AdverseOutcome Lung fibrosis Aop:416 Event:18 MolecularInitiatingEvent Activation, AhR Aop:416 Event:1921 KeyEvent Altered gene expression, NF-kB dependent Interleukin-6 pathway Aop:416 Event:1670 AdverseOutcome Lung cancer Aop:416 Event:1669 KeyEvent Increased, DNA damage and mutation Aop:416 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:416 Event:1933 KeyEvent Increased, Interleukin-6 production Aop:417 Event:18 MolecularInitiatingEvent Activation, AhR Aop:417 Event:1922 KeyEvent Increased, Reactive metabolites production Aop:417 Event:1669 KeyEvent Increased, DNA damage and mutation Aop:417 Event:1670 AdverseOutcome Lung cancer Aop:417 Event:17 KeyEvent Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway Aop:418 Event:18 KeyEvent Activation, AhR Aop:418 Event:17 KeyEvent Altered gene expression, AHR nuclear translocator (ARNT)-dependent pathway Aop:418 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:418 Event:1825 KeyEvent Increase, Cell death Aop:418 Event:1250 KeyEvent Decrease, Lung function Aop:419 Event:18 KeyEvent Activation, AhR Aop:419 Event:1923 KeyEvent Altered gene expression, P53 dependent apoptosis pathway Aop:419 Event:1262 KeyEvent Apoptosis Aop:419 Event:1250 AdverseOutcome Decrease, Lung function Aop:420 Event:18 MolecularInitiatingEvent Activation, AhR Aop:420 Event:1917 KeyEvent Altered gene expression, NRF2 dependent antioxidant pathway Aop:420 Event:870 KeyEvent Increase, Cell Proliferation Aop:420 Event:1670 KeyEvent Lung cancer Aop:421 Event:1917 KeyEvent Altered gene expression, NRF2 dependent antioxidant pathway Aop:422 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:422 Event:1738 KeyEvent SARS-CoV-2 cell entry Aop:422 Event:1847 KeyEvent Increased SARS-CoV-2 production Aop:422 Event:1931 KeyEvent Intestinal barrier, disruption Aop:422 Event:1901 KeyEvent Interferon-I antiviral response, antagonized by SARS-CoV-2 Aop:423 Event:2030 MolecularInitiatingEvent Activation, PARP1 Aop:423 Event:2031 KeyEvent Releasing, Apoptosis-Inducing Factor (AIF) Aop:423 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:423 Event:1194 KeyEvent Increase, DNA damage Aop:423 Event:1817 AdverseOutcome Apoptotic cell death Aop:423 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:424 Event:1906 KeyEvent Cystic Fibrosis Transmembrane Regulator Function, Decreased Aop:424 Event:1392 MolecularInitiatingEvent Increase, Oxidative Stress Aop:424 Event:1907 KeyEvent Airway Surface Liquid Height, Decreased Aop:424 Event:1909 KeyEvent Mucociliary Clearance, Decreased Aop:424 Event:1908 KeyEvent Cilia Beat Frequency, Decreased Aop:424 Event:1250 AdverseOutcome Decrease, Lung function Aop:425 Event:1392 MolecularInitiatingEvent Increase, Oxidative Stress Aop:425 Event:1911 KeyEvent FOXJ1 Protein, Decreased Aop:425 Event:1912 KeyEvent Motile Cilia Number/Length, Decreased Aop:425 Event:1908 KeyEvent Cilia Beat Frequency, Decreased Aop:425 Event:1909 KeyEvent Mucociliary Clearance, Decreased Aop:425 Event:1250 AdverseOutcome Decrease, Lung function Aop:426 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:426 Event:1738 KeyEvent SARS-CoV-2 cell entry Aop:426 Event:1535 KeyEvent Heart failure Aop:426 Event:1666 KeyEvent Induced, dysfunction of microcirculation Aop:426 Event:1750 KeyEvent Increased inflammatory immune responses Aop:426 Event:1913 KeyEvent Endothelial cell dysfunction Aop:426 Event:1934 AdverseOutcome Myocardial Infarction Aop:426 Event:1946 KeyEvent Impaired mechanotransduction of pericytes Aop:426 Event:1947 KeyEvent Pericyte dysfunction Aop:426 Event:1948 KeyEvent Increased ACE2 expression Aop:427 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:427 Event:1787 KeyEvent Downregulation, ACE2 Aop:427 Event:1935 KeyEvent Angiotensin (1-7) levels diminished Aop:427 Event:1853 KeyEvent Hyperactivation of ACE/Ang-II/AT1R axis Aop:427 Event:1535 AdverseOutcome Heart failure Aop:427 Event:1741 KeyEvent Induced, Angiotensin (Ang) II accumulation Aop:427 Event:1936 KeyEvent Angiotensin II degradation reduced Aop:427 Event:1937 KeyEvent ADAM17 expression induction Aop:427 Event:1938 KeyEvent ACE2 increased shedding Aop:428 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:428 Event:1854 KeyEvent Dysregulation, ACE2 expression and activity Aop:428 Event:1954 KeyEvent Gut microbiota, alteration Aop:429 Event:1816 KeyEvent Mitochondrial dysfunction EMPTY Aop:429 Event:1392 KeyEvent Increase, Oxidative Stress Aop:429 Event:1941 AdverseOutcome Memory Loss Aop:429 Event:1582 KeyEvent Impaired axonial transport Aop:429 Event:386 KeyEvent Decrease of neuronal network function Aop:429 Event:188 KeyEvent Neuroinflammation Aop:429 Event:1942 KeyEvent Accumulation, Cytosolic toxic Tau oligomers Aop:429 Event:1943 KeyEvent Hyperphosphorylation of Tau Aop:429 Event:1945 KeyEvent Dysfunctional Autophagy Aop:429 Event:1944 KeyEvent Synaptic dysfunction Aop:430 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:430 Event:1738 KeyEvent SARS-CoV-2 cell entry Aop:430 Event:1901 KeyEvent Interferon-I antiviral response, antagonized by SARS-CoV-2 Aop:430 Event:1847 KeyEvent Increased SARS-CoV-2 production Aop:430 Event:1939 AdverseOutcome Viral infection and host-to-host transmission, proliferated Aop:431 Event:1950 MolecularInitiatingEvent Increase, TNF Aop:431 Event:1949 KeyEvent Decrease, GLUT4 Aop:431 Event:1951 KeyEvent Decrease, Glucose uptake Aop:431 Event:1952 KeyEvent Abnormal, Glucose homeostasis Aop:431 Event:1953 AdverseOutcome Gestational diabetes mellitus Aop:432 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:432 Event:1632 KeyEvent Increase in reactive oxygen and nitrogen species (RONS) Aop:432 Event:1194 KeyEvent Increase, DNA damage Aop:432 Event:1493 KeyEvent Increased Pro-inflammatory mediators Aop:432 Event:876 KeyEvent Increase, Mutations in Critical Genes Aop:432 Event:1955 AdverseOutcome Acute Myeloid Leukemia Aop:432 Event:155 KeyEvent Inadequate DNA repair Aop:432 Event:870 KeyEvent Increase, Cell Proliferation Aop:432 Event:403 KeyEvent Suppression, Immune system Aop:433 Event:2099 MolecularInitiatingEvent hERG channel blockade Aop:433 Event:2100 KeyEvent Inhibition of rapid delayed rectifying potassium current Aop:433 Event:1961 KeyEvent Prolongation of Action Potential Duration Aop:433 Event:1962 KeyEvent Prolongation of QT interval Aop:433 Event:1963 KeyEvent Torsades de Pointes Aop:433 Event:1964 AdverseOutcome Sudden cardiac death Aop:435 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:435 Event:1194 KeyEvent Increase, DNA damage Aop:435 Event:752 KeyEvent Altered, Meiotic chromosome dynamics Aop:435 Event:1965 KeyEvent Increase, Pollen abnormal Aop:435 Event:1863 AdverseOutcome Decrease, Reproduction Aop:435 Event:442 AdverseOutcome Decreased, Population trajectory Aop:436 Event:1880 MolecularInitiatingEvent Decreased, ALDH1A (RALDH) enzyme activity Aop:436 Event:1881 KeyEvent Decreased, all-trans retinoic acid (atRA) concentration Aop:436 Event:1682 KeyEvent Disruption, Progenitor cells of second heart field Aop:436 Event:1557 KeyEvent Neural crest cell migration, reduced Aop:436 Event:1970 AdverseOutcome transposition of the great arteries Aop:437 Event:105 MolecularInitiatingEvent Inhibition, Mitochondrial Electron Transport Chain Complexes Aop:437 Event:709 KeyEvent Increase, Cytotoxicity (renal tubular cell) Aop:437 Event:814 AdverseOutcome Occurrence, Kidney toxicity Aop:437 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:437 Event:1392 KeyEvent Increase, Oxidative Stress Aop:439 Event:18 MolecularInitiatingEvent Activation, AhR Aop:439 Event:149 KeyEvent Increase, Inflammation Aop:439 Event:1262 KeyEvent Apoptosis Aop:439 Event:1241 KeyEvent Increased, Motility Aop:439 Event:1190 KeyEvent Increased, Migration (Endothelial Cells) Aop:439 Event:1196 KeyEvent Increased, Invasion Aop:439 Event:1376 KeyEvent Increase, angiogenesis Aop:439 Event:1971 KeyEvent Increased, tumor growth Aop:439 Event:1982 AdverseOutcome metastatic breast cancer Aop:440 Event:1046 MolecularInitiatingEvent Suppression, Estrogen receptor (ER) activity Aop:440 Event:1047 KeyEvent Increased, secretion of GnRH from hypothalamus Aop:440 Event:1050 KeyEvent Increased, secretion of LH from anterior pituitary Aop:440 Event:1972 KeyEvent Increased, Steroidogenic acute regulatory protein (StAR) Aop:440 Event:1973 KeyEvent Increased, estrogens Aop:440 Event:1076 KeyEvent Increased, circulating estrogen levels Aop:440 Event:1052 KeyEvent Hyperplasia, ovarian epithelium Aop:440 Event:1053 AdverseOutcome Promotion, ovarian adenomas Aop:440 Event:2092 AdverseOutcome Promotion, Ovarian Cancer Aop:441 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:441 Event:1194 KeyEvent Increase, DNA damage Aop:441 Event:1974 KeyEvent Activation of Tumor Protein 53 Aop:441 Event:1978 AdverseOutcome Increase risk, microcephaly Aop:441 Event:1979 KeyEvent Premature cell differentiation Aop:441 Event:1262 KeyEvent Apoptosis Aop:441 Event:2200 KeyEvent decline, neural progenitor cells Aop:442 Event:1353 MolecularInitiatingEvent Binding to voltage-gated sodium channel Aop:442 Event:1977 KeyEvent Disruption of sodium channel gating kinetics Aop:442 Event:1983 KeyEvent Disruption, action potential generation Aop:442 Event:2005 KeyEvent Altered neurotransmission in development Aop:442 Event:757 KeyEvent Hippocampal anatomy, Altered Aop:442 Event:758 KeyEvent Hippocampal Physiology, Altered Aop:442 Event:402 AdverseOutcome Cognitive function, decreased Aop:443 Event:1669 MolecularInitiatingEvent Increased, DNA damage and mutation Aop:443 Event:155 KeyEvent Inadequate DNA repair Aop:443 Event:185 KeyEvent Increase, Mutations Aop:443 Event:1980 KeyEvent Increased microRNA expression Aop:443 Event:1981 KeyEvent Decreased SIRT1 expression Aop:443 Event:1172 KeyEvent Increased activation, Nuclear factor kappa B (NF-kB) Aop:443 Event:112 KeyEvent Antagonism, Estrogen receptor Aop:443 Event:1457 KeyEvent Epithelial Mesenchymal Transition Aop:443 Event:1982 AdverseOutcome metastatic breast cancer Aop:443 Event:1554 KeyEvent Increase Chromosomal Aberrations Aop:444 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:444 Event:1632 MolecularInitiatingEvent Increase in reactive oxygen and nitrogen species (RONS) Aop:444 Event:1194 MolecularInitiatingEvent Increase, DNA damage Aop:444 Event:1365 KeyEvent Increase, Apoptosis Aop:444 Event:1798 KeyEvent Decreased spermatogenesis Aop:444 Event:328 KeyEvent Decrease, Fecundity Aop:444 Event:1863 KeyEvent Decrease, Reproduction Aop:444 Event:360 AdverseOutcome Decrease, Population growth rate Aop:444 Event:1392 KeyEvent Increase, Oxidative Stress Aop:445 Event:1985 KeyEvent Increased Kisspeptin levels in anteroventral periventricular nucleus (AVPV) Aop:445 Event:1986 KeyEvent Decreased, Gonadotropins Aop:445 Event:1987 KeyEvent Decreased, Androgen and Progestin Aop:445 Event:1988 KeyEvent Decreased, Maturation Inducing Steroid Surge by Granulosa cells Aop:445 Event:1989 KeyEvent Impaired, Oocyte maturation and ovulation Aop:445 Event:1990 KeyEvent Increased, Oocyte Atresia Aop:445 Event:1991 AdverseOutcome Impaired, Reproduction Aop:445 Event:1065 MolecularInitiatingEvent Activation, estrogen receptor alpha Aop:447 Event:105 KeyEvent Inhibition, Mitochondrial Electron Transport Chain Complexes Aop:447 Event:1770 KeyEvent Decrease, Mitochondrial membrane potential Aop:447 Event:1917 KeyEvent Altered gene expression, NRF2 dependent antioxidant pathway Aop:447 Event:202 KeyEvent Inhibition, Nuclear factor kappa B (NF-kB) Aop:447 Event:1815 KeyEvent Increase, Endoplasmic reticulum stress Aop:447 Event:1365 KeyEvent Increase, Apoptosis Aop:447 Event:1633 KeyEvent Increase in inflammation Aop:447 Event:1097 KeyEvent Occurrence, renal proximal tubular necrosis Aop:447 Event:814 KeyEvent Occurrence, Kidney toxicity Aop:447 Event:759 AdverseOutcome Increased, Kidney Failure Aop:447 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:447 Event:1392 KeyEvent Increase, Oxidative Stress Aop:449 Event:2023 MolecularInitiatingEvent Inhibition of Ceramide Synthase Aop:449 Event:2024 KeyEvent Reduced complex sphingolipids Aop:449 Event:2025 KeyEvent Affected folate transporter Aop:449 Event:2026 KeyEvent decreased folate uptake Aop:449 Event:2033 KeyEvent Increased sphingolipid-1-phosphate Aop:449 Event:1502 KeyEvent Histone deacetylase inhibition Aop:449 Event:1561 AdverseOutcome Neural tube defects Aop:450 Event:12 MolecularInitiatingEvent Acetylcholinesterase (AchE) Inhibition Aop:450 Event:1391 KeyEvent Activation of Cyp2E1 Aop:450 Event:352 KeyEvent N/A, Neurodegeneration Aop:450 Event:618 KeyEvent Decreased, Neuronal network function in adult brain Aop:450 Event:351 AdverseOutcome Increased Mortality Aop:450 Event:1583 AdverseOutcome Sensory axonal peripheral neuropathy Aop:450 Event:1392 KeyEvent Increase, Oxidative Stress Aop:451 Event:1495 MolecularInitiatingEvent Substance interaction with the lung resident cell membrane components Aop:451 Event:1496 KeyEvent Increased, secretion of proinflammatory mediators Aop:451 Event:1497 KeyEvent Increased, recruitment of inflammatory cells Aop:451 Event:780 KeyEvent Increase, Cytotoxicity (epithelial cells) Aop:451 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:451 Event:2006 KeyEvent Secondary genotoxicity Aop:451 Event:1669 KeyEvent Increased, DNA damage and mutation Aop:451 Event:870 KeyEvent Increase, Cell Proliferation Aop:451 Event:1670 AdverseOutcome Lung cancer Aop:452 Event:2007 MolecularInitiatingEvent Non-coding RNA expression profile alteration Aop:452 Event:2008 AdverseOutcome Chronic obstructive pulmonary disease Aop:452 Event:2009 KeyEvent Activation of inflammation pathway Aop:452 Event:1262 KeyEvent Apoptosis Aop:452 Event:1945 KeyEvent Dysfunctional Autophagy Aop:452 Event:1392 KeyEvent Increase, Oxidative Stress Aop:452 Event:2010 KeyEvent Pulmonary inflammation Aop:452 Event:2011 KeyEvent Emphysema Aop:452 Event:2012 KeyEvent Fibroblast proliferation and differentiation Aop:452 Event:2013 KeyEvent Airway remodeling Aop:452 Event:1457 KeyEvent Epithelial Mesenchymal Transition Aop:454 Event:2017 KeyEvent Endoplasmic reticulum stress Aop:454 Event:2019 KeyEvent Non-alcoholic fatty liver disease Aop:454 Event:2065 KeyEvent Inhibition, Fatty acid oxidation Aop:454 Event:2119 KeyEvent Increase, Insulin resistance Aop:455 Event:18 MolecularInitiatingEvent Activation, AhR Aop:455 Event:944 KeyEvent dimerization, AHR/ARNT Aop:455 Event:2020 KeyEvent Decrease, sox9 expression Aop:455 Event:947 AdverseOutcome Increase, Early Life Stage Mortality Aop:455 Event:1559 AdverseOutcome Facial cartilage structures are reduced in size and morphologically distorted Aop:455 Event:2021 KeyEvent Increase, slincR expression Aop:456 Event:18 MolecularInitiatingEvent Activation, AhR Aop:456 Event:944 KeyEvent dimerization, AHR/ARNT Aop:456 Event:2020 KeyEvent Decrease, sox9 expression Aop:456 Event:2021 KeyEvent Increase, slincR expression Aop:456 Event:317 KeyEvent Altered, Cardiovascular development/function Aop:456 Event:947 AdverseOutcome Increase, Early Life Stage Mortality Aop:457 Event:2118 MolecularInitiatingEvent Succinate dehydrogenase, inhibited Aop:457 Event:2119 AdverseOutcome Increase, Insulin resistance Aop:457 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:457 Event:2120 KeyEvent Superoxide generation, increased Aop:457 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:457 Event:1392 KeyEvent Increase, Oxidative Stress Aop:458 Event:18 MolecularInitiatingEvent Activation, AhR Aop:458 Event:295 KeyEvent Induction, Upregulation of glucuronyltransferase activity Aop:458 Event:961 KeyEvent Increased, Clearance of thyroxine from serum Aop:458 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:458 Event:280 KeyEvent Thyroxine (T4) in neuronal tissue, Decreased Aop:458 Event:756 KeyEvent Hippocampal gene expression, Altered Aop:458 Event:758 KeyEvent Hippocampal Physiology, Altered Aop:458 Event:402 AdverseOutcome Cognitive function, decreased Aop:459 Event:18 MolecularInitiatingEvent Activation, AhR Aop:459 Event:850 KeyEvent Induction, CYP1A2/CYP1A5 Aop:459 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:459 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:459 Event:280 KeyEvent Thyroxine (T4) in neuronal tissue, Decreased Aop:459 Event:756 KeyEvent Hippocampal gene expression, Altered Aop:459 Event:758 KeyEvent Hippocampal Physiology, Altered Aop:459 Event:402 AdverseOutcome Cognitive function, decreased Aop:459 Event:1392 KeyEvent Increase, Oxidative Stress Aop:460 Event:2027 MolecularInitiatingEvent Antagonism, Smoothened receptor Aop:460 Event:2028 KeyEvent Decrease, GLI1/2 translocation to nucleus Aop:460 Event:2040 KeyEvent Decrease, GLI1/2 target gene expression Aop:460 Event:1821 KeyEvent Decrease, Cell proliferation Aop:460 Event:2041 KeyEvent Decrease, facial prominence outgrowth Aop:460 Event:2042 AdverseOutcome Increase, Orofacial clefting Aop:460 Event:2043 KeyEvent Decrease, Sonic Hedgehog second messenger production Aop:460 Event:2044 KeyEvent Decrease, Smoothend relocation and activation Aop:460 Event:1262 KeyEvent Apoptosis Aop:462 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:462 Event:1392 KeyEvent Increase, Oxidative Stress Aop:462 Event:2068 KeyEvent Increase, Endothelial Dysfunction Aop:462 Event:901 KeyEvent Infiltration, Inflammatory cells Aop:462 Event:1198 KeyEvent Activation, Macrophages Aop:462 Event:467 KeyEvent Increased, LDL uptake Aop:462 Event:1442 KeyEvent Foam cell formation Aop:463 Event:2034 KeyEvent liver dysfunction Aop:464 Event:2036 MolecularInitiatingEvent Activation of metabotropic glutamate receptor Aop:464 Event:2037 MolecularInitiatingEvent Inositol triphosphate receptor activation Aop:464 Event:389 KeyEvent Increased, Intracellular Calcium overload Aop:464 Event:2038 KeyEvent Activation of calpain signalling Aop:464 Event:1825 KeyEvent Increase, Cell death Aop:464 Event:896 AdverseOutcome Parkinsonian motor deficits Aop:464 Event:388 MolecularInitiatingEvent Overactivation, NMDARs Aop:464 Event:2039 MolecularInitiatingEvent Inhibition GABAA receptor Aop:464 Event:1527 KeyEvent Increase, Cell membrane depolarization Aop:464 Event:2017 KeyEvent Endoplasmic reticulum stress Aop:464 Event:1512 KeyEvent Unfolded Protein Response Aop:464 Event:1392 KeyEvent Increase, Oxidative Stress Aop:464 Event:1547 KeyEvent Mitochondrial Injury Aop:464 Event:2187 MolecularInitiatingEvent Opening, voltage-gated calcium channels Aop:464 Event:2188 KeyEvent Activation, caspases Aop:464 Event:1585 KeyEvent Proteasomal dysfunction Aop:464 Event:1812 KeyEvent Increase, Cytochrome c release Aop:464 Event:1605 KeyEvent Accumulation of misfolded proteins Aop:464 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:465 Event:2045 MolecularInitiatingEvent Increase, Alcohol dehydrogenase Aop:465 Event:748 KeyEvent Increased, Estrogen receptor (ER) activity Aop:465 Event:2046 KeyEvent Increase, Vitellogenin mRNA Aop:465 Event:2047 KeyEvent Delay, Ovarian maturation Aop:465 Event:2048 KeyEvent Increase, Body volume of female adults Aop:465 Event:2049 KeyEvent Increase, sex ratio (F/M) Aop:465 Event:2050 KeyEvent Increase, developmental abnormalities Aop:465 Event:350 KeyEvent Increase, Mortality Aop:466 Event:2051 MolecularInitiatingEvent Decrease, Tyrosine Aop:466 Event:2052 KeyEvent Decrease, dopa decarboxylase Aop:466 Event:2053 KeyEvent Increase, Defects in tanning of new cuticle Aop:466 Event:2054 KeyEvent Increase, impairment of cuticle sclerotization Aop:466 Event:2055 KeyEvent Increase, pigmentation Aop:466 Event:990 KeyEvent Increase, Incomplete ecdysis Aop:466 Event:2056 KeyEvent Increase, delay in oviposition Aop:466 Event:350 KeyEvent Increase, Mortality Aop:466 Event:2057 KeyEvent Decrease, hatching of egg Aop:467 Event:2058 MolecularInitiatingEvent Decrease, 20-hydroxyecdysone Aop:467 Event:2059 KeyEvent Decrease, knickkopf gene Aop:467 Event:2060 KeyEvent Decrease, Chitin laminar organization Aop:467 Event:2061 KeyEvent Decrease, Prevent chitin degradation by chitinases Aop:467 Event:2062 KeyEvent Weak, Procuticle protection Aop:467 Event:2063 KeyEvent Decrease, New cuticle secretion Aop:467 Event:990 KeyEvent Increase, Incomplete ecdysis Aop:467 Event:2050 KeyEvent Increase, developmental abnormalities Aop:467 Event:350 KeyEvent Increase, Mortality Aop:468 Event:1739 MolecularInitiatingEvent Binding to ACE2 Aop:468 Event:1738 KeyEvent SARS-CoV-2 cell entry Aop:468 Event:1901 KeyEvent Interferon-I antiviral response, antagonized by SARS-CoV-2 Aop:468 Event:1847 KeyEvent Increased SARS-CoV-2 production Aop:468 Event:1825 KeyEvent Increase, Cell death Aop:468 Event:1496 KeyEvent Increased, secretion of proinflammatory mediators Aop:468 Event:1497 KeyEvent Increased, recruitment of inflammatory cells Aop:468 Event:1868 AdverseOutcome Hyperinflammation Aop:470 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:470 Event:1392 KeyEvent Increase, Oxidative Stress Aop:470 Event:1493 KeyEvent Increased Pro-inflammatory mediators Aop:470 Event:2067 KeyEvent Altered, Nitric Oxide Levels Aop:470 Event:2068 KeyEvent Increase, Endothelial Dysfunction Aop:470 Event:2069 AdverseOutcome Occurrence, Abnormal Vascular Remodeling Aop:470 Event:1635 KeyEvent Increase, DNA strand breaks Aop:470 Event:2244 KeyEvent Altered Stress Response Signaling Aop:471 Event:2195 MolecularInitiatingEvent Increase, CNS Neural cell death Aop:471 Event:352 KeyEvent N/A, Neurodegeneration Aop:471 Event:2196 KeyEvent Decrease, elavl3 Aop:471 Event:2197 KeyEvent Decrease, sox10 Aop:471 Event:2198 KeyEvent Decrease, mbp Aop:471 Event:188 KeyEvent Neuroinflammation Aop:471 Event:618 KeyEvent Decreased, Neuronal network function in adult brain Aop:471 Event:10 KeyEvent Acetylcholine accumulation in synapses Aop:471 Event:12 KeyEvent Acetylcholinesterase (AchE) Inhibition Aop:471 Event:1944 KeyEvent Synaptic dysfunction Aop:471 Event:1582 KeyEvent Impaired axonial transport Aop:471 Event:1583 KeyEvent Sensory axonal peripheral neuropathy Aop:471 Event:388 KeyEvent Overactivation, NMDARs Aop:471 Event:2150 KeyEvent Neurological disorder Aop:471 Event:191 KeyEvent Neuronal dysfunction Aop:471 Event:890 KeyEvent Degeneration of dopaminergic neurons of the nigrostriatal pathway Aop:471 Event:637 AdverseOutcome impaired, Learning and memory Aop:471 Event:1841 AdverseOutcome Encephalitis Aop:471 Event:2078 KeyEvent Loss of drebrin Aop:471 Event:896 AdverseOutcome Parkinsonian motor deficits Aop:471 Event:2151 KeyEvent Disruption, neurotransmitter release Aop:471 Event:1348 AdverseOutcome Increase, seizure Aop:471 Event:1363 AdverseOutcome Increased, epilepsy Aop:471 Event:350 AdverseOutcome Increase, Mortality Aop:471 Event:1018 KeyEvent Activation, Glutamate-gated chloride channels Aop:471 Event:1349 KeyEvent Activated, presynaptic neuron 1 Aop:471 Event:1016 AdverseOutcome Inhibition, Feeding Aop:471 Event:1177 KeyEvent Decreased, Ionotropic GABA receptor chloride channel conductance Aop:471 Event:1012 KeyEvent Increased, Inhibitory postsynaptic potential Aop:471 Event:1014 KeyEvent Induction, Somatic muscle paralysis Aop:471 Event:1015 KeyEvent Increased, Neuronal synaptic inhibition Aop:471 Event:1392 KeyEvent Increase, Oxidative Stress Aop:473 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:473 Event:1632 KeyEvent Increase in reactive oxygen and nitrogen species (RONS) Aop:473 Event:2073 KeyEvent increase oxidation of the di-copper moiety of the hemocyanin active site Aop:473 Event:2074 KeyEvent Decreased, oxygen binding capacity by hemocyanin Aop:473 Event:2075 KeyEvent Cognitive, sensed as hypoxic/low oxygen environment Aop:473 Event:2076 KeyEvent Increase, hemocyanin mRNA Aop:473 Event:2077 KeyEvent Increase, pulmonate breathing Aop:473 Event:1521 AdverseOutcome Decrease, Growth Aop:473 Event:1141 AdverseOutcome Decreased, Reproductive Success Aop:474 Event:2118 MolecularInitiatingEvent Succinate dehydrogenase, inhibited Aop:474 Event:1619 KeyEvent Increase, DNA methyltransferase inhibition Aop:474 Event:1457 KeyEvent Epithelial Mesenchymal Transition Aop:474 Event:2243 KeyEvent Succinate Accumulation Aop:474 Event:885 AdverseOutcome Increase, Cancer Aop:475 Event:875 MolecularInitiatingEvent Binding of agonist, Ionotropic glutamate receptors Aop:475 Event:388 KeyEvent Overactivation, NMDARs Aop:475 Event:2078 KeyEvent Loss of drebrin Aop:475 Event:1944 KeyEvent Synaptic dysfunction Aop:475 Event:341 AdverseOutcome Impairment, Learning and memory Aop:475 Event:389 KeyEvent Increased, Intracellular Calcium overload Aop:475 Event:386 KeyEvent Decrease of neuronal network function Aop:475 Event:2242 KeyEvent Abnormality, dendritic spine morphology Aop:476 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:476 Event:1194 KeyEvent Increase, DNA damage Aop:476 Event:496 KeyEvent Increased apoptosis, decreased fetal/adult Leydig Cells Aop:476 Event:1262 KeyEvent Apoptosis Aop:476 Event:2079 KeyEvent Increased, glycolipid levels Aop:476 Event:2080 KeyEvent Impaired, blood testis barrier Aop:476 Event:446 KeyEvent Reduction, fetal/adult testosterone Aop:476 Event:520 AdverseOutcome Decreased sperm quantity or quality in the adult, Decreased fertility Aop:476 Event:1688 AdverseOutcome anogenital distance (AGD), decreased Aop:476 Event:1616 AdverseOutcome Malformation, cryptorchidism - maldescended testis Aop:476 Event:1863 AdverseOutcome Decrease, Reproduction Aop:476 Event:2141 MolecularInitiatingEvent Disruption, Estrogen receptor Aop:476 Event:26 MolecularInitiatingEvent Antagonism, Androgen receptor Aop:476 Event:2142 KeyEvent Depletion, Ectoplasmic specialization (ES) Aop:476 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:476 Event:1392 KeyEvent Increase, Oxidative Stress Aop:477 Event:2082 AdverseOutcome Hypospadias, increased Aop:477 Event:26 MolecularInitiatingEvent Antagonism, Androgen receptor Aop:477 Event:1614 KeyEvent Decrease, androgen receptor activation Aop:477 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:478 Event:2081 KeyEvent Increased Modified Proteins Aop:478 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:478 Event:1634 KeyEvent Increase, Oxidative DNA damage Aop:478 Event:1635 KeyEvent Increase, DNA strand breaks Aop:478 Event:155 KeyEvent Inadequate DNA repair Aop:478 Event:185 KeyEvent Increase, Mutations Aop:478 Event:1636 KeyEvent Increase, Chromosomal aberrations Aop:478 Event:870 KeyEvent Increase, Cell Proliferation Aop:478 Event:2083 AdverseOutcome Occurrence of Cataracts Aop:478 Event:1392 KeyEvent Increase, Oxidative Stress Aop:479 Event:105 MolecularInitiatingEvent Inhibition, Mitochondrial Electron Transport Chain Complexes Aop:479 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:479 Event:1392 KeyEvent Increase, Oxidative Stress Aop:479 Event:55 KeyEvent Increase, Cell injury/death Aop:479 Event:2084 KeyEvent Increase, Cardiac remodelling Aop:479 Event:1532 KeyEvent Decrease, Cardiac contractility Aop:479 Event:2215 AdverseOutcome Decrease Left Ventricular function Aop:480 Event:105 MolecularInitiatingEvent Inhibition, Mitochondrial Electron Transport Chain Complexes Aop:480 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:480 Event:40 KeyEvent Mitochondrial ATP production, decreased Aop:480 Event:1532 KeyEvent Decrease, Cardiac contractility Aop:480 Event:2215 AdverseOutcome Decrease Left Ventricular function Aop:481 Event:1392 KeyEvent Increase, Oxidative Stress Aop:481 Event:1586 KeyEvent Airway epithelial injury Aop:481 Event:1198 KeyEvent Activation, Macrophages Aop:481 Event:2085 KeyEvent Pulmonary epithelial injury Aop:481 Event:1197 KeyEvent Activation, Fibroblasts Aop:481 Event:2086 KeyEvent Airway inflammation Aop:481 Event:2010 KeyEvent Pulmonary inflammation Aop:481 Event:1458 KeyEvent Pulmonary fibrosis Aop:481 Event:2087 AdverseOutcome Increased incidence of respiratory disease Aop:481 Event:2088 AdverseOutcome Dysfunction of respiratory system Aop:481 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:481 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:482 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:482 Event:1392 KeyEvent Increase, Oxidative Stress Aop:482 Event:1825 KeyEvent Increase, Cell death Aop:482 Event:2089 KeyEvent Altered Bone Cell Homeostasis Aop:482 Event:2090 KeyEvent Increase, Bone Remodeling Aop:482 Event:2091 AdverseOutcome Occurrence, Bone Loss Aop:482 Event:2245 KeyEvent Altered Cell Differentiation Signaling Aop:483 Event:1686 MolecularInitiatingEvent Deposition of Energy Aop:483 Event:1392 KeyEvent Increase, Oxidative Stress Aop:483 Event:1492 KeyEvent Tissue resident cell activation Aop:483 Event:2097 KeyEvent Increase, Pro-Inflammatory Mediators Aop:483 Event:2098 KeyEvent Increase, Abnormal Neural Remodeling Aop:483 Event:1635 KeyEvent Increase, DNA strand breaks Aop:483 Event:341 AdverseOutcome Impairment, Learning and memory Aop:483 Event:2244 KeyEvent Altered Stress Response Signaling Aop:485 Event:1656 MolecularInitiatingEvent Antagonism, Thyroid Receptor Aop:485 Event:2104 KeyEvent Decreased, thyroid hormone binding to thyroid hormone receptor Aop:485 Event:2105 KeyEvent Decreased, myelin basic protein expression in oligodendrocytes Aop:485 Event:2106 KeyEvent Impaired, oligodendrocyte maturation Aop:485 Event:2107 KeyEvent Hypomyelination Aop:485 Event:2108 KeyEvent Altered, white brain matter Aop:485 Event:402 AdverseOutcome Cognitive function, decreased Aop:486 Event:2109 MolecularInitiatingEvent Binding, extracellular matrix protein laminin Aop:486 Event:2110 KeyEvent Disrupted binding, laminin-beta1-integrin receptors with laminin Aop:486 Event:2111 KeyEvent Decreased, neural progenitor cell adhesion to laminin Aop:486 Event:2112 KeyEvent Disturbed, radial glia cell alignment and migration Aop:486 Event:2113 KeyEvent Decreased, radial glia cell density Aop:486 Event:2114 KeyEvent Disturbed, cortical architecture Aop:486 Event:402 AdverseOutcome Cognitive function, decreased Aop:487 Event:1114 MolecularInitiatingEvent Unknown, MIE Aop:487 Event:2115 KeyEvent Altered, cholesterol metabolism Aop:487 Event:2116 KeyEvent Decreased, oligodendrocyte differentiation Aop:487 Event:2107 KeyEvent Hypomyelination Aop:487 Event:2108 KeyEvent Altered, white brain matter Aop:487 Event:402 AdverseOutcome Cognitive function, decreased Aop:488 Event:2116 KeyEvent Decreased, oligodendrocyte differentiation Aop:488 Event:2107 KeyEvent Hypomyelination Aop:488 Event:2108 KeyEvent Altered, white brain matter Aop:488 Event:402 AdverseOutcome Cognitive function, decreased Aop:488 Event:1869 KeyEvent Diminished protective oxidative stress response Aop:488 Event:1392 KeyEvent Increase, Oxidative Stress Aop:488 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:489 Event:1353 MolecularInitiatingEvent Binding to voltage-gated sodium channel Aop:489 Event:1977 KeyEvent Disruption of sodium channel gating kinetics Aop:489 Event:2116 KeyEvent Decreased, oligodendrocyte differentiation Aop:489 Event:2107 KeyEvent Hypomyelination Aop:489 Event:2108 KeyEvent Altered, white brain matter Aop:489 Event:402 AdverseOutcome Cognitive function, decreased Aop:490 Event:1350 KeyEvent Increased, glutamate Aop:490 Event:1998 KeyEvent Activation, Microglia Aop:490 Event:188 KeyEvent Neuroinflammation Aop:490 Event:758 KeyEvent Hippocampal Physiology, Altered Aop:490 Event:341 AdverseOutcome Impairment, Learning and memory Aop:490 Event:2123 KeyEvent decreased, Bcl-2 expression Aop:490 Event:2124 KeyEvent increased, Bax expression Aop:490 Event:2121 AdverseOutcome decreased, Intellectual Quotient Aop:490 Event:55 KeyEvent Increase, Cell injury/death Aop:490 Event:2186 MolecularInitiatingEvent Ryanodine receptor activation Aop:490 Event:2037 MolecularInitiatingEvent Inositol triphosphate receptor activation Aop:490 Event:2122 AdverseOutcome increased, socio-economic burden Aop:491 Event:2040 MolecularInitiatingEvent Decrease, GLI1/2 target gene expression Aop:491 Event:2043 KeyEvent Decrease, Sonic Hedgehog second messenger production Aop:491 Event:1821 KeyEvent Decrease, Cell proliferation Aop:491 Event:2041 KeyEvent Decrease, facial prominence outgrowth Aop:491 Event:2042 AdverseOutcome Increase, Orofacial clefting Aop:491 Event:1262 KeyEvent Apoptosis Aop:492 Event:130 KeyEvent Depletion, GSH Aop:492 Event:2131 MolecularInitiatingEvent Conjugation, GSH Aop:492 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:492 Event:1445 KeyEvent Increase, Lipid peroxidation Aop:492 Event:406 AdverseOutcome decreased, Fertility Aop:493 Event:1497 KeyEvent Increased, recruitment of inflammatory cells Aop:493 Event:2127 KeyEvent Increased adipocyte size Aop:493 Event:2128 KeyEvent Increased adipocyte numbers Aop:493 Event:2129 AdverseOutcome Metabolically unhealthy Obesity Aop:493 Event:2125 KeyEvent Increased fat mass Aop:493 Event:2126 MolecularInitiatingEvent Estrogen receptor alpha inactivation Aop:493 Event:2130 KeyEvent increased lipid accumulation Aop:493 Event:2132 KeyEvent Increased pro-inflammatory cytokine expression Aop:493 Event:1633 KeyEvent Increase in inflammation Aop:493 Event:2119 KeyEvent Increase, Insulin resistance Aop:494 Event:18 MolecularInitiatingEvent Activation, AhR Aop:494 Event:55 KeyEvent Increase, Cell injury/death Aop:494 Event:265 KeyEvent Increase, Hepatic stellate cell activation Aop:494 Event:1501 KeyEvent Increase, Extracellular matrix deposition Aop:494 Event:344 AdverseOutcome Increase, Liver fibrosis Aop:494 Event:459 KeyEvent Increase, Liver steatosis Aop:495 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:495 Event:2134 KeyEvent Increase, Androgen receptor protein expression/abundance Aop:495 Event:1183 KeyEvent Decreased, Apoptosis (Epithelial Cells) Aop:495 Event:1599 KeyEvent Inflamatory events in light-exposed tissues Aop:495 Event:854 KeyEvent Alterations, Cellular proliferation / hyperplasia Aop:495 Event:1196 KeyEvent Increased, Invasion Aop:495 Event:2136 KeyEvent prostatic intraepithelial neoplasia Aop:495 Event:2135 AdverseOutcome Prostate cancer Aop:495 Event:25 MolecularInitiatingEvent Agonism, Androgen receptor Aop:496 Event:25 MolecularInitiatingEvent Agonism, Androgen receptor Aop:496 Event:2137 KeyEvent Increase, Gonadotropins concentration in plasma Aop:496 Event:219 KeyEvent Reduction, Plasma 17beta-estradiol concentrations Aop:496 Event:2139 KeyEvent Reduction, the ratio of 17beta-estradiol/11-Keto Testosterone in plasma Aop:496 Event:221 KeyEvent Reduction, Plasma vitellogenin concentrations Aop:496 Event:309 KeyEvent Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Aop:496 Event:78 KeyEvent Reduction, Cumulative fecundity and spawning Aop:496 Event:442 AdverseOutcome Decreased, Population trajectory Aop:496 Event:1690 KeyEvent Decrease, circulating testosterone levels Aop:496 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:497 Event:2126 MolecularInitiatingEvent Estrogen receptor alpha inactivation Aop:497 Event:179 KeyEvent Decrease, Fatty acid beta-oxidation Aop:497 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:497 Event:2144 KeyEvent Impaired insulin signaling Aop:497 Event:2145 AdverseOutcome Metabolic syndrome Aop:497 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:497 Event:2119 AdverseOutcome Increase, Insulin resistance Aop:497 Event:1392 KeyEvent Increase, Oxidative Stress Aop:498 Event:2148 MolecularInitiatingEvent Increased LCN2/iron complex binds to SLC22A17 receptor in neuron Aop:498 Event:2149 KeyEvent Increased intracelluar Iron accumulation Aop:498 Event:191 KeyEvent Neuronal dysfunction Aop:498 Event:2150 AdverseOutcome Neurological disorder Aop:499 Event:2146 MolecularInitiatingEvent Activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase 1/2 Aop:499 Event:1339 KeyEvent Increase, intracellular calcium Aop:499 Event:341 AdverseOutcome Impairment, Learning and memory Aop:499 Event:2151 KeyEvent Disruption, neurotransmitter release Aop:500 Event:2146 MolecularInitiatingEvent Activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase 1/2 Aop:500 Event:1339 KeyEvent Increase, intracellular calcium Aop:500 Event:341 AdverseOutcome Impairment, Learning and memory Aop:500 Event:352 KeyEvent N/A, Neurodegeneration Aop:500 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:500 Event:1262 KeyEvent Apoptosis Aop:500 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:501 Event:2149 MolecularInitiatingEvent Increased intracelluar Iron accumulation Aop:501 Event:386 KeyEvent Decrease of neuronal network function Aop:501 Event:2150 AdverseOutcome Neurological disorder Aop:501 Event:1392 KeyEvent Increase, Oxidative Stress Aop:502 Event:2042 AdverseOutcome Increase, Orofacial clefting Aop:502 Event:2041 KeyEvent Decrease, facial prominence outgrowth Aop:502 Event:1821 KeyEvent Decrease, Cell proliferation Aop:502 Event:2043 KeyEvent Decrease, Sonic Hedgehog second messenger production Aop:502 Event:1262 KeyEvent Apoptosis Aop:502 Event:2040 KeyEvent Decrease, GLI1/2 target gene expression Aop:502 Event:2028 KeyEvent Decrease, GLI1/2 translocation to nucleus Aop:503 Event:1065 MolecularInitiatingEvent Activation, estrogen receptor alpha Aop:503 Event:2152 KeyEvent Epigenetic modification process Aop:503 Event:2153 KeyEvent Expression of factors ruling proliferation, modified Aop:503 Event:772 KeyEvent Increase, Hyperplasia (glandular epithelial cells of endometrium) Aop:503 Event:1896 KeyEvent Genomic instability Aop:503 Event:2154 AdverseOutcome Uterine adenocarcinoma (endometrioid adenocarcinoma Type I) Aop:504 Event:2155 MolecularInitiatingEvent Inhibition of Sulfotransferase E1 (SULT1E1) Aop:504 Event:2251 KeyEvent Estradiol availability, increased Aop:504 Event:1065 AdverseOutcome Activation, estrogen receptor alpha Aop:505 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:505 Event:1392 KeyEvent Increase, Oxidative Stress Aop:505 Event:149 KeyEvent Increase, Inflammation Aop:505 Event:1513 KeyEvent General Apoptosis Aop:505 Event:885 AdverseOutcome Increase, Cancer Aop:506 Event:2158 MolecularInitiatingEvent Influenza A Virus (IAV) binds sialic acid glycan receptor Aop:506 Event:2159 KeyEvent Influenza A virus (IAV) cell entry Aop:506 Event:2180 KeyEvent Immune mechanisms antagonized by viral proteins Aop:506 Event:2192 KeyEvent Influenza A Virus production increased Aop:506 Event:2193 KeyEvent Influenza A Virus (IAV) budding Aop:506 Event:2194 AdverseOutcome Influenza A Virus (IAV) shedding and transmission Aop:507 Event:1417 MolecularInitiatingEvent NFE2/Nrf2 repression Aop:507 Event:2009 KeyEvent Activation of inflammation pathway Aop:507 Event:1928 KeyEvent increased，Vascular endothelial dysfunction Aop:507 Event:2161 AdverseOutcome Increase, Vascular disrupting effects Aop:507 Event:2181 KeyEvent Angiogenesis dysfunction Aop:507 Event:1392 KeyEvent Increase, Oxidative Stress Aop:508 Event:1417 MolecularInitiatingEvent NFE2/Nrf2 repression Aop:508 Event:2162 KeyEvent Activation, HIF1α Aop:508 Event:2163 KeyEvent Activation Sema6A Aop:508 Event:2164 KeyEvent Activation, Dll4-Notch pathway Aop:508 Event:1928 KeyEvent increased，Vascular endothelial dysfunction Aop:508 Event:2161 AdverseOutcome Increase, Vascular disrupting effects Aop:508 Event:2181 KeyEvent Angiogenesis dysfunction Aop:509 Event:1417 MolecularInitiatingEvent NFE2/Nrf2 repression Aop:509 Event:1365 KeyEvent Increase, Apoptosis Aop:509 Event:1928 KeyEvent increased，Vascular endothelial dysfunction Aop:509 Event:2161 AdverseOutcome Increase, Vascular disrupting effects Aop:509 Event:2181 KeyEvent Angiogenesis dysfunction Aop:509 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:509 Event:1392 KeyEvent Increase, Oxidative Stress Aop:510 Event:228 MolecularInitiatingEvent peroxisome proliferator activated receptor promoter demethylation Aop:510 Event:2165 KeyEvent Activation of PPAR Aop:510 Event:2166 KeyEvent Abnormal expression of NO Aop:510 Event:2167 KeyEvent Activation of MMP-2 MMP-9 Aop:510 Event:2168 KeyEvent Activation of angiopoietin like protein 4 Aop:510 Event:2169 KeyEvent Activation of Angiogenic cytokines Aop:510 Event:1928 KeyEvent increased，Vascular endothelial dysfunction Aop:510 Event:2161 AdverseOutcome Increase, Vascular disrupting effects Aop:510 Event:2181 KeyEvent Angiogenesis dysfunction Aop:510 Event:1392 KeyEvent Increase, Oxidative Stress Aop:511 Event:2009 KeyEvent Activation of inflammation pathway Aop:511 Event:2170 KeyEvent Activated ANG/Tie2 pathway Aop:511 Event:2164 KeyEvent Activation, Dll4-Notch pathway Aop:511 Event:2171 KeyEvent Activated BMP/TGF-beta pathway Aop:511 Event:2172 KeyEvent Activated Wnt/Frizzled pathway Aop:511 Event:932 KeyEvent KE4 : Uncoupling, eNOS Aop:511 Event:2173 KeyEvent Activated AKT/ERK/PI3K pathway Aop:511 Event:2174 KeyEvent Inhibition VEGF/VEGFR pathway Aop:511 Event:2178 KeyEvent Vascular barrier disruption Aop:511 Event:2179 KeyEvent Impaired Platelet Aggregation Aop:511 Event:2161 AdverseOutcome Increase, Vascular disrupting effects Aop:511 Event:1928 KeyEvent increased，Vascular endothelial dysfunction Aop:511 Event:2181 KeyEvent Angiogenesis dysfunction Aop:511 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:511 Event:1392 KeyEvent Increase, Oxidative Stress Aop:511 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:512 Event:531 KeyEvent Decreased, LH Surge Aop:513 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:513 Event:233 KeyEvent Decreased, PPAR-gamma activation Aop:513 Event:1060 KeyEvent Alteration, lipid metabolism Aop:513 Event:1513 KeyEvent General Apoptosis Aop:513 Event:885 AdverseOutcome Increase, Cancer Aop:516 Event:1562 MolecularInitiatingEvent Decreased Na/K ATPase activity Aop:516 Event:952 AdverseOutcome Hypertension Aop:517 Event:239 MolecularInitiatingEvent Activation, Pregnane-X receptor, NR1l2 Aop:517 Event:54 KeyEvent Up Regulation, CD36 Aop:517 Event:115 KeyEvent Increase, Fatty acid influx Aop:517 Event:291 KeyEvent Accumulation, Triglyceride Aop:517 Event:459 AdverseOutcome Increase, Liver steatosis Aop:518 Event:167 MolecularInitiatingEvent Activation, LXR Aop:518 Event:2199 KeyEvent Increased, Expression of LXR activated genes Aop:518 Event:89 KeyEvent Synthesis, De Novo Fatty Acid (FA) Aop:518 Event:291 KeyEvent Accumulation, Triglyceride Aop:518 Event:459 AdverseOutcome Increase, Liver steatosis Aop:519 Event:2282 MolecularInitiatingEvent Cardiac ion channels blockade Aop:519 Event:1961 KeyEvent Prolongation of Action Potential Duration Aop:519 Event:2283 KeyEvent Increased the early premature depolarizations during repolarization Aop:519 Event:1929 AdverseOutcome Increased incidence of cardiovascular morbidity and mortality in the general population Aop:520 Event:2201 MolecularInitiatingEvent Agonism, Retinoic acid receptor Aop:520 Event:2202 KeyEvent Altered expression of cell cycle genes Aop:520 Event:2203 KeyEvent Decreased proliferation of cortical neural progenitor cells Aop:520 Event:2204 KeyEvent Altered brain morphology Aop:520 Event:341 AdverseOutcome Impairment, Learning and memory Aop:521 Event:2205 MolecularInitiatingEvent Increased, essential element imbalance Aop:521 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:521 Event:1392 KeyEvent Increase, Oxidative Stress Aop:521 Event:1445 KeyEvent Increase, Lipid peroxidation Aop:521 Event:2206 KeyEvent Increased, histomorphological alteration of testis Aop:521 Event:1758 KeyEvent Impaired, Spermatogenesis Aop:521 Event:2147 AdverseOutcome Decreased, Viable Offspring Aop:522 Event:112 MolecularInitiatingEvent Antagonism, Estrogen receptor Aop:522 Event:2207 KeyEvent inhibition, EKR1/2 signaling pathway Aop:522 Event:195 KeyEvent Inhibition, NMDARs Aop:522 Event:2208 KeyEvent Aberrant, synaptic formation and plasticity Aop:522 Event:386 KeyEvent Decrease of neuronal network function Aop:522 Event:2209 AdverseOutcome autism-like behavior Aop:523 Event:2201 MolecularInitiatingEvent Agonism, Retinoic acid receptor Aop:523 Event:2202 KeyEvent Altered expression of cell cycle genes Aop:523 Event:2203 KeyEvent Decreased proliferation of cortical neural progenitor cells Aop:523 Event:2210 KeyEvent Reduced cortical thickness Aop:523 Event:1978 AdverseOutcome Increase risk, microcephaly Aop:524 Event:2252 MolecularInitiatingEvent Human leukocyte antigen DQ2/8-gluten complexes, formation Aop:524 Event:2253 MolecularInitiatingEvent Gluten-reactive T cell receptors, generation Aop:524 Event:2254 MolecularInitiatingEvent Gluten-reactive and transglutaminase 2 reactive B cell receptors, generation Aop:524 Event:2255 KeyEvent Innate immune response, activation Aop:524 Event:2256 KeyEvent Gluten-reactive B cells and transglutaminase 2-reactive B cells, activation Aop:524 Event:1931 KeyEvent Intestinal barrier, disruption Aop:524 Event:2257 AdverseOutcome Celiac disease Aop:524 Event:2260 KeyEvent Gluten-reactive CD4+ T cells, activation Aop:524 Event:2275 KeyEvent Gluten reactive adaptive T-cells with antigen presenting cells, co-localization Aop:525 Event:2216 MolecularInitiatingEvent Binding of antagonist to thyroid hormone receptor Aop:525 Event:2217 MolecularInitiatingEvent Binding of antagonist to glucocorticoid hormone receptor Aop:525 Event:2218 MolecularInitiatingEvent Binding of (ant)agonist to liver X receptor Aop:525 Event:2219 MolecularInitiatingEvent Binding of (ant)agonist to peroxisome proliferator–activated receptor alpha Aop:525 Event:1656 KeyEvent Antagonism, Thyroid Receptor Aop:525 Event:2220 KeyEvent Antagonism, Glucocorticoid hormone receptor Aop:525 Event:2221 KeyEvent Altered Liver X receptor activity Aop:525 Event:2222 KeyEvent Altered peroxisome proliferator–activated receptor alpha activity Aop:525 Event:2115 KeyEvent Altered, cholesterol metabolism Aop:525 Event:2223 KeyEvent Reduced number of oligodendrocytes Aop:525 Event:2107 KeyEvent Hypomyelination Aop:525 Event:2108 KeyEvent Altered, white brain matter Aop:525 Event:341 AdverseOutcome Impairment, Learning and memory Aop:526 Event:656 KeyEvent Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) Aop:526 Event:647 KeyEvent Decreased, steroidogenic protein expression Aop:526 Event:1690 KeyEvent Decrease, circulating testosterone levels Aop:526 Event:2212 KeyEvent Epididymal agenesis Aop:526 Event:1758 AdverseOutcome Impaired, Spermatogenesis Aop:527 Event:656 KeyEvent Decreased, Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP-TFII) Aop:527 Event:647 KeyEvent Decreased, steroidogenic protein expression Aop:527 Event:1613 KeyEvent Decrease, dihydrotestosterone (DHT) levels Aop:527 Event:2213 KeyEvent Impaired, urethral tube closure Aop:527 Event:2082 AdverseOutcome Hypospadias, increased Aop:528 Event:2214 KeyEvent Decreased, Insulin-like peptide 3 (INSL3) Aop:528 Event:1615 KeyEvent Impaired inguinoscrotal testicular descent phase Aop:528 Event:1616 AdverseOutcome Malformation, cryptorchidism - maldescended testis Aop:529 Event:327 KeyEvent Accumulation, Fatty acid Aop:529 Event:459 AdverseOutcome Increase, Liver steatosis Aop:529 Event:179 KeyEvent Decrease, Fatty acid beta-oxidation Aop:529 Event:291 KeyEvent Accumulation, Triglyceride Aop:529 Event:2224 KeyEvent Dysregulation of transcriptional expression within PPAR signaling network Aop:529 Event:2225 KeyEvent Disrupted Lipid Storage Aop:529 Event:2226 MolecularInitiatingEvent Stressor binding PPAR isoforms Aop:529 Event:2227 KeyEvent Disrupted PPAR isoform nuclear signaling Aop:530 Event:1539 MolecularInitiatingEvent Endocytotic lysosomal uptake Aop:530 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:530 Event:55 KeyEvent Increase, Cell injury/death Aop:530 Event:1931 AdverseOutcome Intestinal barrier, disruption Aop:530 Event:898 KeyEvent Disruption, Lysosome Aop:532 Event:2201 MolecularInitiatingEvent Agonism, Retinoic acid receptor Aop:532 Event:2228 KeyEvent Cerebellar gene expression. Altered Aop:532 Event:2229 KeyEvent Cerebellar neuronal differentiation. Decreased Aop:532 Event:2230 KeyEvent Cerebellar hypoplasia Aop:532 Event:2231 AdverseOutcome Locomotor function. Impaired Aop:533 Event:2232 MolecularInitiatingEvent Antagonism, Retinoic acid receptors Aop:533 Event:1239 KeyEvent Altered, Gene Expression Aop:533 Event:851 KeyEvent Decrease of GABAergic interneurons Aop:533 Event:385 KeyEvent Decrease of synaptogenesis Aop:533 Event:386 KeyEvent Decrease of neuronal network function Aop:533 Event:341 AdverseOutcome Impairment, Learning and memory Aop:534 Event:2118 MolecularInitiatingEvent Succinate dehydrogenase, inhibited Aop:534 Event:1446 KeyEvent Decrease, Coupling of oxidative phosphorylation Aop:534 Event:1553 KeyEvent Increase mutations Aop:534 Event:885 AdverseOutcome Increase, Cancer Aop:534 Event:1392 KeyEvent Increase, Oxidative Stress Aop:534 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:535 Event:2029 MolecularInitiatingEvent protein-coupled estrogen receptor 1 (GPER) activation Aop:535 Event:389 KeyEvent Increased, Intracellular Calcium overload Aop:535 Event:2233 KeyEvent Decreased, ERαβ heterodimers Aop:535 Event:1392 KeyEvent Increase, Oxidative Stress Aop:535 Event:1262 KeyEvent Apoptosis Aop:535 Event:2208 KeyEvent Aberrant, synaptic formation and plasticity Aop:535 Event:2151 KeyEvent Disruption, neurotransmitter release Aop:535 Event:188 KeyEvent Neuroinflammation Aop:535 Event:341 AdverseOutcome Impairment, Learning and memory Aop:536 Event:111 MolecularInitiatingEvent Agonism, Estrogen receptor Aop:536 Event:307 KeyEvent Increase, Vitellogenin synthesis in liver Aop:536 Event:220 KeyEvent Increase, Plasma vitellogenin concentrations Aop:536 Event:252 KeyEvent Increase, Renal pathology due to VTG deposition Aop:536 Event:351 KeyEvent Increased Mortality Aop:536 Event:360 KeyEvent Decrease, Population growth rate Aop:537 Event:111 MolecularInitiatingEvent Agonism, Estrogen receptor Aop:537 Event:307 KeyEvent Increase, Vitellogenin synthesis in liver Aop:537 Event:220 KeyEvent Increase, Plasma vitellogenin concentrations Aop:537 Event:364 KeyEvent Impaired development of, Reproductive organs Aop:537 Event:78 AdverseOutcome Reduction, Cumulative fecundity and spawning Aop:538 Event:1392 KeyEvent Increase, Oxidative Stress Aop:538 Event:2240 KeyEvent The NO synthase pathway activation Aop:538 Event:1928 KeyEvent increased，Vascular endothelial dysfunction Aop:538 Event:2161 AdverseOutcome Increase, Vascular disrupting effects Aop:538 Event:2241 KeyEvent Ferroptosis related pathways activation Aop:539 Event:1562 MolecularInitiatingEvent Decreased Na/K ATPase activity Aop:539 Event:2236 KeyEvent Decreased, Sodium uptake in gills Aop:539 Event:2237 KeyEvent Decreased, Plasma sodium concentrations Aop:539 Event:2238 KeyEvent Increased, Blood viscosity Aop:539 Event:2239 KeyEvent Increased, Cardiac stress Aop:539 Event:1535 AdverseOutcome Heart failure Aop:539 Event:2261 KeyEvent Decreased, blood plasma volume Aop:540 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:540 Event:1392 KeyEvent Increase, Oxidative Stress Aop:540 Event:1262 KeyEvent Apoptosis Aop:540 Event:3 KeyEvent Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Aop:540 Event:285 KeyEvent Reduction, Vitellogenin synthesis in liver Aop:540 Event:221 KeyEvent Reduction, Plasma vitellogenin concentrations Aop:540 Event:309 KeyEvent Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Aop:540 Event:78 KeyEvent Reduction, Cumulative fecundity and spawning Aop:540 Event:360 AdverseOutcome Decrease, Population growth rate Aop:543 Event:2262 MolecularInitiatingEvent Neuropathy target esterase, inhibited Aop:543 Event:2263 KeyEvent Lysolecithin, increased Aop:543 Event:2264 KeyEvent Lysolecithin cell membrane integration, increased Aop:543 Event:2265 KeyEvent Oligodendrocyte death, increased Aop:543 Event:2266 KeyEvent Demyelination, increased Aop:543 Event:2267 AdverseOutcome Delayed neuropathy, increased Aop:544 Event:2262 MolecularInitiatingEvent Neuropathy target esterase, inhibited Aop:544 Event:2263 KeyEvent Lysolecithin, increased Aop:544 Event:149 KeyEvent Increase, Inflammation Aop:544 Event:2265 KeyEvent Oligodendrocyte death, increased Aop:544 Event:2266 KeyEvent Demyelination, increased Aop:544 Event:2267 AdverseOutcome Delayed neuropathy, increased Aop:545 Event:239 MolecularInitiatingEvent Activation, Pregnane-X receptor, NR1l2 Aop:545 Event:2268 KeyEvent Decreased, insulin-induced gene 1 (INSIG1) protein activity Aop:545 Event:2269 KeyEvent Increased, Sterol Regulatory Element Binding Protein 2 (SREBP2) protein expression Aop:545 Event:2270 KeyEvent Increased, cholesterol synthesis enzymes Aop:545 Event:2271 AdverseOutcome Increased, plasma low-density lipoprotein (LDL) cholesterol Aop:546 Event:2118 MolecularInitiatingEvent Succinate dehydrogenase, inhibited Aop:546 Event:2243 KeyEvent Succinate Accumulation Aop:546 Event:798 KeyEvent Inhibition, Prolyl hydroxylases Aop:546 Event:590 KeyEvent N/A, hypoxia Aop:546 Event:885 AdverseOutcome Increase, Cancer Aop:547 Event:2274 KeyEvent Androgen receptor activation, increased Aop:547 Event:25 MolecularInitiatingEvent Agonism, Androgen receptor Aop:547 Event:2365 AdverseOutcome Anogenital distance (AGD), increased Aop:548 Event:239 MolecularInitiatingEvent Activation, Pregnane-X receptor, NR1l2 Aop:548 Event:2268 KeyEvent Decreased, insulin-induced gene 1 (INSIG1) protein activity Aop:548 Event:2269 KeyEvent Increased, Sterol Regulatory Element Binding Protein 2 (SREBP2) protein expression Aop:548 Event:2276 KeyEvent Increased, protein expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) Aop:548 Event:2271 AdverseOutcome Increased, plasma low-density lipoprotein (LDL) cholesterol Aop:549 Event:36 MolecularInitiatingEvent Inhibition, Aromatase Aop:549 Event:219 KeyEvent Reduction, Plasma 17beta-estradiol concentrations Aop:549 Event:221 KeyEvent Reduction, Plasma vitellogenin concentrations Aop:549 Event:2277 KeyEvent Inhibition, aromatase activity in plasma Aop:549 Event:309 KeyEvent Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Aop:549 Event:78 AdverseOutcome Reduction, Cumulative fecundity and spawning Aop:549 Event:442 AdverseOutcome Decreased, Population trajectory Aop:549 Event:1467 AdverseOutcome Growth, reduction Aop:550 Event:2278 MolecularInitiatingEvent Increased LMNA Mutation Aop:550 Event:2279 KeyEvent Structural changes in lamin A/C Aop:550 Event:2066 KeyEvent Altered Signaling Pathways Aop:550 Event:1924 KeyEvent Increased，Cardiac fibrosis Aop:550 Event:1535 AdverseOutcome Heart failure Aop:551 Event:1106 AdverseOutcome Occurrence, cardiac arrhythmia Aop:551 Event:1602 MolecularInitiatingEvent Increased Muscarinic Acetylcholine Receptors Aop:551 Event:1098 KeyEvent Increased, blood potassium concentration Aop:551 Event:1983 KeyEvent Disruption, action potential generation Aop:551 Event:2280 KeyEvent Increased delay in heart electrical conduction Aop:552 Event:1529 MolecularInitiatingEvent Blockade, L-Type Calcium Channels Aop:552 Event:698 KeyEvent Altered, Action Potential Aop:552 Event:1962 KeyEvent Prolongation of QT interval Aop:552 Event:1963 KeyEvent Torsades de Pointes Aop:552 Event:2281 KeyEvent Increased uncoordinated cardiac contraction Aop:552 Event:1535 AdverseOutcome Heart failure Aop:553 Event:584 MolecularInitiatingEvent Inhibition, sodium channel Aop:553 Event:698 KeyEvent Altered, Action Potential Aop:553 Event:1532 KeyEvent Decrease, Cardiac contractility Aop:553 Event:1535 AdverseOutcome Heart failure Aop:554 Event:1038 MolecularInitiatingEvent Activation, beta-2 adrenergic receptor Aop:554 Event:2284 KeyEvent Increased Intracellular cAMP Levels Aop:554 Event:2285 KeyEvent Increased the delayed and early afterdepolarizations Aop:554 Event:1106 AdverseOutcome Occurrence, cardiac arrhythmia Aop:555 Event:593 MolecularInitiatingEvent Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel Aop:555 Event:1961 KeyEvent Prolongation of Action Potential Duration Aop:555 Event:1962 KeyEvent Prolongation of QT interval Aop:555 Event:2283 KeyEvent Increased the early premature depolarizations during repolarization Aop:555 Event:1535 AdverseOutcome Heart failure Aop:556 Event:1535 AdverseOutcome Heart failure Aop:556 Event:1321 KeyEvent Increased, intracellular sodium (Na+) Aop:556 Event:2287 KeyEvent Impaired Sodium-Calcium Exchange Aop:556 Event:389 KeyEvent Increased, Intracellular Calcium overload Aop:556 Event:1532 KeyEvent Decrease, Cardiac contractility Aop:556 Event:1562 MolecularInitiatingEvent Decreased Na/K ATPase activity Aop:557 Event:1039 MolecularInitiatingEvent Increased activity, beta-2 adrenergic receptor Aop:557 Event:2157 AdverseOutcome Abnormal Cardiac Structure and Function Aop:558 Event:2288 MolecularInitiatingEvent Phosphodiesterase inhibition Aop:558 Event:2289 KeyEvent Hyperphosphorylation of ryanodine receptor (RyR2) Aop:558 Event:389 KeyEvent Increased, Intracellular Calcium overload Aop:558 Event:1532 KeyEvent Decrease, Cardiac contractility Aop:558 Event:1535 AdverseOutcome Heart failure Aop:558 Event:693 KeyEvent Increased, cyclic adenosine monophosphate Aop:559 Event:12 MolecularInitiatingEvent Acetylcholinesterase (AchE) Inhibition Aop:559 Event:1602 KeyEvent Increased Muscarinic Acetylcholine Receptors Aop:559 Event:698 KeyEvent Altered, Action Potential Aop:559 Event:2280 KeyEvent Increased delay in heart electrical conduction Aop:559 Event:1106 AdverseOutcome Occurrence, cardiac arrhythmia Aop:560 Event:2290 MolecularInitiatingEvent Inhibition of Funny current (If) Aop:560 Event:2291 KeyEvent Slowed Heart Rate Aop:560 Event:2292 KeyEvent Altered Cardiac Electrical Conduction Aop:560 Event:1106 AdverseOutcome Occurrence, cardiac arrhythmia Aop:561 Event:2293 MolecularInitiatingEvent Aromatase, induction Aop:561 Event:1076 KeyEvent Increased, circulating estrogen levels Aop:561 Event:2251 KeyEvent Estradiol availability, increased Aop:561 Event:1065 AdverseOutcome Activation, estrogen receptor alpha Aop:561 Event:2294 KeyEvent Plasma estradiol, increased Aop:562 Event:2295 MolecularInitiatingEvent HCN Channel Inhibition Aop:562 Event:2296 KeyEvent Reduced Pacemaker Activity in SA Node Aop:562 Event:2291 KeyEvent Slowed Heart Rate Aop:562 Event:2292 KeyEvent Altered Cardiac Electrical Conduction Aop:562 Event:1106 AdverseOutcome Occurrence, cardiac arrhythmia Aop:563 Event:18 MolecularInitiatingEvent Activation, AhR Aop:563 Event:944 KeyEvent dimerization, AHR/ARNT Aop:563 Event:2124 KeyEvent increased, Bax expression Aop:563 Event:1262 KeyEvent Apoptosis Aop:563 Event:1883 KeyEvent Decreased, size of the ovarian reserve Aop:563 Event:2305 AdverseOutcome Premature ovarian Insufficiency Aop:564 Event:1541 MolecularInitiatingEvent Mitochondrial Complex I inhibition Aop:564 Event:2299 KeyEvent Altered, Redox Homeostasis Aop:564 Event:178 KeyEvent Mitochondrial electron transport chain, disrupted Aop:564 Event:40 KeyEvent Mitochondrial ATP production, decreased Aop:564 Event:2300 KeyEvent Disruption, Glucolipid metabolism Aop:564 Event:2151 KeyEvent Disruption, neurotransmitter release Aop:564 Event:2301 KeyEvent Abnormal, Behavior Aop:564 Event:566 AdverseOutcome impaired, Larval development Aop:564 Event:2302 AdverseOutcome Increase, Malformations Aop:564 Event:351 AdverseOutcome Increased Mortality Aop:564 Event:360 AdverseOutcome Decrease, Population growth rate Aop:565 Event:2250 MolecularInitiatingEvent 17β-Hydroxysteroid dehydrogenase 2, inhibition Aop:565 Event:2251 KeyEvent Estradiol availability, increased Aop:565 Event:1065 KeyEvent Activation, estrogen receptor alpha Aop:566 Event:530 KeyEvent Decreased, GnRH pulsatility/release Aop:566 Event:531 KeyEvent Decreased, LH Surge Aop:566 Event:1695 KeyEvent Impaired ovulation Aop:566 Event:2303 KeyEvent Increased plasma estradiol to progesterone ratio (estrogen dominance/unopposed estrogen) Aop:566 Event:2251 KeyEvent Estradiol availability, increased Aop:566 Event:2306 AdverseOutcome Persistent vaginal cornification Aop:567 Event:2307 MolecularInitiatingEvent Binding of plastoquinone B (QB) within D1 protein of Photosystem II Aop:567 Event:1862 KeyEvent Decrease, Photosystem II efficiency Aop:567 Event:1475 KeyEvent Decrease, Photosynthesis Aop:567 Event:1545 KeyEvent Decreased, mitochondrial oxidative phosphorylation Aop:567 Event:1472 KeyEvent Decrease, ATP production Aop:567 Event:360 AdverseOutcome Decrease, Population growth rate Aop:568 Event:619 MolecularInitiatingEvent Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) Aop:568 Event:1320 KeyEvent Increased, extracellular serotonin Aop:568 Event:2308 KeyEvent Increased, stimulation of brain serotonin 5-HT1a, 5-HT2c receptors Aop:568 Event:1016 AdverseOutcome Inhibition, Feeding Aop:569 Event:2309 MolecularInitiatingEvent Decreased DNA methylation of FAM50B/PTCHD3 Aop:569 Event:2310 KeyEvent Elevated gene expression of FAM50B/PTCHD3 Aop:569 Event:2311 KeyEvent Inhibition of PI3K-Akt pathway Aop:569 Event:2195 KeyEvent Increase, CNS Neural cell death Aop:569 Event:2121 AdverseOutcome decreased, Intellectual Quotient Aop:569 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:570 Event:2298 KeyEvent Decrease, intratesticular testosterone levels Aop:570 Event:1690 KeyEvent Decrease, circulating testosterone levels Aop:570 Event:1614 KeyEvent Decrease, androgen receptor activation Aop:570 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:570 Event:2082 AdverseOutcome Hypospadias, increased Aop:571 Event:1617 MolecularInitiatingEvent Inhibition, 5α-reductase Aop:571 Event:1613 KeyEvent Decrease, dihydrotestosterone (DHT) levels Aop:571 Event:1614 KeyEvent Decrease, androgen receptor activation Aop:571 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:571 Event:2082 AdverseOutcome Hypospadias, increased Aop:573 Event:1840 MolecularInitiatingEvent Inhibition, cytochrome oxidase Aop:573 Event:1825 KeyEvent Increase, Cell death Aop:573 Event:2316 AdverseOutcome Increased, pulmonary edema Aop:574 Event:1840 MolecularInitiatingEvent Inhibition, cytochrome oxidase Aop:574 Event:1825 KeyEvent Increase, Cell death Aop:574 Event:2317 AdverseOutcome Loss of olfactory function Aop:575 Event:2298 KeyEvent Decrease, intratesticular testosterone levels Aop:575 Event:1690 KeyEvent Decrease, circulating testosterone levels Aop:575 Event:1614 KeyEvent Decrease, androgen receptor activation Aop:575 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:575 Event:1786 AdverseOutcome Nipple retention (NR), increased Aop:576 Event:1617 MolecularInitiatingEvent Inhibition, 5α-reductase Aop:576 Event:1613 KeyEvent Decrease, dihydrotestosterone (DHT) levels Aop:576 Event:1614 KeyEvent Decrease, androgen receptor activation Aop:576 Event:286 KeyEvent Altered, Transcription of genes by the androgen receptor Aop:576 Event:1786 AdverseOutcome Nipple retention (NR), increased Aop:577 Event:18 MolecularInitiatingEvent Activation, AhR Aop:577 Event:149 KeyEvent Increase, Inflammation Aop:578 Event:18 MolecularInitiatingEvent Activation, AhR Aop:578 Event:2323 KeyEvent Over-expression of PD-L1 in cancer cells Aop:578 Event:2324 KeyEvent Increased of Treg/Th17 cell ratio Aop:578 Event:2326 KeyEvent CTL cytotoxic activity disruption Aop:578 Event:1971 AdverseOutcome Increased, tumor growth Aop:580 Event:2331 MolecularInitiatingEvent Activation, Mineralocorticoid Receptor Aop:580 Event:291 KeyEvent Accumulation, Triglyceride Aop:580 Event:2332 KeyEvent Increase, Lipid droplet Aop:580 Event:2333 KeyEvent Increase, Fat mass Aop:580 Event:2334 KeyEvent Increase, DGAT1 Aop:580 Event:2335 AdverseOutcome Increase, body mass index Aop:580 Event:2336 KeyEvent Increase, SREBF1 Aop:580 Event:2337 KeyEvent Increase, perilipin-2 Aop:581 Event:122 MolecularInitiatingEvent Increase, Glucocorticoid receptor activation Aop:581 Event:2202 KeyEvent Altered expression of cell cycle genes Aop:581 Event:2203 KeyEvent Decreased proliferation of cortical neural progenitor cells Aop:581 Event:2211 KeyEvent Microcephaly Aop:581 Event:402 AdverseOutcome Cognitive function, decreased Aop:587 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:587 Event:890 KeyEvent Degeneration of dopaminergic neurons of the nigrostriatal pathway Aop:587 Event:896 AdverseOutcome Parkinsonian motor deficits Aop:587 Event:1542 MolecularInitiatingEvent Inhibition, Mitochondrial complex III Aop:588 Event:2118 MolecularInitiatingEvent Succinate dehydrogenase, inhibited Aop:588 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:588 Event:890 KeyEvent Degeneration of dopaminergic neurons of the nigrostriatal pathway Aop:588 Event:896 AdverseOutcome Parkinsonian motor deficits Aop:589 Event:1543 MolecularInitiatingEvent Mitochondrial Complex IV inhibition Aop:589 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:589 Event:890 KeyEvent Degeneration of dopaminergic neurons of the nigrostriatal pathway Aop:589 Event:896 AdverseOutcome Parkinsonian motor deficits Aop:590 Event:2339 MolecularInitiatingEvent Intracellular copper, increased Aop:590 Event:2340 KeyEvent Oligomerisation of dihydrolipoamide acetyltransferase (DLAT), increased Aop:590 Event:40 KeyEvent Mitochondrial ATP production, decreased Aop:590 Event:2341 KeyEvent Tricarboxylic acid (TCA) cycle, disrupted Aop:590 Event:2342 KeyEvent Iron-sulfur cluster assembly, impaired Aop:590 Event:2343 AdverseOutcome Cuproptosis, increased Aop:590 Event:889 KeyEvent Proteostasis, impaired Aop:590 Event:178 KeyEvent Mitochondrial electron transport chain, disrupted Aop:591 Event:1194 MolecularInitiatingEvent Increase, DNA damage Aop:591 Event:2344 KeyEvent Upregulation, growth arrest and DNA-damage-inducible beta a Aop:591 Event:2345 KeyEvent Activation, MAPK Aop:591 Event:1293 KeyEvent Activation, FOXO Aop:591 Event:2346 KeyEvent Decrease, Proliferating Cell Nuclear Antigen Aop:591 Event:1505 KeyEvent Cell cycle, disrupted Aop:591 Event:1821 KeyEvent Decrease, Cell proliferation Aop:591 Event:291 KeyEvent Accumulation, Triglyceride Aop:591 Event:2347 KeyEvent Increase, Lipid degradation Aop:591 Event:459 KeyEvent Increase, Liver steatosis Aop:591 Event:2348 KeyEvent Inhibition, Liver regeneration Aop:591 Event:2019 AdverseOutcome Non-alcoholic fatty liver disease Aop:592 Event:1635 MolecularInitiatingEvent Increase, DNA strand breaks Aop:592 Event:2349 MolecularInitiatingEvent Inhibition of LDH activity Aop:592 Event:1281 KeyEvent Increased, DNA Damage-Repair Aop:592 Event:2350 KeyEvent Decreased, Glycolysis Aop:592 Event:2351 KeyEvent Increased, OXPHOS Aop:592 Event:2352 KeyEvent Increased, MMP Aop:592 Event:2353 KeyEvent Disrupted, energy metabolism Aop:592 Event:2354 KeyEvent Activation, Apoptosis signaling Aop:592 Event:2355 AdverseOutcome Disrupted, Spermatogenesis and Sperm quality Aop:592 Event:406 AdverseOutcome decreased, Fertility Aop:592 Event:360 AdverseOutcome Decrease, Population growth rate Aop:593 Event:2362 MolecularInitiatingEvent Redox cycling of a chemical by mitochondria Aop:593 Event:2363 KeyEvent Elevated mitochondrial ROS and dysfunction Aop:593 Event:890 KeyEvent Degeneration of dopaminergic neurons of the nigrostriatal pathway Aop:593 Event:896 AdverseOutcome Parkinsonian motor deficits Aop:593 Event:889 KeyEvent Proteostasis, impaired Aop:594 Event:1238 MolecularInitiatingEvent Activation of oxidative stress pathway Aop:594 Event:1288 KeyEvent Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene Aop:594 Event:1277 AdverseOutcome Reproductive failure Aop:595 Event:112 MolecularInitiatingEvent Antagonism, Estrogen receptor Aop:595 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:595 Event:26 MolecularInitiatingEvent Antagonism, Androgen receptor Aop:595 Event:1392 KeyEvent Increase, Oxidative Stress Aop:595 Event:1262 KeyEvent Apoptosis Aop:595 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:595 Event:495 KeyEvent Repressed expression of steroidogenic enzymes Aop:595 Event:2080 KeyEvent Impaired, blood testis barrier Aop:595 Event:1690 KeyEvent Decrease, circulating testosterone levels Aop:595 Event:1758 KeyEvent Impaired, Spermatogenesis Aop:595 Event:520 AdverseOutcome Decreased sperm quantity or quality in the adult, Decreased fertility Aop:595 Event:1863 AdverseOutcome Decrease, Reproduction Aop:595 Event:3 KeyEvent Reduction, 17beta-estradiol synthesis by ovarian granulosa cells Aop:595 Event:1696 AdverseOutcome Decrease of egg production and cummulative fecundity Aop:595 Event:2366 KeyEvent ovarian retardation Aop:595 Event:2367 KeyEvent Steroidogenesis Dysregulation Aop:595 Event:1837 KeyEvent decreased oocyte maturation Aop:595 Event:2369 KeyEvent Granulosa cell damage Aop:596 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:596 Event:1392 KeyEvent Increase, Oxidative Stress Aop:596 Event:1767 KeyEvent Increase, Protein oxidation Aop:596 Event:1446 KeyEvent Decrease, Coupling of oxidative phosphorylation Aop:596 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:596 Event:55 KeyEvent Increase, Cell injury/death Aop:596 Event:1521 AdverseOutcome Decrease, Growth Aop:598 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:598 Event:1392 KeyEvent Increase, Oxidative Stress Aop:598 Event:1767 KeyEvent Increase, Protein oxidation Aop:598 Event:1446 KeyEvent Decrease, Coupling of oxidative phosphorylation Aop:598 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:598 Event:1821 KeyEvent Decrease, Cell proliferation Aop:598 Event:1521 AdverseOutcome Decrease, Growth Aop:599 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:599 Event:1392 KeyEvent Increase, Oxidative Stress Aop:599 Event:1767 KeyEvent Increase, Protein oxidation Aop:599 Event:179 KeyEvent Decrease, Fatty acid beta-oxidation Aop:599 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:599 Event:55 KeyEvent Increase, Cell injury/death Aop:599 Event:1521 AdverseOutcome Decrease, Growth Aop:600 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:600 Event:1392 KeyEvent Increase, Oxidative Stress Aop:600 Event:1767 KeyEvent Increase, Protein oxidation Aop:600 Event:179 KeyEvent Decrease, Fatty acid beta-oxidation Aop:600 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:600 Event:2327 KeyEvent Decrease, Cell growth Aop:600 Event:1521 AdverseOutcome Decrease, Growth Aop:601 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:601 Event:1392 KeyEvent Increase, Oxidative Stress Aop:601 Event:1767 KeyEvent Increase, Protein oxidation Aop:601 Event:179 KeyEvent Decrease, Fatty acid beta-oxidation Aop:601 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:601 Event:1821 KeyEvent Decrease, Cell proliferation Aop:601 Event:1521 AdverseOutcome Decrease, Growth Aop:602 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:602 Event:1392 KeyEvent Increase, Oxidative Stress Aop:602 Event:1634 KeyEvent Increase, Oxidative DNA damage Aop:602 Event:155 KeyEvent Inadequate DNA repair Aop:602 Event:1635 KeyEvent Increase, DNA strand breaks Aop:602 Event:1505 KeyEvent Cell cycle, disrupted Aop:602 Event:1821 KeyEvent Decrease, Cell proliferation Aop:602 Event:1521 AdverseOutcome Decrease, Growth Aop:603 Event:1115 MolecularInitiatingEvent Increase, Reactive oxygen species Aop:603 Event:1392 KeyEvent Increase, Oxidative Stress Aop:603 Event:1767 KeyEvent Increase, Protein oxidation Aop:603 Event:1505 KeyEvent Cell cycle, disrupted Aop:603 Event:1821 KeyEvent Decrease, Cell proliferation Aop:603 Event:1521 AdverseOutcome Decrease, Growth Aop:604 Event:2370 MolecularInitiatingEvent Antagonism binding, α1-Adrenoreceptor Aop:604 Event:2371 KeyEvent Increased cortisol Aop:604 Event:1335 KeyEvent Reduced, BDNF (Brain-derived neurotrophic factor) Aop:604 Event:1330 KeyEvent Decreased, neuroplasticity Aop:604 Event:1346 AdverseOutcome Increased, depression Aop:605 Event:279 MolecularInitiatingEvent Thyroperoxidase, Inhibition Aop:605 Event:277 KeyEvent Thyroid hormone synthesis, Decreased Aop:605 Event:281 KeyEvent Thyroxine (T4) in serum, Decreased Aop:605 Event:1003 KeyEvent Decreased, Triiodothyronine (T3) Aop:605 Event:2106 KeyEvent Impaired, oligodendrocyte maturation Aop:605 Event:2107 KeyEvent Hypomyelination Aop:605 Event:1005 KeyEvent Reduced, Swimming performance Aop:605 Event:351 AdverseOutcome Increased Mortality Aop:605 Event:360 AdverseOutcome Decrease, Population growth rate Aop:606 Event:2374 MolecularInitiatingEvent Increase, Ecdysone receptor antagonism Aop:606 Event:2375 KeyEvent Decrease, Mis-timed ecdysone receptor-responsive nuclear receptor cascade Aop:606 Event:1522 KeyEvent Inhibition, Chitin synthase 1 Aop:606 Event:1523 KeyEvent Decrease, Cuticular chitin content Aop:606 Event:1524 AdverseOutcome Increase, Premature molting Aop:606 Event:350 AdverseOutcome Increase, Mortality Aop:608 Event:1392 KeyEvent Increase, Oxidative Stress Aop:608 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:608 Event:2106 KeyEvent Impaired, oligodendrocyte maturation Aop:608 Event:2107 KeyEvent Hypomyelination Aop:608 Event:1005 KeyEvent Reduced, Swimming performance Aop:608 Event:351 KeyEvent Increased Mortality Aop:608 Event:360 KeyEvent Decrease, Population growth rate Aop:609 Event:1065 MolecularInitiatingEvent Activation, estrogen receptor alpha Aop:609 Event:968 KeyEvent Decreased, release of kisspeptin from anteroventral periventricular nucleus (AVPV) neurons Aop:609 Event:530 KeyEvent Decreased, GnRH pulsatility/release Aop:609 Event:1986 KeyEvent Decreased, Gonadotropins Aop:609 Event:1075 AdverseOutcome prolonged, estrus cycle Aop:610 Event:2258 MolecularInitiatingEvent Inhibition, monocarboxylate transporter 8 (MCT8) Aop:610 Event:1656 MolecularInitiatingEvent Antagonism, Thyroid Receptor Aop:610 Event:1505 KeyEvent Cell cycle, disrupted Aop:610 Event:2376 MolecularInitiatingEvent Inhibition, organic anion-transporting polypeptide 1C1 (OATP1C1) Aop:610 Event:1002 MolecularInitiatingEvent Inhibition, Deiodinase 2 Aop:610 Event:2093 KeyEvent Brain thyroid hormone (T4/T3) decreased Aop:610 Event:2266 KeyEvent Demyelination, increased Aop:610 Event:386 KeyEvent Decrease of neuronal network function Aop:610 Event:2108 KeyEvent Altered, white brain matter Aop:610 Event:381 KeyEvent Reduced levels of BDNF Aop:610 Event:385 KeyEvent Decrease of synaptogenesis Aop:610 Event:2231 AdverseOutcome Locomotor function. Impaired Aop:610 Event:341 AdverseOutcome Impairment, Learning and memory Aop:610 Event:2377 KeyEvent Decrease, neural network maturation Aop:610 Event:2378 KeyEvent Impaired axonal insulation Aop:610 Event:2105 KeyEvent Decreased, myelin basic protein expression in oligodendrocytes Aop:611 Event:2379 MolecularInitiatingEvent Disruption of the regulatory function of dopamine signaling components. Aop:611 Event:2380 KeyEvent Increase, transcription of the dopamine transporter (SLC6A3) gene Aop:611 Event:2381 KeyEvent Increase, transcription of the dopamine receptor (drd) gene. Aop:611 Event:746 KeyEvent Increase, Dopaminergic activity Aop:611 Event:602 KeyEvent Increased, Ataxia, paralysis, or hyperactivity Aop:611 Event:1005 KeyEvent Reduced, Swimming performance Aop:611 Event:2382 AdverseOutcome Increase, nerve spasm Aop:612 Event:227 MolecularInitiatingEvent Activation, PPARα Aop:612 Event:1312 KeyEvent Increase, Fatty acid beta-oxidation Aop:612 Event:1446 KeyEvent Decrease, Coupling of oxidative phosphorylation Aop:612 Event:1771 KeyEvent Decrease, Adenosine triphosphate pool Aop:612 Event:2384 KeyEvent Decrease, Vascular integrity Aop:612 Event:2383 KeyEvent Increase, Hemopericardium Aop:612 Event:947 AdverseOutcome Increase, Early Life Stage Mortality Aop:613 Event:227 MolecularInitiatingEvent Activation, PPARα Aop:613 Event:1312 KeyEvent Increase, Fatty acid beta-oxidation Aop:613 Event:1446 KeyEvent Decrease, Coupling of oxidative phosphorylation Aop:613 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:613 Event:2384 KeyEvent Decrease, Vascular integrity Aop:613 Event:2383 KeyEvent Increase, Hemopericardium Aop:613 Event:947 AdverseOutcome Increase, Early Life Stage Mortality Aop:614 Event:227 MolecularInitiatingEvent Activation, PPARα Aop:614 Event:948 KeyEvent reduced production, VEGF Aop:614 Event:28 KeyEvent Reduction, Angiogenesis Aop:614 Event:2383 KeyEvent Increase, Hemopericardium Aop:614 Event:947 AdverseOutcome Increase, Early Life Stage Mortality Aop:615 Event:2385 MolecularInitiatingEvent Suppression of Keap1 cysteine oxidation Aop:615 Event:1417 KeyEvent NFE2/Nrf2 repression Aop:615 Event:1994 KeyEvent Increase, Ferroptosis Aop:615 Event:902 AdverseOutcome Inflammation, Liver Aop:615 Event:1445 KeyEvent Increase, Lipid peroxidation Aop:616 Event:2387 MolecularInitiatingEvent MIE-A: Direct ligand interaction with nuclear hormone receptors (ERα/ERβ, AR) or interference with steroidogenic enzymes (e.g., CYP19A1) → receptor activation/antagonism or enzyme inhibition. Aop:616 Event:2388 MolecularInitiatingEvent MIE-B: Photoactivation / photoproduct formation leading to ROS generation Aop:616 Event:2389 KeyEvent KE1: Altered steroidogenesis (gene/protein level) Aop:616 Event:1392 KeyEvent Increase, Oxidative Stress Aop:616 Event:2363 KeyEvent Elevated mitochondrial ROS and dysfunction Aop:616 Event:1262 KeyEvent Apoptosis Aop:616 Event:2390 KeyEvent KE5: Altered circulating reproductive hormones Aop:616 Event:2391 AdverseOutcome Reduced fertility / fecundity Aop:616 Event:363 KeyEvent Altered, Reproductive behaviour Aop:616 Event:364 KeyEvent Impaired development of, Reproductive organs Aop:616 Event:1757 KeyEvent Reduce, Sperm count Aop:616 Event:971 KeyEvent Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required for ovulation Aop:618 Event:202 KeyEvent Inhibition, Nuclear factor kappa B (NF-kB) Aop:618 Event:2394 KeyEvent Diminished survival of naive B lymphocytes Aop:618 Event:2395 KeyEvent Diminished proliferation of activated B lymphocytes Aop:618 Event:2396 KeyEvent Diminished differentiation of activated B lymphocytes Aop:618 Event:2397 AdverseOutcome Diminished vaccine response Aop:618 Event:2398 KeyEvent Reduced antibody production Aop:618 Event:1028 MolecularInitiatingEvent Activation of specific nuclear receptors, PPAR-gamma activation Aop:619 Event:26 MolecularInitiatingEvent Antagonism, Androgen receptor Aop:619 Event:2393 KeyEvent Androgen receptor nuclear transcriptional activity in genital-tubercle tissues, reduced Aop:619 Event:2399 KeyEvent Fibroblast growth factor 10, fibroblast growth factor receptor 2 isoform IIIb signaling in genital tissue, reduced Aop:619 Event:2400 KeyEvent Preputial epithelial morphogenesis, disrupted Aop:619 Event:2401 AdverseOutcome Male preputial separation, failed/delayed Aop:622 Event:1172 KeyEvent Increased activation, Nuclear factor kappa B (NF-kB) Aop:622 Event:1174 KeyEvent Activation, NADPH Oxidase Aop:622 Event:1115 KeyEvent Increase, Reactive oxygen species Aop:622 Event:1392 KeyEvent Increase, Oxidative Stress Aop:622 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:622 Event:1283 KeyEvent Activation, TGF-beta pathway Aop:622 Event:1365 KeyEvent Increase, Apoptosis Aop:622 Event:759 AdverseOutcome Increased, Kidney Failure Aop:622 Event:2403 KeyEvent Metabolic impairment Aop:622 Event:2404 KeyEvent Increase, kidney fibrosis Aop:623 Event:1065 MolecularInitiatingEvent Activation, estrogen receptor alpha Aop:623 Event:1985 KeyEvent Increased Kisspeptin levels in anteroventral periventricular nucleus (AVPV) Aop:623 Event:1047 KeyEvent Increased, secretion of GnRH from hypothalamus Aop:623 Event:2137 KeyEvent Increase, Gonadotropins concentration in plasma Aop:623 Event:2402 KeyEvent Increased, estradiol (E2) production in ovaries Aop:623 Event:2294 KeyEvent Plasma estradiol, increased Aop:623 Event:2306 AdverseOutcome Persistent vaginal cornification Aop:624 Event:2410 MolecularInitiatingEvent Increase, 11β-Hydroxysteroid dehydrogenase type 1 activity Aop:624 Event:2412 KeyEvent Increase, Hepatic intracellular active glucocorticoids Aop:624 Event:122 KeyEvent Increase, Glucocorticoid receptor activation Aop:624 Event:2119 KeyEvent Increase, Insulin resistance Aop:624 Event:2408 KeyEvent Increase, Adipose lipolysis Aop:624 Event:465 KeyEvent Increased, Fatty acid influx Aop:624 Event:459 AdverseOutcome Increase, Liver steatosis Aop:624 Event:2405 KeyEvent Increase, Hepatocellular lipotoxicity Aop:624 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:624 Event:55 KeyEvent Increase, Cell injury/death Aop:624 Event:134 KeyEvent Increase, Kupffer cell activation Aop:624 Event:1489 AdverseOutcome Increase, Steatohepatitis Aop:624 Event:1271 KeyEvent Increase, Transforming growth factor-beta signaling Aop:624 Event:265 KeyEvent Increase, Hepatic stellate cell activation Aop:624 Event:68 KeyEvent Increase, Collagen accumulation Aop:624 Event:344 AdverseOutcome Increase, Liver fibrosis Aop:624 Event:2406 KeyEvent Increase, Regenerative nodule formation Aop:624 Event:2407 AdverseOutcome Increase, Cirrhosis Aop:625 Event:2410 MolecularInitiatingEvent Increase, 11β-Hydroxysteroid dehydrogenase type 1 activity Aop:625 Event:2412 KeyEvent Increase, Hepatic intracellular active glucocorticoids Aop:625 Event:122 KeyEvent Increase, Glucocorticoid receptor activation Aop:625 Event:2119 KeyEvent Increase, Insulin resistance Aop:625 Event:2408 KeyEvent Increase, Adipose lipolysis Aop:625 Event:465 KeyEvent Increased, Fatty acid influx Aop:625 Event:459 AdverseOutcome Increase, Liver steatosis Aop:625 Event:2405 KeyEvent Increase, Hepatocellular lipotoxicity Aop:625 Event:1392 KeyEvent Increase, Oxidative Stress Aop:625 Event:55 KeyEvent Increase, Cell injury/death Aop:625 Event:134 KeyEvent Increase, Kupffer cell activation Aop:625 Event:1489 AdverseOutcome Increase, Steatohepatitis Aop:625 Event:1271 KeyEvent Increase, Transforming growth factor-beta signaling Aop:625 Event:265 KeyEvent Increase, Hepatic stellate cell activation Aop:625 Event:68 KeyEvent Increase, Collagen accumulation Aop:625 Event:344 AdverseOutcome Increase, Liver fibrosis Aop:625 Event:2406 KeyEvent Increase, Regenerative nodule formation Aop:625 Event:2407 AdverseOutcome Increase, Cirrhosis Aop:626 Event:2410 MolecularInitiatingEvent Increase, 11β-Hydroxysteroid dehydrogenase type 1 activity Aop:626 Event:2412 KeyEvent Increase, Hepatic intracellular active glucocorticoids Aop:626 Event:122 KeyEvent Increase, Glucocorticoid receptor activation Aop:626 Event:2119 KeyEvent Increase, Insulin resistance Aop:626 Event:2408 KeyEvent Increase, Adipose lipolysis Aop:626 Event:465 KeyEvent Increased, Fatty acid influx Aop:626 Event:459 AdverseOutcome Increase, Liver steatosis Aop:626 Event:2405 KeyEvent Increase, Hepatocellular lipotoxicity Aop:626 Event:1815 KeyEvent Increase, Endoplasmic reticulum stress Aop:626 Event:55 KeyEvent Increase, Cell injury/death Aop:626 Event:134 KeyEvent Increase, Kupffer cell activation Aop:626 Event:1489 AdverseOutcome Increase, Steatohepatitis Aop:626 Event:1271 KeyEvent Increase, Transforming growth factor-beta signaling Aop:626 Event:265 KeyEvent Increase, Hepatic stellate cell activation Aop:626 Event:68 KeyEvent Increase, Collagen accumulation Aop:626 Event:344 AdverseOutcome Increase, Liver fibrosis Aop:626 Event:2406 KeyEvent Increase, Regenerative nodule formation Aop:626 Event:2407 AdverseOutcome Increase, Cirrhosis Aop:627 Event:2410 MolecularInitiatingEvent Increase, 11β-Hydroxysteroid dehydrogenase type 1 activity Aop:627 Event:2412 KeyEvent Increase, Hepatic intracellular active glucocorticoids Aop:627 Event:122 KeyEvent Increase, Glucocorticoid receptor activation Aop:627 Event:1306 KeyEvent Increase, De novo lipogenesis Aop:627 Event:459 AdverseOutcome Increase, Liver steatosis Aop:627 Event:2405 KeyEvent Increase, Hepatocellular lipotoxicity Aop:627 Event:177 KeyEvent Increase, Mitochondrial dysfunction Aop:627 Event:55 KeyEvent Increase, Cell injury/death Aop:627 Event:134 KeyEvent Increase, Kupffer cell activation Aop:627 Event:1489 AdverseOutcome Increase, Steatohepatitis Aop:627 Event:1271 KeyEvent Increase, Transforming growth factor-beta signaling Aop:627 Event:265 KeyEvent Increase, Hepatic stellate cell activation Aop:627 Event:68 KeyEvent Increase, Collagen accumulation Aop:627 Event:344 AdverseOutcome Increase, Liver fibrosis Aop:627 Event:2406 KeyEvent Increase, Regenerative nodule formation Aop:627 Event:2407 AdverseOutcome Increase, Cirrhosis Aop:628 Event:2410 MolecularInitiatingEvent Increase, 11β-Hydroxysteroid dehydrogenase type 1 activity Aop:628 Event:2412 KeyEvent Increase, Hepatic intracellular active glucocorticoids Aop:628 Event:122 KeyEvent Increase, Glucocorticoid receptor activation Aop:628 Event:1306 KeyEvent Increase, De novo lipogenesis Aop:628 Event:459 AdverseOutcome Increase, Liver steatosis Aop:628 Event:2405 KeyEvent Increase, Hepatocellular lipotoxicity Aop:628 Event:1392 KeyEvent Increase, Oxidative Stress Aop:628 Event:55 KeyEvent Increase, Cell injury/death Aop:628 Event:134 KeyEvent Increase, Kupffer cell activation Aop:628 Event:1489 AdverseOutcome Increase, Steatohepatitis Aop:628 Event:1271 KeyEvent Increase, Transforming growth factor-beta signaling Aop:628 Event:265 KeyEvent Increase, Hepatic stellate cell activation Aop:628 Event:68 KeyEvent Increase, Collagen accumulation Aop:628 Event:344 AdverseOutcome Increase, Liver fibrosis Aop:628 Event:2406 KeyEvent Increase, Regenerative nodule formation Aop:628 Event:2407 AdverseOutcome Increase, Cirrhosis Aop:629 Event:2410 MolecularInitiatingEvent Increase, 11β-Hydroxysteroid dehydrogenase type 1 activity Aop:629 Event:2412 KeyEvent Increase, Hepatic intracellular active glucocorticoids Aop:629 Event:122 KeyEvent Increase, Glucocorticoid receptor activation Aop:629 Event:1306 KeyEvent Increase, De novo lipogenesis Aop:629 Event:459 AdverseOutcome Increase, Liver steatosis Aop:629 Event:2405 KeyEvent Increase, Hepatocellular lipotoxicity Aop:629 Event:1815 KeyEvent Increase, Endoplasmic reticulum stress Aop:629 Event:55 KeyEvent Increase, Cell injury/death Aop:629 Event:134 KeyEvent Increase, Kupffer cell activation Aop:629 Event:1489 AdverseOutcome Increase, Steatohepatitis Aop:629 Event:1271 KeyEvent Increase, Transforming growth factor-beta signaling Aop:629 Event:265 KeyEvent Increase, Hepatic stellate cell activation Aop:629 Event:68 KeyEvent Increase, Collagen accumulation Aop:629 Event:344 AdverseOutcome Increase, Liver fibrosis Aop:629 Event:2406 KeyEvent Increase, Regenerative nodule formation Aop:629 Event:2407 AdverseOutcome Increase, Cirrhosis Aop:630 Event:2409 MolecularInitiatingEvent Decrease, 11β-Hydroxysteroid dehydrogenase type 2 activity